

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
12 June 2003 (12.06.2003)

PCT

(10) International Publication Number  
**WO 03/048345 A1**(51) International Patent Classification<sup>7</sup>: **C12N 5/00**

(21) International Application Number: PCT/KR02/02309

(22) International Filing Date: 7 December 2002 (07.12.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/338,441	7 December 2001 (07.12.2001)	US
60/376,053	26 April 2002 (26.04.2002)	US
60/400,904	2 August 2002 (02.08.2002)	US
60/401,089	5 August 2002 (05.08.2002)	US

(71) Applicant (for all designated States except US): **TOOL-GEN, INC.** [KR/KR]; Daedeok Biocommunity, 461-6, Jeonmin-dong, Yuseong-gu, 305-390 Daejeon (KR).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **KIM, Jin-Soo** [KR/KR]; #202 Jeonmin-dong 299-8, Yuseong-gu, 305-390 Daejeon (KR). **PARK, Kyung-Soon** [KR/KR]; 107-1307, Lucky Hana Apartment, Sinseong-dong, Yuseong-gu, 305-720 Daejeon (KR). **LEE, Dong-ki** [KR/KR]; 101-1406, Chung-gu Apartment, Jeonmin-dong, Yuseong-gu, 305-729 Daejeon (KR). **SEOL, Wongi** [KR/KR]; 110-404, Daerim Durae Apartment, Sinseong-dong, Yuseong-gu, 305-720 Daejeon (KR). **LEE, Horim** [KR/KR]; 101-204, Hanbit Apartment, Shinguan-dong, 314-110 Gongju, Chungcheongnam-do (KR). **LEE, Seong-il** [KR/KR]; Jeonmin-dong 297-4,Yuseong-gu, 305-390 Daejeon (KR). **YANG, Hyo-Young** [KR/KR]; Jeonmin-dong 297-2, Yuseong-gu, 305-390 Daejeon (KR). **LEE, Yangsoon** [KR/KR]; #202, Jeonmin-dong 299-3, Yuseong-gu, 305-390 Daejeon (KR). **JANG, Young-Soon** [KR/KR]; #202, Sinseong-dong 210-59, Yuseong-gu, 305-720 Daejeon (KR).(74) Agents: **JANG, Seongku** et al.; 19th Fl., KEC Building, #275-7, Yangjae-dong, Seocho-ku, 137-130 Seoul (KR).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PHENOTYPIC SCREEN OF CHIMERIC PROTEINS

(57) Abstract: In one aspect, a library of nucleic acids that encode different artificial, chimeric proteins is screened to identify a chimeric protein that alters a phenotypic trait of a cell or organism. The chimeric protein can be identified without *a priori* knowledge of a particular target gene or pathway. Some chimeric proteins include multiple zinc finger domains and can induce, for example, thermotolerance, solvent-tolerance, altered cellular growth, insulin production, differentiation, and drug resistance.

## PHENOTYPIC SCREEN OF CHIMERIC PROTEINS

### BACKGROUND

Most genes are regulated at the transcriptional level by polypeptide transcription factors that bind to specific DNA sites within the gene, typically in promoter or enhancer regions. These proteins activate or repress transcriptional initiation by RNA polymerase at the promoter, thereby regulating expression of the target gene. Many transcription factors, both activators and repressors, include structurally distinct domains that have specific functions, such as DNA binding, dimerization, or interaction with the transcriptional machinery. The DNA binding portion of the transcription factor itself can be composed of independent structural domains that contact DNA. The three-dimensional structures of many DNA-binding domains, including zinc finger domains, homeodomains, and helix-turn-helix domains, have been determined from NMR and X-ray crystallographic data. Effector domains such as activation domains or repression domains retain their function when transferred to DNA-binding domains of heterologous transcription factors (Brent and Ptashne, (1985) *Cell* 43:729-36; Dawson *et al.*, (1995) *Mol. Cell Biol.* 15:6923-31).

Artificial transcription factors can be produced that are chimeras of zinc finger domains. For example, WO 01/60970 (Kim *et al.*) describes methods for determining the specificity of zinc finger domains and for constructing artificial transcription factors that recognize particular target sites. One application for artificial transcription factors is to alter the expression of a particular target gene. Target sites are identified in the regulatory region of the target gene, and artificial transcription factors are engineered to recognize one or more of the target sites. When such artificial transcription factors are introduced into cells, they may bind to the corresponding target sites and modulate transcription. This strategy for controlling the expression of a target gene is sometimes referred to as the "target-driven" approach for identifying transcription factors.

### SUMMARY

In one aspect, the invention features a method that includes: (1) providing a library of cells, the library comprising a plurality of cells that each have a heterologous nucleic acid that expresses an artificial, chimeric polypeptide comprising a first and a

second binding domain, wherein the first and second binding domain are heterologous to each other, and the first and second binding domain of each member of the plurality differ from those of the other members of the plurality; and (2) identifying, from the library, a cell that has a trait that is altered relative to a reference cell. The binding domains can be, for example, independently folded modules, e.g., zinc finger domains. In many embodiments, the binding domains are DNA binding domain. Typically, the reference cell is a cell which does not include a library nucleic acid or which includes a control nucleic acid. The reference cell may be a parental cell from which the library of cells was made, or a derivative thereof.

10 The trait can be any detectable phenotype, e.g., a phenotype that can be observed, selected, inferred, and/or quantitated. As used herein, a chimeric protein includes at least two binding domains that are heterologous to each other. The two binding domains can be from different naturally occurring proteins. The two regions can also be from the same naturally occurring protein, but are positioned in a different configuration in the chimeric protein relative to the corresponding naturally occurring protein.

15 In many embodiments, the cell does not include a reporter gene. In other words, the cells can be screened without having, *a priori*, information about a target gene whose regulation is altered by expression of the chimeric polypeptide. In addition, the cell may include a reporter gene as an additional indicator of a marker that is related or unrelated to the trait. Likewise, one or more target genes may be known prior to the screening.

20 In another example, the trait is production of a compound (e.g., a natural or artificial compound). The compound can be an antibiotic, an anti-proliferative drug, an analgesic, a protein and so on.

25 In yet another example, the trait is resistance to an environmental condition, e.g., heavy metals, salinity, environmental toxins, biological toxins, pathogens, parasites, other environmental extremes (e.g., desiccation, heat, cold), and so forth. In a related example, the trait is stress resistance (e.g., to heat, cold, extreme pH, chemicals, such as ammonia, drugs, osmolarity, and ionizing radiation). In yet another example, the trait is drug resistance. The change in the trait can be in either direction, e.g., towards sensitivity or further resistance.

30 In yet another example, the cell is a plant, animal (e.g., mammalian), fungal, or bacterial cell. For mammals, the trait can be cell proliferation, production of a cytokine,

hormone, or signaling molecule, activation of a cell signaling pathway, activation of a physiological pathway (e.g., glucose homeostasis, metabolism, obesity).

The DNA binding domains can be, for example, zinc finger domains. Typically, the first zinc finger domain varies among nucleic acids of the library, and the second zinc  
5 finger domain also varies among nucleic acids of the plurality. The nucleic acid can also express at least a third DNA binding domain, e.g., a third zinc finger domain.

The zinc finger domains of each expressed polypeptide can be identical to zinc finger domains from different naturally occurring proteins, or can be variants of naturally-  
10 occurring proteins, e.g., mutants at the DNA contacting positions. The naturally-occurring protein can be any eukaryotic zinc finger protein: for example, a fungal (e.g., yeast), plant, or animal protein (e.g., a mammalian protein, such as a human or murine protein). Each polypeptide can further include a third, fourth, fifth, and/or sixth zinc finger domain. Each zinc finger domain can be a mammalian, e.g., human zinc finger domain.

15 Optionally, the nucleic acids of the plurality of cells encode a sufficient number of different zinc finger domains to recognize at least 10, 20, 30, 40, or 50 different 3-base pair DNA sites. In one embodiment, the nucleic acids of the plurality encode a sufficient number of different zinc finger domains to recognize no more than 30, 20, 10, or 5 different 3-base pair DNA sites.

20 The polypeptide expressed from each nucleic acid of the library of cells can also include a functional transcriptional regulatory domain, e.g., a transcription activation, repression domain methylation domain, acetylation domain, or deacetylation domain. Also many chimeric polypeptides are functional without fusion to a particular transcriptional regulatory domain. The nucleic acid encoding the polypeptide can be  
25 operably linked to a constitutive or inducible promoter.

The method can further include isolating the nucleic acid from the identified cell. The nucleic acid can be sequenced. The polypeptide encoded by the nucleic acid can be isolated. The method can further include identifying a nucleic acid binding site specifically recognized by the polypeptide. The binding site can be identified, e.g., by a  
30 computer string or profile search of a sequence database, particularly, a database of regulatory sequences or by selecting in vitro nucleic acids that bind to the polypeptide (e.g., SELEX). A computer database of nucleic acid sequences can be analyzed to



identify occurrences of the identified nucleic acid binding site or sites similar to the identified binding site.

The method can include analyzing the expression of one or more endogenous genes or the level/activity of one or more endogenously expressed polypeptides in the identified cell, e.g., using mRNA profiling (e.g., using microarray analysis), 2-D gel electrophoresis, an array of protein ligands (e.g., antibodies), and/or mass spectroscopy. Also, a single or small number of genes or proteins can also be profiled. In one embodiment, the profile is compared to a database of reference profiles. In another embodiment, regulatory regions of genes whose expression is altered by expression of the identified chimeric polypeptide are compared to identify candidate sites that determine coordinate regulation that results directly or indirectly from expression of the chimeric polypeptide.

The method can also include cultivating the cell to exploit the altered trait. For example, if the altered trait is increased production of a metabolite, the method can include cultivating the cell to produce the metabolite. The cell can be the cell isolated from the library, or a cell into which the nucleic acid encoding the chimeric polypeptide has been re-introduced. Expression of the chimeric polypeptide can be tuned, e.g., using an inducible promoter, in order to finely vary the trait, or another conditional promoter (e.g., a cell type specific promoter). A cell containing the nucleic acid encoding the chimeric polypeptide can be introduced into an organism (e.g., ex vivo treatment), or used to make a transgenic organism.

In one embodiment, at least some library members encode proteins having different regulatory domains. For example, some library members can include an activation domain, and other members, an inhibitory domain. A particular combination of DNA binding domains, for example, may be represented in the library in one instance as a fusion to an activation domain, and in another instance as a fusion to a repression domain. In another example, some library members include an activation domain, whereas others do not have a regulatory domain.

The following are some exemplary phenotypes: expansion of stem cells populations (e.g., hematopoietic stem cells, neuronal stem cells, epidermal stem cells, or cord blood stem cells) and other cells having a limited ability to expand *in vitro*; inhibition of stem cell differentiation s not differentiate; increased pluripotency of a cell

(e.g., a differentiated cell or a stem cell); altered stress resistance (e.g., increased or decreased resistance to a condition such as heat, cold, extreme pH, chemicals such as ammonia which can be produced during cell culture, drugs, salt (osmality), ionizing irradiation, etc.); sensitivity to ionizing irradiation or a toxic agent (e.g., an anticancer drug cells), e.g., increased sensitivity in cancer cells; ability to support viral infection/replication (e.g., hepatitis C replication); ability to resist a pathogen, e.g., a virus, bacteria, or protist; enhancement of RNAi efficiency in cells; enhancing transfection efficiency; retardation or delay of the aging process in cells or organisms; growth in a serum-free, chemically-defined media, in the absence of added growth factors; reduction or elimination of inclusion body formation; and enhanced protein secretion in a cell.

Exemplary applications of these methods include: identifying essential genes in a pathogen (e.g., a pathogenic microbe), identifying genes (of the host or pathogen) required for pathogenesis of microbes, identifying targets of drug candidates, gene discovery in signal transduction pathways, microbial engineering and industrial biotechnology, increasing yield of metabolites of commercial interests, and modulating growth behavior (e.g. improving growth of a microorganism, or reducing growth of a cancer cell).

In another aspect, the invention features a cultured cell that includes (a) a gene (endogenous or exogenous) encoding a protein, and (b) an artificial transcription factor, wherein the cell produces the protein at a higher level than does an identical cell that comprises the gene but not the transcription factor, and wherein the transcription factor exerts its effect on production of the protein in a manner other than by binding to a regulatory region operably linked to the gene. The term "artificial" means not naturally-occurring. The term "gene" means a "coding sequence", either cDNA or genomic (i.e., with introns), and either endogenous or exogenous (transiently or stably transfected).

The artificial transcription factor can include a chimeric DNA binding domain that includes at least two, three, or four zinc finger domains. The artificial transcription factor can further include a regulatory domain (list of activation and repression domain in summary). At least one or two of the individual zinc finger domains may be naturally-occurring (e.g., mammalian, plant, or human). In one embodiment, all the zinc finger domains present are naturally occurring.

The artificial transcription factor can be encoded by a heterologous gene of the cell. The heterologous gene encoding the heterologous transcription factor can be regulated by an inducible promoter. The cell can further include at least a second artificial transcription factor.

5 For example, (i) the artificial transcription factor causes the cell or a culture cell lacking the first gene, but otherwise identical to produce a second protein encoded by a second gene operably linked to a regulatory region other than the regulatory region operably linked to the first gene at a higher level than does an identical cell including the second gene but not the transcription factor, and (ii) the transcription factor exerts its  
10 effect on production of the second protein in a manner other than by binding to a regulatory region operably linked to the second gene. In another example, (i) the cell further includes a second gene encoding a second protein, (ii) the cell produces the second protein at a higher level than does an identical cell including the second gene but not the transcription factor, and (iii) the transcription factor exerts its effect on production of the  
15 second protein in a manner other than by binding to a regulatory region operably linked to the second gene. The regulatory region operably linked to the first gene can be different from the regulatory region operably linked to the second gene.

The first and second transcription factors are selected from the group consisting of:

20 a) a polypeptide including the amino acid sequence of SEQ ID NO:21 (FECKDCGKAFIQKSNLIRHQRTHTGEKPYACPVESCDRRFSDSSNLTRHIRIHTGEKPYACPVESCDRRFSDSSNLTRHIRIH);

b) a polypeptide including the amino acid sequence of SEQ ID NO:22 (SCGICGKSFSFDSSAKRRHCILHTGEKPYVCDVEGCTWKFARSDKLNHRHKKRHTG  
25 EKPYVCDVEGCTWKFARSDELNRHKKRHTGEKPYECHDCGKSFRQSTHLTRHRRIH)

c) a polypeptide including the amino acid sequence of SEQ ID NO:23 (YECDHCGKSFSQSSHLNVHKKRTHTGEKPYRCEECGKAFRWPSNLTRHKRIHTGEKPYRCEECGKAFRWPSNLTRHKRIHTGEKPFACPEC PKRFMRSDNLTQH IKTH).

30 In another aspect, the invention features a method of producing a protein. The method includes providing a cell described herein (e.g., above); culturing the cell under conditions that permit production of the protein at a level higher (e.g., at least two, three,

five, ten, or a hundred fold) than the level produced by an identical cell that includes the gene but not the transcription factor; detecting the protein produced by the cell and/or purifying the expressed protein from the cell and/or from a medium that surrounds the cell. The gene can be an endogenous or exogenous gene. An endogenous gene can be a  
5 naturally occurring gene or a gene that is genetically altered relative to a naturally-occurring gene (e.g., by insertion or modification of regulatory sequences). Examples of endogenous genes include genes encoding a hormone, a cell surface receptor, an antibody, a growth factor, an adhesion protein, a neurotransmitter, and an enzyme. An exogenous gene can be operably linked to a viral promoter, e.g., a CMV or adenovirus promoter.  
10 The cell can be a mammalian cell.

The method can further include introducing the cell into a subject. The method can further include formulating the purified protein with a pharmaceutically acceptable carrier.

The method can include one or more of the following features: the transcription  
15 factor is present in the cell in an amount effective to increase production of a luciferase marker protein encoded by a gene operably linked to a CMV promoter at least 1.1, or 2 fold; the transcription factor is present in the cell in an amount effective to increase production of a secreted alkaline phosphatase marker protein encoded by a gene operably  
20 linked to an SV40 promoter at least 2, 5, 7, 10 fold; the transcription factor directly alters the expression of a plurality of endogenous genes; the transcription factor alters the rate of division of the cell; the transcription factor competes for binding to a naturally-occurring DNA binding site specifically recognized by PB08, K\_F02, or K\_D10, and has a dissociation constant for a DNA site of less than 50 nM; the transcription factor  
25 specifically recognizes a DNA site that partially overlaps the DNA binding site specifically recognized by PB08, K\_F02, or K\_D10; the transcription factor includes two consecutive zinc finger domains selected from the group of QSNR-DSNR; DSNR-DSNR; DSAR-RDKR; RDKR-RDER; RDER-QTHR; QSHV-WSNR; WSNR-WSNR; WSNR-RDNQ, QSNR1-QSNK; QSNK-CSNR1 wherein each four letter identifier identifies the amino acid present at the -1, +2, +3, and +6 DNA contacting residues of a zinc finger  
30 domain; the transcription factor includes the amino acid sequence of SEQ ID NO:21, 22, or 23.

The transcription factor can include an amino acid sequence that differs by 1 to 8 amino acid substitutions, insertions, or deletions of SEQ ID NO:21, 22, or 23. The substitution may be at a position other than a DNA contacting residue, e.g., between a metal coordinating cysteine and position -1. The substitutions can be conservative substitutions. The transcription factor includes an amino acid encoded by a nucleic acid sequence in FIGs. 17, 18, and 19.

In another example, the transcription factor includes the following three zinc finger domains:

a) Cys-X<sub>2-5</sub>-Cys-X<sub>3</sub>-X<sub>a</sub>-X-Gln-X-Ser-Asn-X<sub>b</sub>-X-Arg-His-X<sub>3-5</sub>-His (SEQ ID NO:24);

b) Cys-X<sub>2-5</sub>-Cys-X<sub>3</sub>-X<sub>a</sub>-X-Asp-X-Ser-Asn-X<sub>b</sub>-X-Arg-His-X<sub>3-5</sub>-His (SEQ ID NO:25); and

c) Cys-X<sub>2-5</sub>-Cys-X<sub>3</sub>-X<sub>a</sub>-X-Asp-X-Ser-Asn-X<sub>b</sub>-X-Arg-His-X<sub>3-5</sub>-His (SEQ ID NO:26), e.g., with between one and three substitutions at the invariant positions.

In another example, the transcription factor includes at least three of the following four zinc finger domains (in this order):

a) Cys-X<sub>2-5</sub>-Cys-X<sub>3</sub>-X<sub>a</sub>-X-Asp-X-Ser-Ala-X<sub>b</sub>-X-Arg-His-X<sub>3-5</sub>-His (SEQ ID NO:27);

b) Cys-X<sub>2-5</sub>-Cys-X<sub>3</sub>-X<sub>a</sub>-X-Arg-X-Asp-Lys-X<sub>b</sub>-X-Arg-His-X<sub>3-5</sub>-His (SEQ ID NO:28);

c) Cys-X<sub>2-5</sub>-Cys-X<sub>3</sub>-X<sub>a</sub>-X-Arg-X-Asp-Glu-X<sub>b</sub>-X-Arg-His-X<sub>3-5</sub>-His (SEQ ID NO:29); and

d) Cys-X<sub>2-5</sub>-Cys-X<sub>3</sub>-X<sub>a</sub>-X-Gln-X-Thr-His-X<sub>b</sub>-X-Arg-His-X<sub>3-5</sub>-His (SEQ ID NO:30), e.g., with between one and three substitutions at the invariant positions.

In another example, the transcription factor includes at least three of the following four zinc finger domains (in this order):

a) Cys-X<sub>2-5</sub>-Cys-X<sub>3</sub>-X<sub>a</sub>-X-Gln-X-Ser-His-X<sub>b</sub>-X-Val-His-X<sub>3-5</sub>-His (SEQ ID NO:31);

b) Cys-X<sub>2-5</sub>-Cys-X<sub>3</sub>-X<sub>a</sub>-X-Trp-X-Ser-Asn-X<sub>b</sub>-X-Arg-His-X<sub>3-5</sub>-His (SEQ ID NO:32);

c) Cys-X<sub>2-5</sub>-Cys-X<sub>3</sub>-X<sub>a</sub>-X-Trp-X-Ser-Asn-X<sub>b</sub>-X-Arg-His-X<sub>3-5</sub>-His (SEQ ID NO:33); and

d) Cys-X<sub>2-5</sub>-Cys-X<sub>3</sub>-X<sub>a</sub>-X-Arg-X-Asn-X<sub>b</sub>-X-Lys-His-X<sub>3-5</sub>-His (SEQ ID NO:34), e.g., with between one and three substitutions at the invariant positions. In the above listings, X<sub>a</sub> is any amino acid, or optionally phenylalanine or tyrosine; and X<sub>b</sub> is any amino acid, or optionally, a hydrophobic amino acid.

5 In another aspect, the invention features a method of producing a target protein that includes expressing a nucleic acid encoding the target protein in a cell (e.g., in vitro or in vivo), wherein the cell includes a heterologous, artificial transcription factor that increase the amount of protein produced relative to a cell that does not include the heterologous transcription factor. In one embodiment, the heterologous transcription  
10 factor causes the increase by a mechanism other than by directly regulating transcription of the gene encoding the target protein. For example, the heterologous transcription factor does not bind to a transcriptional regulatory region that directly regulates the nucleic acid encoding the target gene. The transcription factor can be introduced into the cell as a protein or by introduction and transcription of a nucleic acid encoding it. The  
15 method can include other features described herein.

In still another aspect, the invention features a method of identifying a transcription factor. The method includes: providing a nucleic acid library that includes a plurality of nucleic acids, each encoding a different artificial transcription factor, each transcription factor including at least two zinc finger domains that are chimeric with  
20 respect to each other; introducing a member of the library into each of a plurality of cells; identifying a cell from the plurality that has enhanced production of a first target protein, wherein the first target protein is encoded by a gene operably linked to a first transcriptional regulatory sequence; and evaluating the ability of the member of the library to enhance production of a second target protein encoded by a gene operably  
25 linked to a second transcriptional regulatory sequence that is different from the first transcriptional regulatory sequence.

The method can include one or more of the following features: the first and second target proteins are the same; the cells into which the library members are introduced each includes the gene encoding the second target protein operably linked to  
30 the second transcriptional regulatory sequence; the cell is a eukaryotic cell; the first and/or second transcriptional regulatory sequences includes a viral regulatory sequence; the method further includes preparing a host cell that includes a gene encoding

transcription factor encoded by a member of the library that enhances production of the first and the second target protein; the method further includes producing a third target protein, different from the first and second target protein from the host cell; and the evaluating includes evaluating the identified cell. The second or third target protein can be, for example, a secreted protein, e.g., erythropoietin, thrombopoietin, a growth factor, an interleukin, or a chemokine. In another example, the target protein is an enzyme, e.g., that catalyzes a reaction in a metabolite producing pathway. Other features described herein can also be included.

In a related aspect, the invention features a method of identifying a protein chimera. The method includes: providing a nucleic acid library that comprises a plurality of nucleic acids, each encoding a different artificial protein chimera that comprises at least two zinc finger domains; providing a test cell that produces a given level of a first target protein under a specific condition; wherein the first target protein is encoded by a gene operably linked to a first transcriptional regulatory sequence; introducing each member of the plurality into a replicate of the test cell to provide a plurality of transformed cells; identifying, from the plurality of transformed cells or progeny cells thereof, a cell that produces, under the specific condition, a level of the first target protein that differs from the given level; and evaluating the ability of the member of the library in the identified cell to enhance production of a second target protein, encoded by a gene operably linked to a second transcriptional regulatory sequence, different from the first transcriptional regulatory sequence. Other features described herein can also be included.

In another aspect, the invention features a host cell, whose genetic material includes: a heterologous gene that encodes an artificial transcription factor that increases production of a target protein encoded by a target gene at least 30% relative to an otherwise identical control host cell lacking the heterologous gene. In one embodiment, the transcription factor does not directly regulate transcription of the target protein. In another embodiment, the transcription factor directly regulates transcription of the target protein. The host cell can include a sequence or a reporter construct such as a sequence encoding lacZ, secreted alkaline phosphatase (SEAP), GFP, luciferase etc) operably linked to a promoter (e.g., a viral promoter). The cell can include other features described herein.

In another aspect, the invention features a host cell, whose genetic material includes a heterologous gene that encodes a polypeptide that includes at least two, three, or four zinc finger domains, binds to an naturally-occurring DNA site, e.g., with an equilibrium dissociation constant of less than 50 nM, and competes with PB08, K\_F02, or K\_D10 for binding to the naturally-occurring DNA binding site. The cell can include other features described herein.

In another aspect, the invention features a host cell, whose genetic material includes a first heterologous gene that encodes a target protein, and a second heterologous gene that encodes an artificial transcription factor that increases production of the target protein at least 30% relative to an otherwise identical control host cell lacking the second heterologous gene, wherein the transcription factor does not directly regulate transcription of the target protein. The cell can include other features described herein.

In still another aspect, the invention features an isolated polypeptide that includes: the sequence:  $X_a$ -X-Cys- $X_{2.5}$ -Cys- $X_3$ - $X_a$ - $X_5$ - $X_b$ -X-Arg-His- $X_{3.5}$ -His- $X_{1.6}$ - $X_a$ -X-Cys- $X_{2.5}$ -Cys- $X_3$ - $X_a$ - $X_5$ - $X_b$ -X-Arg-His- $X_{3.5}$ -His- $X_{1.6}$ - $X_a$ -X-Cys- $X_{2.5}$ -Cys- $X_3$ - $X_a$ - $X_5$ - $X_b$ -X-Arg-His- $X_{3.5}$ -His (SEQ ID NO:35), and that has one or more of the following effects when present at an effective concentration in a human 293 cell: a) increases expression of a gene encoding a luciferase operably linked to a CMV promoter at least 2 fold; b) increases expression of a gene encoding SEAP operably linked to a SV40 promoter at least 2 fold and c) increases or decreases the rate of cell division at least 50%.

In another aspect, the invention features a method of altering the differentiated state of a metazoan cell, the method including: expressing an artificial transcription factor in the cell in an amount effective to alter the differentiated state of the cell. In one embodiment, the differentiated state can be characterized by a neuronal phenotype (e.g., neurite extension, synapse formation, or neuronal marker expression) or an osteoblasts phenotype (e.g., osteoblasts marker expression). In one embodiment, the differentiated state is altered so as to increase the pluripotency of the cell, e.g., to make it less differentiated, e.g., functional as a stem cell or a precursor cell. In one embodiment, the differentiated state is altered from one differentiated state to another (e.g., from a myogenic cell state to an osteoblast state, from a neuronal state to a glial state, and so forth). In one embodiment, the artificial transcription factor induces neurite extension. The cell can be, for example, a stem cell, a neuronal cell, a neural crest cell, or a neuronal



progenitor cell. The artificial transcription factor can be a transcription factor described herein, e.g., Neuro1-p65 or a Neuro1 related molecule (see below). The artificial transcription factor can compete for binding to a natural DNA binding site with Neuro1-p65. The artificial transcription factor may bind to the same site as Neuro1-p65 or a site  
5 that overlaps a DNA site bound by Neuro1-p65.

In another embodiment, the artificial transcription factor induces an osteoblasts-specific marker, e.g., in an initially non-osteoblast cell, e.g., a myoblast.

In another aspect, the invention features a method of identifying a transcription factor. The method includes: providing a nucleic acid library that includes a plurality of  
10 nucleic acids, each encoding a different artificial transcription factor, each transcription factor including at least two zinc finger domains; introducing a member of the library into each of a plurality of cells; and identifying a cell from the plurality that has an altered differentiated state. The method can include one or more of the following features: the cell is a stem cell; the cell is a neuronal cell, a neural crest cell, or a neuronal progenitor  
15 cell; and the differentiated state includes neuronal outgrowth or neurite formation. Other features can also be included.

In still another aspect, the invention features a method of identifying a plurality of transcription factors. The method includes: providing a nucleic acid library that includes a plurality of nucleic acids, each encoding a different artificial transcription factor, each  
20 transcription factor including at least two zinc finger domains; identifying a first member of the library which alters a given trait of a cell; and screening cells to identify a cell in which the given trait is further altered, wherein each screened cell expresses the transcription factor encoded by the first member of the library and a transcription factor encoded by second member of the same nucleic acid library or another nucleic acid  
25 library of artificial transcription factors. The method can include additional rounds of screening in the presence of the first and second transcription factors. In some cases, the method includes identifying a second member of the library that reverses the change in phenotypic state effected by the first member. The method can include other features described herein.

30 In another aspect, the invention features a method of preparing a modified cell, the method including providing a nucleic acid library that includes a plurality of nucleic acids, each encoding a different artificial transcription factor, each transcription factor including

at least two zinc finger domains; identifying a first and a second member of the library which alters a given trait of a cell; and preparing a cell that can express first and second polypeptides, the first and second polypeptides being encoded respectively by the first and second identified library members. The method can also be extended to additional  
5 member, e.g., a third member. The method can further include evaluating the given trait for the prepared cell.

The method can further include one or more of the following features: the preparing includes introducing a first gene encoding the first polypeptide and a second gene encoding the second polypeptide into the cell; the first and second gene are  
10 components of the same nucleic acid; wherein the preparing includes fusing a first cell that includes a first gene encoding the first polypeptide to a second cell that includes a second gene encoding the second polypeptide; the given trait is production of a metabolite; the given trait is production of a target polypeptide; the production includes secretion. Other features described herein can also be used.

15 The following method relates to using viruses to screening organismal properties of a ZFP library. A method of identifying a transcription factor can include: providing a nucleic acid library that includes a plurality of nucleic acids, each encoding a different artificial transcription factor, each transcription factor including at least two zinc finger domains; packaging each member of the library into a virus or viral particle that infects  
20 mammalian cells to form a plurality of viruses or viral particles; introducing the plurality of viruses or viral particles into a plurality of non-human mammalian subjects; and identifying a subject from the plurality that has an altered phenotype. For example, each subject has a detectable disorder; the plurality of viruses or viral particles is divided into pools, and each pool is introduced into one of the subjects from the plurality of subjects;  
25 the plurality of viruses or viral particles includes separate samples, each sample having packaged within a single nucleic acid of the nucleic acid library, and a single sample is introduced into each subject.

In one aspect, the invention features a modified cell that includes a heterologous nucleic acid encoding an artificial transcription factor that confers stress resistance to the  
30 modified cell relative to a reference cell that is substantially identical to the modified cell and that lacks the heterologous nucleic acid and the artificial transcription factor. For example, the artificial transcription factor includes at least two zinc finger domains. One

or more of the zinc finger domains can be naturally occurring, e.g., a naturally occurring domain in Table 1. Exemplary artificial transcription factors include transcription factors that have one or more consecutive motifs as described herein, e.g., a thermotolerant or solvent tolerant protein described herein.

5           The modified cell can be a prokaryotic or eukaryotic cell. The stress resistance can include one or more the following traits: heat resistance, solvent resistance, heavy metal resistance, osmolarity resistance, resistance to extreme pH, chemical resistance, cold resistance, and resistance to a genotoxic agent, resistance to radioactivity. Stress resistance enables a resistant cell to survive or grow in a condition in which a non-  
10 resistant cell would die or fail to grow. For example, the modified cell can express the artificial transcription factor and resist stress to a greater extent than a substantially identical culture cell that lacks the artificial transcription factor. The invention also provides such artificial proteins, and proteins that alter sensitivity of the cell to a toxic agent relative to an identical cell that does not contain the nucleic acid.

15           In another aspect, the method includes a method of producing a cellular product. The method includes providing a modified cell that includes a heterologous nucleic acid encoding an artificial transcription factor; maintaining the modified cell under conditions in which the artificial transcription factor is produced; and recovering a product produced by the cultured cell, wherein the product is other than the artificial transcription factor.  
20 For example, the artificial transcription factor can confer stress resistance, or another property described herein, e.g., altered protein production, altered metabolite production, and so forth. For example, the artificial transcription factor includes at least two zinc finger domains. One or more of the zinc finger domains can be naturally occurring, e.g., a naturally occurring domain in Table 1. Exemplary artificial transcription factors include  
25 transcription factors that have one or more consecutive motifs (e.g., at least two, three or four consecutive motifs, or at least three motifs in the same pattern, including non-consecutive patterns) as described herein.

Exemplary products include a metabolite or a protein (e.g., an endogenous or heterologous protein. For example, the modified cell includes a nucleic acid encoding a  
30 heterologous protein, other than the artificial transcription factor, and the product is the heterologous protein. In another example, the modified cell further includes a second nucleic acid encoding a heterologous protein, and the heterologous protein participates in

production of the metabolite. The modified cell can be maintained at a temperature between 20°C and 40°C or greater than 37°C. In one embodiment, the modified cell is maintained under conditions which would inhibit the growth of a substantially identical cell that lacks the artificial transcription factor.

5 In one embodiment, the zinc finger domain includes a set of DNA contacting residues that correspond to DNA contacting residues of a zinc finger domain listed in Table 15. In a related embodiment, the artificial transcription factor includes an array of at least three zinc finger domains, wherein the DNA contacting residues of each of the zinc finger domains of the array correspond respectively to DNA contacting residues of  
10 any three consecutive zinc finger domains listed in a row of Table 15. In still another embodiment, the artificial transcription factor competes with a protein that includes the array of zinc finger domains listed in a row of Table 15.

In another aspect, the invention features a cell that contains a gene (e.g., an endogenous or heterologous gene) encoding a target protein and a heterologous nucleic  
15 acid that includes a sequence encoding an artificial protein chimera that (1) increases the amount of the protein produced by the cell relative to a cell that does not include the heterologous nucleic acid, and (2) does not bind to a transcriptional regulatory region that directly regulates transcription of the gene encoding the target protein. For example, the artificial transcription factor includes at least two zinc finger domains, and, e.g., binds  
20 DNA. One or more of the zinc finger domains can be naturally occurring, e.g., a naturally occurring domain in Table 1. Exemplary artificial transcription factors include transcription factors that have one or more consecutive motifs as described herein. In one embodiment, the cell is a eukaryotic cell, and the artificial protein chimera competes with PB08, K\_F02, or K\_D10 for binding to a genomic DNA site.

25 In one embodiment, the artificial protein chimera alters (e.g., increases or decrease) the rate of cell cycle progression by the cell. The invention also provides such artificial transcription factors.

The cell can be used in a method of producing a protein, the method including: providing the cell, and maintaining the cell under conditions in which the artificial protein  
30 chimera increases the amount of the target protein produced by the cell relative to a cell that does not include the heterologous nucleic acid. For example, the protein is a secreted protein, a cytoplasmic protein, or a nuclear protein.

In another aspect, the invention features a cell that contains an endogenous gene encoding a secreted protein and a heterologous nucleic acid that includes a sequence encoding an artificial transcription factor that increases the amount of the secreted protein produced by the cell relative to a cell that does not include the heterologous nucleic acid.

5 In one embodiment, the cell is a eukaryotic cell, and the secreted protein is insulin. In one embodiment, the artificial transcription factor specifically binds to an endogenous DNA site that is also specifically bound by 08\_D04\_p65. In another embodiment, the artificial transcription factor specifically binds to an endogenous DNA site and the artificial transcription factor competes with 08\_D04\_p65 for binding to the endogenous  
10 DNA site. For example, the artificial transcription factor includes an amino acid sequence as follows:

CX<sub>(2-5)</sub>CXXXBXRSHJXRHX<sub>(3-5)</sub>HX<sub>(1-6)</sub>BXCX<sub>(2-5)</sub>CXXXBXRDXHJXTHX<sub>(3-5)</sub>H (SEQ ID NO:45); or

CX<sub>(2-5)</sub>CXXXBXRDXHJXTHX<sub>(3-5)</sub>HX<sub>(1-6)</sub>BXCX<sub>(2-5)</sub>CXXXBXVXSJXRHX<sub>(3-5)</sub>H (SEQ ID NO:46)  
15

where B is phenylalanine or tyrosine; and J is a hydrophobic amino acid.

The cell can be used in a method of producing a secreted protein (e.g., insulin). For example, the cell is maintained under conditions in which the artificial transcription factor increases the amount of insulin produced by the cell relative to a cell that does not  
20 include the heterologous nucleic acid. Similarly, the invention provides an artificial transcription factor including at least two zinc finger domains, wherein the artificial transcription factor induces expression of an endogenous insulin gene in a mammalian cell that does not express an endogenous insulin gene in the absence of the artificial transcription factor.

25 In another aspect, the invention features an artificial transcription factor that alters sensitivity of the cell to a toxic agent (e.g., a drug, e.g., an anti-fungal drug, e.g., ketoconazole) relative to an identical cell that does not contain the nucleic acid. The sensitivity can be increased or decreased. In one embodiment, the cell is a fungal cell. For example, the artificial transcription factor includes at least two zinc finger domains,  
30 e.g., at least three. One or more of the zinc finger domains can be naturally occurring, e.g., a naturally occurring domain in Table 1. Exemplary artificial transcription factors include transcription factors that have one or more consecutive motifs as described herein.

For example, the artificial transcription factor binds to an endogenous DNA site and the artificial transcription factor competes with a zinc finger protein listed in Table 5 for binding to the endogenous DNA site.

5 In another aspect, the invention features a method of altering the drug resistance of a fungal cell. The method includes altering the expression or activity of a protein that is at least 70% identical to AQY1, YJR147W, YLL052C, YLL053C, or YPL091W in the cell. The expression can be altered, e.g., using a transcription factor.

10 In still another aspect, the invention features a method of identifying an artificial chimeric protein that alters the sensitivity of a cell to a toxic agent, the method including: providing a nucleic acid library that includes a plurality of nucleic acids, each nucleic acid of the plurality encoding a chimeric protein that includes an array of at least three zinc finger domains wherein at least two adjacent zinc finger domains do not occur adjacent to each other in a naturally occurring protein; introducing members of the library into replicates of a test cell to yield transformed cells; cultivating the transformed cells in the presence of a toxic agent; and identifying, from the transformed cells, a cell whose sensitivity to the toxic agent is altered relative to the test cell. For example, the test cell is a fungal cell, and the toxic agent is an anti-fungal agent. In another example, the test cell is a cancer cell, and the toxic agent is an anti-mitotic agent. The chimeric protein encoded by each nucleic acid of the plurality can include a transcriptional regulatory domain.

20 The method can further include constructing a nucleic acid that encodes a second chimeric protein that includes the array of zinc finger domains of the chimeric protein encoded by the library member in the selected cell, but does not include the transcriptional regulatory domain of the chimeric protein encoded by the library member in the identified cell. The method can further include constructing a nucleic acid that encodes a second chimeric protein that includes (i) the array of zinc finger domains of the chimeric protein encoded by the library member in the selected cell, and (ii) a transcriptional regulatory domain, other than the transcriptional regulatory domain of the chimeric protein encoded by the library member in the identified cell.

30 In another aspect, the invention features a nucleic acid that includes a sequence encoding an artificial transcription factor including three zinc finger domains, wherein expression of the artificial transcription factor induces a neuronal phenotype in at least

one vertebrate cell. In one example, at least one of the zinc finger domains has the sequence:

Cys-X<sub>2.5</sub>-Cys-X<sub>3</sub>-X<sub>a</sub>-X-Gln-X<sub>b</sub>-X-Ser-Asn-His-X<sub>3.5</sub>-His (SEQ ID NO:250)

Cys-X<sub>2.5</sub>-Cys-X<sub>3</sub>-X<sub>a</sub>-X-Gln-X<sub>b</sub>-X-Ser-Asn-His-X<sub>3.5</sub>-His (SEQ ID NO:251); or

5 Cys-X<sub>2.5</sub>-Cys-X<sub>3</sub>-X<sub>a</sub>-X-Cys-X<sub>b</sub>-X-Ser-Asn-His-X<sub>3.5</sub>-His (SEQ ID NO:252),  
wherein X<sub>a</sub> is phenylalanine or tyrosine; and X<sub>b</sub> is a hydrophobic amino acid. E.g., the  
artificial transcription factor includes the sequence: Cys-X<sub>2.5</sub>-Cys-X<sub>3</sub>-X<sub>a</sub>-X-Gln-X<sub>b</sub>-X-  
Ser-Asn-His-X<sub>3.5</sub>-His-X<sub>1.6</sub>-Cys-X<sub>2.5</sub>-Cys-X<sub>3</sub>-X<sub>a</sub>-X-Gln-X<sub>b</sub>-X-Ser-Asn-His-X<sub>3.5</sub>-His-X<sub>1.6</sub>-  
Cys-X<sub>2.5</sub>-Cys-X<sub>3</sub>-X<sub>a</sub>-X-Cys-X<sub>b</sub>-X-Ser-Asn-His-X<sub>3.5</sub>-His (SEQ ID NO:253), wherein X<sub>a</sub>  
10 is phenylalanine or tyrosine; and X<sub>b</sub> is a hydrophobic amino acid.

One method includes providing a vertebrate cell (e.g., a mammalian cell, a  
human) that contains the nucleic acid; and maintaining the vertebrate cell under  
conditions in which the artificial transcription factor is produced and neurite formation is  
induced. In one example, the vertebrate cell is a stem cell prior to production of the  
15 artificial transcription factor.

In another aspect, the invention features a nucleic acid that includes a sequence  
encoding an artificial transcription factor included of three zinc finger domains, wherein  
expression of the artificial transcription factor induces osteogenesis in at least one  
20 vertebrate cell. For example, at least one of the zinc finger domains has the sequence:

Cys-X<sub>2.5</sub>-Cys-X<sub>3</sub>-X<sub>a</sub>-X-Arg-X<sub>b</sub>-X-Asp-Lys-His-X<sub>3.5</sub>-His (SEQ ID NO:254);

Cys-X<sub>2.5</sub>-Cys-X<sub>3</sub>-X<sub>a</sub>-X-Gln-X<sub>b</sub>-X-Thr-His-His-X<sub>3.5</sub>-His (SEQ ID NO:255);

Cys-X<sub>2.5</sub>-Cys-X<sub>3</sub>-X<sub>a</sub>-X-Val-X<sub>b</sub>-X-Ser-Thr-His-X<sub>3.5</sub>-His (SEQ ID NO:256) or;

Cys-X<sub>2.5</sub>-Cys-X<sub>3</sub>-X<sub>a</sub>-X-Arg-X<sub>b</sub>-X-Asp-Lys-His-X<sub>3.5</sub>-His (SEQ ID NO:257),

25 wherein X<sub>a</sub> is phenylalanine or tyrosine; and X<sub>b</sub> is a hydrophobic amino acid; or the  
artificial transcription factor includes the amino acid sequence:

Cys-X<sub>2.5</sub>-Cys-X<sub>3</sub>-X<sub>a</sub>-X-Arg-X<sub>b</sub>-X-Asp-Lys-His-X<sub>3.5</sub>-His-X<sub>1.6</sub>-Cys-X<sub>2.5</sub>-Cys-X<sub>3</sub>-  
X<sub>a</sub>-X-Gln-X<sub>b</sub>-X-Thr-His-His-X<sub>3.5</sub>-His-X<sub>1.6</sub>-Cys-X<sub>2.5</sub>-Cys-X<sub>3</sub>-X<sub>a</sub>-X-Val-X<sub>b</sub>-X-Ser-Thr-  
His-X<sub>3.5</sub>-His-X<sub>1.6</sub>-Cys-X<sub>2.5</sub>-Cys-X<sub>3</sub>-X<sub>a</sub>-X-Arg-X<sub>b</sub>-X-Asp-Lys-His-X<sub>3.5</sub>-His (SEQ ID  
30 NO:258), wherein X<sub>a</sub> is phenylalanine or tyrosine; and X<sub>b</sub> is a hydrophobic amino acid..

One method includes providing a vertebrate cell that contains the nucleic acid; and  
maintaining the vertebrate cell under conditions in which the artificial transcription factor

is produced and osteogenesis is induced.

In another aspect, the invention features a method of altering the differentiative capacity of a stem cell. The method includes: providing a stem cell and a nucleic acid that includes a sequence encoding an artificial transcription factor includes of a plurality of  
5 zinc finger domains, wherein the artificial transcription factor alters the differentiative capacity of the stem cell; introducing the nucleic into the stem cell; and maintaining the stem cell under conditions in which the artificial transcription factor is produced thereby altering the differentiative capacity of the stem cell. For example, the artificial transcription factor induces differentiation of the stem cell. In another example, the  
10 artificial transcription factor enhances self-renewal potential of the stem cell. The stem cell can be an embryonic stem cell, a vertebrate stem cell, a plant stem cell, a hematopoietic stem cell, a neuronal progenitor cell or muscular progenitor cell.

In still another aspect, the invention features a method that includes: providing a nucleic acid library that includes a plurality of nucleic acids, each encoding a different  
15 artificial transcription factor, each artificial transcription including an array of at least two zinc finger domains and a regulatory domain that activates or represses transcription; providing cell that have a given trait; introducing members of the nucleic acid library into the cells; identifying a member of the library that alters the given trait; and preparing a coding nucleic acid that includes a sequence encoding a DNA binding polypeptide that  
20 includes the array of zinc finger domains from the identified member, but does not include a regulatory domain identical to the regulatory domain of the identified member. For example, the DNA binding polypeptide is lacks the regulatory domain of the identified member. In another example, the DNA binding polypeptide includes a regulatory domain that is mutated relative to the regulatory domain of the identified  
25 member. In one embodiment, the DNA binding polypeptide includes a regulatory domain of opposite functionality relative to the regulatory domain of the identified member.

The method can further include introducing the coding nucleic acid into a cell and assessing the given trait of the cell. The step of identifying can include identifying cells  
30 having a property selected from the group consisting of: resistance to a given environmental condition; differentiation; dedifferentiation; proliferation; apoptosis; serum-independence; pathogen resistance; and pathogen sensitivity.



In another aspect, the invention features an isolated nucleic acid encoding an artificial transcription factor that improves solubility of a heterologous, over-expressed protein in a cell that produces the artificial transcription factor. For example, the artificial transcription factor includes a plurality of zinc finger domains. The cell can be a bacterial cell or a eukaryotic cell. In one example, the protein is a mammalian protein, e.g., AKT protein. In one embodiment, the plurality of zinc finger domains include domains: QSTR-DSAR-RDHT-WSNR or VSTR-DGNV-QSNR-QSNK. The invention also features a modified cell that includes the heterologous nucleic acid of any one of claims 99 to 104. The invention also provides a method of producing a heterologous target protein. The method includes providing the modified cell wherein the modified cell includes a second nucleic acid that includes a sequence encoding a heterologous target protein; and maintaining the modified cell under conditions wherein the artificial transcription factor and the heterologous target protein are produced. The modified cell can be a cultured cell or an in vivo cell, e.g., in a subject.

In another aspect, the invention features a method of transferring an altered trait from a first cell to a second cell. The method includes: providing a nucleic acid library that includes a plurality of nucleic acids, each encoding a different artificial protein chimera that includes at least two zinc finger domains; introducing members of the nucleic acid library into first cells that have a given trait to provide transformed cells; identifying an altered cell from the transformed cells in which a member of the library alters the given trait; recovering a nucleic acid library member from the identified, altered cell; introducing the nucleic acid library member into second cells, wherein the second cells differ from the first cells by a phenotypic trait other than the given trait; and evaluating a second cell that includes the nucleic acid library member and expresses the artificial protein chimera that the nucleic acid library member encodes. For example, the first and second cells are eukaryotic, e.g., yeast cells or mammalian cells. The first and second cells can differ by the proliferative properties or differentiative properties. For example, the first cells are cancer cells, and the second cells are non-cancerous, or vice versa. The evaluated second cell can be evaluated for an alteration to the given trait.

In other aspects, the invention features a nucleic acid including a sequence encoding an artificial transcription factor included of three zinc finger domains. For example, expression of the artificial transcription factor alters a property of at least one

eukaryotic cell, wherein the property is selected from the group consisting of viral replication, virus production, and viral infectivity; expression of the artificial transcription factor alters an ability of a eukaryotic cell to regulate a stem cell that is co-cultured with the eukaryotic cell or that is cultured in media conditioned by the eukaryotic cell;

5 expression of the artificial transcription factor alters an ability of a mammalian culture cell (e.g., a CHO cell) to glycosylate a secreted protein (e.g., an antibody); and expression of the artificial transcription factor alters the ability of a cell to take up exogenous nucleic acid.

In still another aspect, the invention features a method of identifying a

10 transcription factor. The method includes: providing a nucleic acid library that includes a plurality of nucleic acids, each encoding a different artificial transcription factor, each transcription factor including at least two zinc finger domains; introducing members of the nucleic acid library into cells that have a given trait; identifying a member of the library which alters the given trait; and preparing a second library that includes a plurality

15 of nucleic acids, each encoding (1) a variant that differs from the artificial protein chimera corresponding to the identified member by between one and six amino acid substitutions, insertions, or deletions, (2) a protein chimera that comprises the zinc finger domains of the artificial protein chimera corresponding to the identified member and an additional zinc finger domain, wherein the additional zinc finger domain varies among the members

20 of the second library, (3) a variant of the artificial protein chimera corresponding to the identified member, wherein the variant has a subset of the zinc finger domain positions replaced with other zinc finger domains and at least one invariant zinc finger domain that is identical to the zinc finger domain at a corresponding position in the artificial protein chimera corresponding to the identified member, and/or (4) a variant of the artificial

25 protein chimera corresponding to the identified member, wherein, among the members of the second library, one or more zinc finger domain positions are varied such that the particular domain in the artificial protein chimera corresponding to the identified member at that position occurs at a frequency greater than other zinc finger domains at that position. The method can include other features described herein.

30 In another aspect, the invention features a method of identifying a transcription factor, the method includes: providing a nucleic acid library that includes a plurality of nucleic acids, each encoding a different artificial transcription factor, each transcription

factor including a DNA binding component having at least two zinc finger domains and a first regulatory domain that activates or represses transcription; introducing members of the nucleic acid library into cells that have a given trait; identifying a member of the library which alters the given trait; and preparing a nucleic acid that encodes the DNA  
5 binding component of the identified member and a second regulatory domain that differs from the first regulatory domain. A related method includes identifying a transcription factor that lacks a regulatory domain, and adding one; or removing a regulatory domain from a transcription factor that includes one. Some transcription factors can function without a transcriptional regulatory domain. The invention also features an artificial  
10 transcription factor that comprises a plurality of zinc finger domains and a first regulatory domain. The artificial transcription factor produces a first trait when produced in a cell, but produces a second trait if the first regulatory domain is inactivated and a second regulatory domain, of opposite functionality from the first, is included.

In one example, the first regulatory domain activates transcription and the second  
15 regulatory domain represses transcription. In another example, the first regulatory domain represses transcription and the second regulatory domain activates transcription. In still another example, the first regulatory domain activates transcription to a first extent and the second regulatory domain activates transcription to an extent at least 50% less than the first extent. The method can further include introducing the prepared nucleic  
20 acid into a test cell and assessing the test cell, e.g., the given trait of the test cell. In one embodiment, the identified member increases the rate of cell division, and the prepared nucleic acid encodes a transcription factor that decreases the rate of cell division. In another embodiment, the identified member causes resistance to a compound, and the prepared nucleic acid encodes a transcription factor that causes sensitivity to the  
25 compound.

In still another aspect, the invention features a method of identifying a transcription factors, the method including: providing a nucleic acid library that includes first and second pluralities of nucleic acids, wherein each nucleic acid of the first plurality encodes a different artificial transcription factor that includes at least two zinc finger  
30 domains and a regulatory domain that activates transcription, and each nucleic acid of the second plurality encodes a different artificial transcription factor that includes at least two zinc finger domains and a regulatory domain that represses transcription; introducing

members of the nucleic acid library into cells that have a given trait; and identifying a member of the library which alters the given trait.

The invention also features a method that includes evaluating the phenotype of a chimeric artificial zinc finger protein in a first cell, expressing the protein in a second cell, and evaluating a phenotype of the second cell. For example, the method can include identifying a member of a transcription factor library that alters a given phenotype in a first cell (a yeast strain or a human cell line such as 293 cells, for example) and then expressing the member in a different cell (a different yeast strain or HeLa cells, for example). The first cell may be more amenable for screening than other strains or cell lines.

In another aspect, the invention features a method of altering the sensitivity of a fungal strain to an anti-fungal agent. The method includes: introducing a nucleic acid encoding an artificial chimeric protein that comprises at least three zinc finger domains into a fungal cell; and maintaining the fungal cell under conditions that allow for expression of the introduced nucleic acid in the cell. For example, the fungal cell is a yeast cell, e.g., *Candida*, *Pichia*, *Hanseula*, *Histoplasma*, or *Cryptococcus*. In one embodiment, the artificial chimeric protein comprises the amino acid sequence of the zinc finger array of a protein selected from K1 through K11 (see Example 3).

The method can include one or more of the following features: the artificial chimeric protein comprises a transcriptional regulatory domain (e.g., an activation or repression domain); expression of the artificial chimeric protein in the cell alters the transcript level of a water transporter; expression of the artificial chimeric protein in a *S. cerevisiae* cell alters the transcript level of the YLL053 gene or the PDR5 gene; the artificial chimeric protein competes a polypeptide selected from K1 through K11 for binding to a specific DNA site.

In another aspect, the invention features a method of altering the sensitivity of a fungal strain to an anti-fungal agent. The method includes altering the activity or expression of a protein that comprises an amino acid sequence of at least 50 amino acids that is at least 30, 50, 60, 70, 80, 90, or 95% identical to YLL053, AQY1, YJR147W, YLL052C, or YPL091W. For example, the fungal cell is a yeast cell, e.g., *Candida*, *Pichia*, *Hanseula*, *Histoplasma*, or *Cryptococcus*. In one embodiment, the activity or expression is increased to reduce sensitivity, i.e., increase resistance. In another

embodiment, the activity or expression is reduced to increase sensitivity. Altering the activity or expression can include expressing an artificial transcription factor, contacting the cell with a double-stranded RNA (dsRNA) that includes a sequence of at least 20 nucleotides complementary to YLL053, AQY1, YJR147W, YLL052C, or YPL091W gene, or contacting the cell with a chemical compound.

A related method includes screening a test compound (e.g., a small organic compound) for interaction with such a protein, e.g., to identify an inhibitor of a YLL053/AQY1-related protein or screening a test compound for ability to alter the activity or expression of AQY1, YJR147W, YLL052C, YLL053C or YPL091W.

In another aspect, the invention features a method of identifying an artificial chimeric protein that alters the sensitivity of a fungal strain to an anti-fungal agent. The method includes: providing a nucleic acid library that comprises a plurality of nucleic acids, each nucleic acid of the plurality comprising a coding sequence that encodes an artificial, chimeric protein that comprises an array of at least three zinc finger domains wherein at least two adjacent zinc finger domains do not occur adjacent to each other in a naturally occurring protein; introducing each nucleic acid of the plurality into a fungal cell to yield transformed fungal cells; maintaining (e.g., culturing) the transformed fungal cells in the presence of an anti-fungal agent; and selecting a cell from the transformed fungal cells whose sensitivity to the anti-fungal agent is altered relative to a control fungal cell.

The method can include one or more of the following features: the control fungal cell is not transformed or is transformed with a reference nucleic acid; the chimeric protein encoded by each nucleic acid of the plurality comprises a transcriptional regulatory domain; the fungal cell is a pathogenic fungal cell, e.g., a *Candida*, *Histoplasma*, or *Cryptococcus*.

The method can further include, for example, constructing a nucleic acid that encodes a second chimeric protein that comprises (i) the array of zinc finger domains of the chimeric protein encoded by the library member in the selected cell, and (ii) a transcriptional regulatory domain, other than the transcriptional regulatory domain of the chimeric protein encoded by the library member in the selected cell. The method can include other features described herein.

In a further aspect, the invention features a method of identifying an agent that counters resistance of a fungal cell to an anti-fungal agent. The method includes: contacting a test compound to a polypeptide that includes YJR147W, YLL052C, YLL053C or YPL091W; and evaluating interaction between the test compound and the polypeptide, wherein an interaction indicates that the test compound may be useful as an agent to counter resistance to an anti-fungal agent. The method can further include contacting a fungal cell with the test compound and the anti-fungal agent, e.g., and evaluating viability or growth of the cell. The cell can be a cell that is resistant to the anti-fungal agent (e.g., ketoconazole).

In another aspect, the invention features a method of identifying a target gene that is regulated by artificial transcription factors. The method includes: providing a nucleic acid library that comprises a plurality of nucleic acids, each encoding a different artificial transcription factor, each transcription factor comprising at least two zinc finger domains; introducing each member of the plurality into a replicate of a test cell to provide a plurality of transformed cells; identifying a plurality of phenotypically altered cells from the plurality of transformed cells, wherein each phenotypically altered cell has an altered phenotype relative to the test cell; and identifying one or more transcripts or proteins whose abundance is similarly altered in at least two phenotypically altered cells of the plurality relative to the test cell.

In one embodiment, the method further includes, in a test cell, altering the activity of a transcript or protein whose abundance is similarly altered in at least two phenotypically altered cells, e.g., by genetic alteration (e.g., mutation or overexpression) or otherwise (e.g., RNA interference, anti-sense, or antibody binding). In some cases, the activity of a plurality of transcripts or proteins is altered.

In one embodiment, the similarly altered transcripts or proteins are identified by profiling transcripts or protein abundance in each phenotypically altered cell of the plurality to provide a profile for each phenotypically altered cell; and comparing the profiles to each other. Profiles can be obtained using, for example, a nucleic acid or protein array, SAGE tags, differential display, or subtractive hybridization.

In one embodiment, the cell is a cancer cell, e.g., a human cancer cell. One or more of the identified transcripts can be a transcript that is absent from the cell in the absence of any artificial transcription factors.

A polypeptide encoded by one of the identified transcripts can be used as a target polypeptide for screening to find test compounds that interact with the target. The test compound can be evaluated to determine if they enhance or inhibit activity of the target polypeptide. In one embodiment, the test compound is a small molecule having a  
5 molecular weight of less than 10, 5, or 2 kDa.

With respect to all methods described herein, a library of nucleic acids that encode chimeric zinc finger proteins can be used. The term "library" refers to a physical collection of similar, but non-identical biomolecules. The collection can be, for example, together in one vessel or physically separated (into groups or individually) in separate  
10 vessels or on separate locations on a solid support. Duplicates of individual members of the library may be present in the collection. A library can include at least 10,  $10^2$ ,  $10^3$ ,  $10^5$ ,  $10^7$ , or  $10^9$  different members, or fewer than  $10^{13}$ ,  $10^{12}$ ,  $10^{10}$ ,  $10^9$ ,  $10^7$ ,  $10^5$ , or  $10^3$  different members.

A first exemplary library includes a plurality of nucleic acids, each nucleic acid  
15 encoding a polypeptide comprising at least a first, second, and third zinc finger domains. As used herein, "first, second and third" denotes three separate domains that can occur in any order in the polypeptide: e.g., each domain can occur N-terminal or C-terminal to either or both of the others. The first zinc finger domain varies among nucleic acids of the plurality. The second zinc finger domain varies among nucleic acids of the plurality.  
20 At least 10 different first zinc finger domains are represented in the library. In one implementation, at least 0.5, 1, 2, 5%, 10%, or 25% of the members of the library have one or both of the following properties: (1) each represses transcription of at least one p1G reporter plasmid at least 1.25 fold *in vivo*; and (2) each binds at least one target site with a dissociation constant of no more than 7, 5, 3, 2, 1, 0.5, or 0.05 nM. The first and  
25 second zinc finger domains can be from different naturally-occurring proteins or are positioned in a configuration that differs from their relative positions in a naturally-occurring protein. For example, the first and second zinc finger domains may be adjacent in the polypeptide, but may be separated by one or more intervening zinc finger domains in a naturally occurring protein.

30 A second exemplary library includes a plurality of nucleic acids, each nucleic acid encoding a polypeptide that includes at least first and second zinc finger domains. The first and second zinc finger domains of each polypeptide (1) are identical to zinc finger

domains of different naturally occurring proteins (and generally do not occur in the same naturally occurring protein or are positioned in a configuration that differs from their relative positions in a naturally-occurring protein), (2) differ by no more than four, three, two, or one amino acid residues from domains of naturally occurring proteins, or (3) are non-adjacent zinc finger domains from a naturally occurring protein. Identical zinc finger domains refer to zinc finger domains that are identical at each amino acid from the first metal coordinating residue (typically cysteine) to the last metal coordinating residue (typically histidine). The first zinc finger domain varies among nucleic acids of the plurality, and the second zinc finger domain varies among nucleic acids of the plurality.

The naturally occurring protein can be any eukaryotic zinc finger protein: for example, a fungal (e.g., yeast), plant, or animal protein (e.g., a mammalian protein, such as a human or murine protein). Each polypeptide can further include a third, fourth, fifth, and/or sixth zinc finger domain. Each zinc finger domain can be a mammalian, e.g., human, zinc finger domain.

Other types of libraries can also be used, e.g., including mutated zinc finger domains.

In some embodiments, a library of nucleic acids encoding zinc finger proteins or a library of such proteins themselves can include members with different regulatory domains. For example, the library can include at least 10% of members with an activation domain, and at least another 10% of members with a repression domain. In another example, at least 10% have an activation domain or repression domain; another at least 10% has no regulatory domain. In still another example, some include an activation domain; others, a repression domain; still others, no regulatory domain at all. Other percentages, e.g., at least 20, 25, 30, 40, 50, 60% can also be used.

\* \* \*

### **1. Neuro1p65 and Related Molecules**

In still another aspect, the invention features an artificial polypeptide that includes: the sequence:

CX<sub>(2-5)</sub>CXXXBXQXSNJXRHX<sub>(3-5)</sub>HX<sub>(1-6)</sub>BXCX<sub>(2-5)</sub>CXXXBXQXSNJXKH  
X<sub>(3-5)</sub>HX<sub>(1-6)</sub>BXCX<sub>(2-5)</sub>CXXXBXCXSNJXRHX<sub>(3-5)</sub>H (SEQ ID NO:36),



where B is any amino acid, or optionally phenylalanine or tyrosine; and J is any amino acid, or optionally, a hydrophobic amino acid. This array is also abbreviated as: QSNR-QSNK-CSNR. Other exemplary artificial polypeptides include:

5 CX<sub>(2-5)</sub>CXXXBXQXSNJXRHX<sub>(3-5)</sub>HX<sub>(1-6)</sub>BXCX<sub>(2-5)</sub>CXXXBXQXSNJXKH<sub>(3-5)</sub>H (SEQ ID NO:37), and

CX<sub>(2-5)</sub>CXXXBXQXSNJXKH<sub>(3-5)</sub>HX<sub>(1-6)</sub>BXCX<sub>(2-5)</sub>CXXXBXCXSNJXRHX<sub>(3-5)</sub>H (SEQ ID NO:38).

The polypeptide can, for example, induce neurites when present at an effective concentration in a mouse Neuro2a cell. For example, the isolated polypeptide can include  
 10 an amino acid sequence that is identical to the zinc finger array within SEQ ID NO:2 or that differs by no more than 8, 6, 4, 3, or 2 substitutions within the zinc finger domains present in SEQ ID NO:2. The substitutions can be conservative substitutions. The isolated polypeptide can have a sequence that is at least 80, 85, 90, 95, or 97% identical to the zinc finger array within SEQ ID NO:2. In one embodiment, the polypeptide can  
 15 specifically bind to a target DNA site. For example, the polypeptide can compete with the Neuro1p chimeric ZFP (SEQ ID NO:2) for binding to a target DNA site, e.g., a site bound with a K<sub>d</sub> of less than 10 nM. The polypeptide can further include a transcriptional regulatory domain, e.g., an activation or repression domain. The polypeptide can include one, two, or three or more additional zinc finger domains.

20 Also featured are nucleic acids encoding the above polypeptides. For example, the isolated polypeptide that includes the amino acid of SEQ ID NO:2 can be encoded by a nucleic acid sequence that includes the sequence of SEQ ID NO:1. Featured nucleic acids can include operably linked regulatory sequences, e.g., a promoter sequence, an enhancer sequence, an insulator sequence, untranslated regulatory regions, a polyA  
 25 addition site, and so forth. In one embodiment, the coding nucleic acid is operably linked to a conditional promoter such as an inducible promoter or a cell-type specific promoter. The nucleic acid can be included in a vector or integrated into a chromosome.

In addition, the invention features host cells (e.g., mammalian host cells) that include a polypeptide described above. The host cell can include a nucleic acid described  
 30 above and express the nucleic acid. For example, the host cell can be a neuronal cell that extends neurites (e.g., at least in part as a consequence of the polypeptide).

## 2. Osteo1p65 and Related Molecules

In still another aspect, the invention features an artificial polypeptide that includes: the sequence:

5 CX<sub>(2-5)</sub>CXXXBXRDXDKJXRHX<sub>(3-5)</sub>HX<sub>(1-6)</sub>BXCX<sub>(2-5)</sub>CXXXBXQXTHJXRHX<sub>(3-5)</sub>HX<sub>(1-6)</sub>BXCX<sub>(2-5)</sub>CXXXBXVXSTJXRHX<sub>(3-5)</sub>HX<sub>(1-6)</sub>BXCX<sub>(2-5)</sub>CXXXBXRDXDKJXRHX<sub>(3-5)</sub>H (SEQ ID NO:39),

where B is any amino acid, or optionally phenylalanine or tyrosine; and J is any amino acid, or optionally, a hydrophobic amino acid. This array is also abbreviated as: RDKR-QTHR-VSTR-RDKR. Other exemplary artificial polypeptides include:

10 CX<sub>(2-5)</sub>CXXXBXRDXDKJXRHX<sub>(3-5)</sub>HX<sub>(1-6)</sub>BXCX<sub>(2-5)</sub>CXXXBXQXTHJXRHX<sub>(3-5)</sub>HX<sub>(1-6)</sub>BXCX<sub>(2-5)</sub>CXXXBXVXSTJXRHX<sub>(3-5)</sub>H (SEQ ID NO:40);

CX<sub>(2-5)</sub>CXXXBXQXTHJXRHX<sub>(3-5)</sub>HX<sub>(1-6)</sub>BXCX<sub>(2-5)</sub>CXXXBXVXSTJXRHX<sub>(3-5)</sub>HX<sub>(1-6)</sub>BXCX<sub>(2-5)</sub>CXXXBXRDXDKJXRHX<sub>(3-5)</sub>H (SEQ ID NO:41);

15 CX<sub>(2-5)</sub>CXXXBXRDXDKJXRHX<sub>(3-5)</sub>HX<sub>(1-6)</sub>BXCX<sub>(2-5)</sub>CXXXBXQXTHJXRHX<sub>(3-5)</sub>H (SEQ ID NO:42); and

CX<sub>(2-5)</sub>CXXXBXVXSTJXRHX<sub>(3-5)</sub>HX<sub>(1-6)</sub>BXCX<sub>(2-5)</sub>CXXXBXRDXDKJXRHX<sub>(3-5)</sub>H (SEQ ID NO:43).

The polypeptide can, for example, induce alkaline phosphatase or other indicators of osteoblasts differentiation, when present at an effective concentration in a C2C12 myoblast cell line cell. For example, the isolated polypeptide can include an amino acid sequence that is identical to the zinc finger array within SEQ ID NO:4 or that differs by no more than 8, 6, 4, 3, or 2 substitutions within the zinc finger domains present in SEQ ID NO:4. The substitutions can be conservative substitutions. The isolated polypeptide can have a sequence that is at least 80, 85, 90, 95, or 97% identical to the zinc finger array within SEQ ID NO:4. In one embodiment, the polypeptide can specifically bind to a target DNA site. For example, the polypeptide can compete with the Osteo1p chimeric ZFP (SEQ ID NO:4) for binding to a target DNA site, e.g., a site bound with a K<sub>d</sub> of less than 10 nM. The polypeptide can further include a transcriptional regulatory domain, e.g., an activation or repression domain. The polypeptide can include one, two, or three or more additional zinc finger domains.

30

Also featured are nucleic acids encoding the above polypeptides. For example, the isolated polypeptide that includes the amino acid of SEQ ID NO:4 can be encoded by

a nucleic acid sequence that includes the sequence of SEQ ID NO:3. Featured nucleic acids can include operably linked regulatory sequences, e.g., a promoter sequence, an enhancer sequence, an insulator sequence, untranslated regulatory regions, a polyA addition site, and so forth. In one embodiment, the coding nucleic acid is operably linked to a conditional promoter such as an inducible promoter or a cell-type specific promoter. The nucleic acid can be included in a vector or integrated into a chromosome.

In addition, the invention features host cells (e.g., mammalian host cells) that include a polypeptide described above. The host cell can include a nucleic acid described above and express the nucleic acid. For example, the host cell can be a stem cell that has the phenotype of an osteoblasts, e.g., at least partially as a consequence of the artificial chimeric polypeptide.

### 3. 08\_D04\_6 and Related Molecules

In still another aspect, the invention features an artificial polypeptide that includes: the sequence:

$CX_{(2-5)}CXXXBXXRSHJXRHX_{(3-5)}HX_{(1-6)}BXCX_{(2-5)}CXXXBXXRDHJXTHX_{(3-5)}HX_{(1-6)}BXCX_{(2-5)}CXXXBXVXSJXRHX_{(3-5)}H$  (SEQ ID NO:44),

where B is any amino acid, or optionally phenylalanine or tyrosine; and J is any amino acid, or optionally, a hydrophobic amino acid. This array is also abbreviated as: RSHR-RDHT-VSSR. Other exemplary artificial polypeptides include:

$CX_{(2-5)}CXXXBXXRSHJXRHX_{(3-5)}HX_{(1-6)}BXCX_{(2-5)}CXXXBXXRDHJXTHX_{(3-5)}H$  (SEQ ID NO:45); and

$CX_{(2-5)}CXXXBXXRDHJXTHX_{(3-5)}HX_{(1-6)}BXCX_{(2-5)}CXXXBXVXSJXRHX_{(3-5)}H$  (SEQ ID NO:46)

The polypeptide can, for example, induce insulin gene expression, e.g., when present at an effective concentration in a human 293 cell. For example, the isolated polypeptide can include an amino acid sequence that is identical to the zinc finger array within SEQ ID NO:6 or that differs by no more than 8, 6, 4, 3, or 2 substitutions within the zinc finger domains present in SEQ ID NO:6. The substitutions can be conservative substitutions. The isolated polypeptide can have a sequence that is at least 80, 85, 90, 95, or 97% identical to the zinc finger array within SEQ ID NO:6. In one embodiment, the

polypeptide can specifically bind to a target DNA site. For example, the polypeptide can compete with the 08\_D04\_6 chimeric ZFP (SEQ ID NO:6) for binding to a target DNA site, e.g., a site bound with a  $K_d$  of less than 10 nM. The polypeptide can further include a transcriptional regulatory domain, e.g., an activation or repression domain. The polypeptide can include one, two, or three or more additional zinc finger domains.

Also featured are nucleic acids encoding the above polypeptides. For example, the isolated polypeptide that includes the amino acid of SEQ ID NO:6 can be encoded by a nucleic acid sequence that includes the sequence of SEQ ID NO:5. Featured nucleic acids can include operably linked regulatory sequences, e.g., a promoter sequence, an enhancer sequence, an insulator sequence, untranslated regulatory regions, a polyA addition site, and so forth. In one embodiment, the coding nucleic acid is operably linked to a conditional promoter such as an inducible promoter or a cell-type specific promoter. The nucleic acid can be included in a vector or integrated into a chromosome.

In addition, the invention features host cells (e.g., mammalian host cells) that include a polypeptide described above. The host cell can include a nucleic acid described above and express the nucleic acid. For example, the host cell can be a human cell that expresses the insulin gene, e.g., at least partially as a consequence of the artificial chimeric polypeptide. The invention also features a method of producing insulin that includes culturing a cell described herein in vitro, or of producing insulin in a subject by introducing a polypeptide described above or a nucleic acid encoding the polypeptide into a cell of the subject.

#### 4. P\_B08 and Related Molecules

In still another aspect, the invention features an artificial polypeptide that includes: the sequence:

CX<sub>(2-5)</sub>CXXXBXQXSNJXRHX<sub>(3-5)</sub>HX<sub>(1-6)</sub>BXCX<sub>(2-5)</sub>CXXXBXDXSNJXRHX<sub>(3-5)</sub>HX<sub>(1-6)</sub>BXCX<sub>(2-5)</sub>CXXXBXDXSNJXRHX<sub>(3-5)</sub>H (SEQ ID NO:47),

where B is any amino acid, or optionally phenylalanine or tyrosine; and J is any amino acid, or optionally, a hydrophobic amino acid. This array is also abbreviated as: QSNR-DSNR-DSNR. Other exemplary artificial polypeptides include:

$CX_{(2-5)}XXXXBXQXSJXRHX_{(3-5)}HX_{(1-6)}BXCX_{(2-5)}XXXXBXDXSJXRHX_{(3-5)}H$  (SEQ ID NO:48); and

$CX_{(2-5)}XXXXBXDXSJXRHX_{(3-5)}HX_{(1-6)}BXCX_{(2-5)}XXXXBXDXSJXRHX_{(3-5)}H$  (SEQ ID NO:49).

5       The polypeptide can, for example, increase expression of a heterologous polypeptide, e.g., a reporter polypeptide encoded by a SV40-SEAP reporter construct in a 293 cell when present at an effective concentration. For example, the isolated polypeptide can include an amino acid sequence that is identical to the zinc finger array within SEQ ID NO:8 or that differs by no more than 8, 6, 4, 3, or 2 substitutions within  
10       the zinc finger domains present in SEQ ID NO:8. The substitutions can be conservative substitutions. The isolated polypeptide can have a sequence that is at least 80, 85, 90, 95, or 97% identical to the zinc finger array within SEQ ID NO:8. In one embodiment, the polypeptide can specifically bind to a target DNA site. For example, the polypeptide can compete with the P\_B08 chimeric ZFP (SEQ ID NO:8) for binding to a target DNA site,  
15       e.g., a site bound with a  $K_d$  of less than 10 nM. The polypeptide can further include a transcriptional regulatory domain, e.g., an activation or repression domain. The polypeptide can include one, two, or three or more additional zinc finger domains.

Also featured are nucleic acids encoding the above polypeptides. For example, the isolated polypeptide that includes the amino acid of SEQ ID NO:8 can be encoded by  
20       a nucleic acid sequence that includes the sequence of SEQ ID NO:7. Featured nucleic acids can include operably linked regulatory sequences, e.g., a promoter sequence, an enhancer sequence, an insulator sequence, untranslated regulatory regions, a polyA addition site, and so forth. In one embodiment, the coding nucleic acid is operably linked to a conditional promoter such as an inducible promoter or a cell-type specific promoter.  
25       The nucleic acid can be included in a vector or integrated into a chromosome.

In addition, the invention features host cells (e.g., mammalian host cells) that include a polypeptide described above. The host cell can include a nucleic acid described above and express the nucleic acid. For example, the host cell can be a mammalian cell that has increased heterologous polypeptide production.

30

## 5. K\_D10 and Related Molecules

In still another aspect, the invention features an artificial polypeptide that includes: the sequence:

5 CX<sub>(2-5)</sub>CXXXBXQXSHJXVHX<sub>(3-5)</sub>HX<sub>(1-6)</sub>BXCX<sub>(2-5)</sub>CXXXBXWXSNIJXRHX<sub>(3-5)</sub>HX<sub>(1-6)</sub>BXCX<sub>(2-5)</sub>CXXXBXRNDNIJQHX<sub>(3-5)</sub>H (SEQ ID NO:50),

where B is any amino acid, or optionally phenylalanine or tyrosine; and J is any amino acid, or optionally, a hydrophobic amino acid. This array is also abbreviated as: QSHV-WSNR-WSNR-RDNQ. Other exemplary artificial polypeptides include:

10 CX<sub>(2-5)</sub>CXXXBXWXSNIJXRHX<sub>(3-5)</sub>HX<sub>(1-6)</sub>BXCX<sub>(2-5)</sub>CXXXBXWXSNIJXRHX<sub>(3-5)</sub>HX<sub>(1-6)</sub>BXCX<sub>(2-5)</sub>CXXXBXRNDNIJQHX<sub>(3-5)</sub>H (SEQ ID NO:51); and

CX<sub>(2-5)</sub>CXXXBXQXSHJXVHX<sub>(3-5)</sub>HX<sub>(1-6)</sub>BXCX<sub>(2-5)</sub>CXXXBXWXSNIJXRHX<sub>(3-5)</sub>HX<sub>(1-6)</sub>BXCX<sub>(2-5)</sub>CXXXBXWXSNIJXRHX<sub>(3-5)</sub>H (SEQ ID NO:52).

The polypeptide can decrease the cell proliferation when present at an effective concentration in a mammalian cell, e.g., by at least 30, 40, 50, or 60%. Cell proliferation may be assessed by cell number after a predefined incubation time. For example, the isolated polypeptide can include an amino acid sequence that is identical to the zinc finger array within SEQ ID NO:10 or that differs by no more than 8, 6, 4, 3, or 2 substitutions within the zinc finger domains present in SEQ ID NO:10. The substitutions can be conservative substitutions. The isolated polypeptide can have a sequence that is at least 80, 85, 90, 95, or 97% identical to the zinc finger array within SEQ ID NO:10. In one embodiment, the polypeptide can specifically bind to a target DNA site. For example, the polypeptide can compete with the K\_D10 chimeric ZFP (SEQ ID NO:10) for binding to a target DNA site, e.g., a site bound with a K<sub>d</sub> of less than 10 nM. The polypeptide can further include a transcriptional regulatory domain, e.g., an activation or repression domain. The polypeptide can include one, two, or three or more additional zinc finger domains.

Also featured are nucleic acids encoding the above polypeptides. For example, the isolated polypeptide that includes the amino acid of SEQ ID NO:10 can be encoded by a nucleic acid sequence that includes the sequence of SEQ ID NO:9. Featured nucleic acids can include operably linked regulatory sequences, e.g., a promoter sequence, an enhancer sequence, an insulator sequence, untranslated regulatory regions, a polyA

addition site, and so forth. In one embodiment, the coding nucleic acid is operably linked to a conditional promoter such as an inducible promoter or a cell-type specific promoter. The nucleic acid can be included in a vector or integrated into a chromosome.

In addition, the invention features host cells (e.g., eukaryotic, e.g., mammalian host cells) that include a nucleic acid described herein, e.g., a nucleic acid encoding polypeptide described herein. The host cell can also express the nucleic acid. For example, the host cell can be a mammalian cell that has a reduced proliferation rate relative to an otherwise identical cell that does not include the polypeptide.

## 6. K\_F02 and Related Molecules

In still another aspect, the invention features an artificial polypeptide that includes: the sequence:

CX<sub>(2-5)</sub>CXXXBXDXSAJXRHX<sub>(3-5)</sub>HX<sub>(1-6)</sub>BXCX<sub>(2-5)</sub>CXXXBXRDXDKJXRHX<sub>(3-5)</sub>HX<sub>(1-6)</sub>BXCX<sub>(2-5)</sub>CXXXBXRDXDEJXRHX<sub>(3-5)</sub>HX<sub>(1-6)</sub>BXCX<sub>(2-5)</sub>CXXXBXQXTHJXRHX<sub>(3-5)</sub>H (SEQ ID NO:53),

where B is any amino acid, or optionally phenylalanine or tyrosine; and J is any amino acid, or optionally, a hydrophobic amino acid. This array is also abbreviated as: DSAR-RDKR-RDER-QTHR. Other exemplary artificial polypeptides include:

CX<sub>(2-5)</sub>CXXXBXRDXDKJXRHX<sub>(3-5)</sub>HX<sub>(1-6)</sub>BXCX<sub>(2-5)</sub>CXXXBXRDXDEJXRHX<sub>(3-5)</sub>HX<sub>(1-6)</sub>BXCX<sub>(2-5)</sub>CXXXBXQXTHJXRHX<sub>(3-5)</sub> (SEQ ID NO:54); and

CX<sub>(2-5)</sub>CXXXBXDXSAJXRHX<sub>(3-5)</sub>HX<sub>(1-6)</sub>BXCX<sub>(2-5)</sub>CXXXBXRDXDKJXRHX<sub>(3-5)</sub>HX<sub>(1-6)</sub>BXCX<sub>(2-5)</sub>CXXXBXRDXDEJXRHX<sub>(3-5)</sub>H (SEQ ID NO:55).

The polypeptide can increase cell proliferation, e.g., by at least 50, 100, or 120%, in a mammalian cell, e.g., a 293 cell. For example, the isolated polypeptide can include an amino acid sequence that is identical to the zinc finger array within SEQ ID NO:12 or that differs by no more than 8, 6, 4, 3, or 2 substitutions within the zinc finger domains present in SEQ ID NO:12. The substitutions can be conservative substitutions. The isolated polypeptide can have a sequence that is at least 80, 85, 90, 95, or 97% identical to the zinc finger array within SEQ ID NO:12. In one embodiment, the polypeptide can specifically bind to a target DNA site. For example, the polypeptide can compete with the K\_F02 chimeric ZFP (SEQ ID NO:12) for binding to a target DNA site, e.g., a site bound with a K<sub>d</sub> of less than 10 nM. The polypeptide can further include a transcriptional

regulatory domain, e.g., an activation or repression domain. The polypeptide can include one, two, or three or more additional zinc finger domains.

Also featured are nucleic acids encoding the above polypeptides. For example, the isolated polypeptide that includes the amino acid of SEQ ID NO:12 can be encoded by a nucleic acid sequence that includes the sequence of SEQ ID NO:11. Featured nucleic acids can include operably linked regulatory sequences, e.g., a promoter sequence, an enhancer sequence, an insulator sequence, untranslated regulatory regions, a polyA addition site, and so forth. In one embodiment, the coding nucleic acid is operably linked to a conditional promoter such as an inducible promoter or a cell-type specific promoter. The nucleic acid can be included in a vector or integrated into a chromosome.

In addition, the invention features host cells (e.g., mammalian host cells) that include a nucleic acid described above. The host cell can include a nucleic acid described above and express the nucleic acid. For example, the host cell can be a mammalian cell that has an increased rate of cell proliferation relative to an otherwise identical cell that does not include the polypeptide.

## 7. K12\_A11 and Related Molecules

In still another aspect, the invention features an artificial polypeptide that includes: the sequence:

CX<sub>(2-5)</sub>CXXXBXRDXHJXTHX<sub>(3-5)</sub>HX<sub>(1-6)</sub>BXCX<sub>(2-5)</sub>CXXXBXQXSNJXVHX<sub>(3-5)</sub>HX<sub>(1-6)</sub>BXCX<sub>(2-5)</sub>CXXXBXQXTHJXRHX<sub>(3-5)</sub>HX<sub>(1-6)</sub>BXCX<sub>(2-5)</sub>CXXXBXQXFNJXRHX<sub>(3-5)</sub>H (SEQ ID NO:56),

where B is any amino acid, or optionally phenylalanine or tyrosine; and J is any amino acid, or optionally, a hydrophobic amino acid. This array is also abbreviated as: RDHT-QSNV-QTHR-QFNR. Other exemplary polypeptides include:

CX<sub>(2-5)</sub>CXXXBXRDXHJXTHX<sub>(3-5)</sub>HX<sub>(1-6)</sub>BXCX<sub>(2-5)</sub>CXXXBXQXSNJXVHX<sub>(3-5)</sub>HX<sub>(1-6)</sub>BXCX<sub>(2-5)</sub>CXXXBXQXTHJXRHX<sub>(3-5)</sub>H (SEQ ID NO:57); and

CX<sub>(2-5)</sub>CXXXBXQXSNJXVHX<sub>(3-5)</sub>HX<sub>(1-6)</sub>BXCX<sub>(2-5)</sub>CXXXBXQXTHJXRHX<sub>(3-5)</sub>HX<sub>(1-6)</sub>BXCX<sub>(2-5)</sub>CXXXBXQXFNJXRHX<sub>(3-5)</sub>H (SEQ ID NO:58)

The polypeptide can increase heterologous gene expression, e.g., a gene operable linked to a strong promoter such as a viral promoter, in a mammalian cell. For example,



the isolated polypeptide can include an amino acid sequence that is identical to the zinc finger array within SEQ ID NO:260 or that differs by no more than 8, 6, 4, 3, or 2 substitutions within the zinc finger domains present in SEQ ID NO:260. The substitutions can be conservative substitutions. The isolated polypeptide can have a sequence that is at least 80, 85, 90, 95, or 97% identical to the zinc finger array within SEQ ID NO:260. In one embodiment, the polypeptide can specifically bind to a target DNA site. For example, the polypeptide can compete with the K12\_A\_11 chimeric ZFP (SEQ ID NO:260) for binding to a target DNA site, e.g., a site bound with a  $K_d$  of less than 10 nM. The polypeptide can further include a transcriptional regulatory domain, e.g., an activation or repression domain. The polypeptide can include one, two, or three or more additional zinc finger domains. Since the K12\_A\_11 chimeric ZFP includes a repression domain it is unlikely to increase heterologous gene expression by directly binding to the promoter of the heterologous gene.

Also featured are nucleic acids encoding the above polypeptides. For example, the isolated polypeptide that includes the amino acid of SEQ ID NO:260 can be encoded by a nucleic acid sequence that includes the sequence of SEQ ID NO:259. Featured nucleic acids can include operably linked regulatory sequences, e.g., a promoter sequence, an enhancer sequence, an insulator sequence, untranslated regulatory regions, a polyA addition site, and so forth. In one embodiment, the coding nucleic acid is operably linked to a conditional promoter such as an inducible promoter or a cell-type specific promoter. The nucleic acid can be included in a vector or integrated into a chromosome.

In addition, the invention features host cells (e.g., mammalian host cells) that include a nucleic acid described above. The host cell can include a nucleic acid described above and express the nucleic acid.

## 8. K44-16-E12 and Related Molecules

In still another aspect, the invention features an artificial polypeptide that includes: the sequence:

CX<sub>(2-5)</sub>CXXXBXQXSHJXVHX<sub>(3-5)</sub>HX<sub>(1-6)</sub>BXCX<sub>(2-5)</sub>CXXXBXQXSSJXRHX<sub>(3-5)</sub>HX<sub>(1-6)</sub>BXCX<sub>(2-5)</sub>CXXXBXQXTHJXRHX<sub>(3-5)</sub>H (SEQ ID NO:59),

where B is any amino acid, or optionally phenylalanine or tyrosine; and J is any amino acid, or optionally, a hydrophobic amino acid. This array is also abbreviated as: QSHV-QSSR-QTHR. Other exemplary polypeptides include:

5 CX<sub>(2-5)</sub>CXXXBXQXSSJXRHX<sub>(3-5)</sub>HX<sub>(1-6)</sub>BXCX<sub>(2-5)</sub>CXXXBXQXTHJXRHX<sub>(3-5)</sub>H (SEQ ID NO:60); and

CX<sub>(2-5)</sub>CXXXBXQXSHJXVHX<sub>(3-5)</sub>HX<sub>(1-6)</sub>BXCX<sub>(2-5)</sub>CXXXBXQXSSJXRHX<sub>(3-5)</sub>H (SEQ ID NO:61).

The polypeptide can increase heterologous gene expression, e.g., a gene operable linked to a strong promoter such as a viral promoter, in a mammalian cell. For example, 10 the isolated polypeptide can include an amino acid sequence that is identical to the zinc finger array within SEQ ID NO:262 or that differs by no more than 8, 6, 4, 3, or 2 substitutions within the zinc finger domains present in SEQ ID NO:262. The substitutions can be conservative substitutions. The isolated polypeptide can have a sequence that is at least 80, 85, 90, 95, or 97% identical to the zinc finger array within 15 SEQ ID NO:262. In one embodiment, the polypeptide can specifically bind to a target DNA site. For example, the polypeptide can compete with the K44-16-E12 chimeric ZFP (SEQ ID NO:262) for binding to a target DNA site, e.g., a site bound with a K<sub>d</sub> of less than 10 nM. The polypeptide can further include a transcriptional regulatory domain, e.g., an activation or repression domain. The polypeptide can include one, two, or three or 20 more additional zinc finger domains. Since the K44-16-E12 chimeric ZFP includes a repression domain it is unlikely to increase heterologous gene expression by directly binding to the promoter of the heterologous gene.

Also featured are nucleic acids encoding the above polypeptides. For example, the isolated polypeptide that includes the amino acid of SEQ ID NO:262 can be encoded 25 by a nucleic acid sequence that includes the sequence of SEQ ID NO:261. Featured nucleic acids can include operably linked regulatory sequences, e.g., a promoter sequence, an enhancer sequence, an insulator sequence, untranslated regulatory regions, a polyA addition site, and so forth. In one embodiment, the coding nucleic acid is operably linked to a conditional promoter such as an inducible promoter or a cell-type specific promoter. 30 The nucleic acid can be included in a vector or integrated into a chromosome.

In addition, the invention features host cells (e.g., mammalian host cells) that include a nucleic acid described above. The host cell can include a nucleic acid described

above and express the nucleic acid. For example, the host cell can be a mammalian cell (e.g., a 293 cell that has the phenotype of increased heterologous protein production (e.g., both a secreted and intracellular reporter protein encoded by genes operably linked to the CMV promoter).

5

### 9. K13\_B08 and Related Molecules

In still another aspect, the invention features an artificial polypeptide that includes: the sequence:

10 CX<sub>(2-5)</sub>CXXXBXQXSNJXRHX<sub>(3-5)</sub>HX<sub>(1-6)</sub>BXCX<sub>(2-5)</sub>CXXXBXQXSSJXRHX<sub>(3-5)</sub>HX<sub>(1-6)</sub>BXCX<sub>(2-5)</sub>CXXXBXQXTHJXRHX<sub>(3-5)</sub>HX<sub>(1-6)</sub>BXCX<sub>(2-5)</sub>CXXXBXRDKJXRHX<sub>(3-5)</sub>H (SEQ ID NO:62),

where B is any amino acid, or optionally phenylalanine or tyrosine; and J is any amino acid, or optionally, a hydrophobic amino acid. This array is also abbreviated as: QSNR-QSSR-QTHR-RDKR. Other exemplary artificial polypeptides include:

15 CX<sub>(2-5)</sub>CXXXBXQXSSJXRHX<sub>(3-5)</sub>HX<sub>(1-6)</sub>BXCX<sub>(2-5)</sub>CXXXBXQXTHJXRHX<sub>(3-5)</sub>HX<sub>(1-6)</sub>BXCX<sub>(2-5)</sub>CXXXBXRDKJXRHX<sub>(3-5)</sub>H (SEQ ID NO:63); and

CX<sub>(2-5)</sub>CXXXBXQXSNJXRHX<sub>(3-5)</sub>HX<sub>(1-6)</sub>BXCX<sub>(2-5)</sub>CXXXBXQXSSJXRHX<sub>(3-5)</sub>HX<sub>(1-6)</sub>BXCX<sub>(2-5)</sub>CXXXBXQXTHJXRHX<sub>(3-5)</sub>H (SEQ ID NO:64).

20 The polypeptide can cause increased SEAP production for an SEAP protein encoded by a heterologous gene encoded operably linked to the CMV promoter. For example, the isolated polypeptide can include an amino acid sequence that is identical to the zinc finger array within SEQ ID NO:264 or that differs by no more than 8, 6, 4, 3, or 2 substitutions within the zinc finger domains present in SEQ ID NO:264. The substitutions can be conservative substitutions. The isolated polypeptide can have a

25 sequence that is at least 80, 85, 90, 95, or 97% identical to the zinc finger array within SEQ ID NO:264. In one embodiment, the polypeptide can specifically bind to a target DNA site. For example, the polypeptide can compete with the K13\_B08 chimeric ZFP (SEQ ID NO:264) for binding to a target DNA site, e.g., a site bound with a K<sub>d</sub> of less than 10 nM. The polypeptide can further include a transcriptional regulatory domain, e.g.,

30 an activation or repression domain. The polypeptide can include one, two, or three or more additional zinc finger domains.

Also featured are nucleic acids encoding the above polypeptides. For example, the isolated polypeptide that includes the amino acid of SEQ ID NO:264 can be encoded by a nucleic acid sequence that includes the sequence of SEQ ID NO:263. Featured nucleic acids can include operably linked regulatory sequences, e.g., a promoter sequence, an enhancer sequence, an insulator sequence, untranslated regulatory regions, a polyA addition site, and so forth. In one embodiment, the coding nucleic acid is operably linked to a conditional promoter such as an inducible promoter or a cell-type specific promoter. The nucleic acid can be included in a vector or integrated into a chromosome.

In addition, the invention features host cells (e.g., mammalian host cells) that include a nucleic acid described above. The host cell can include a nucleic acid described above and express the nucleic acid.

#### 10. **F104 p65 and Related Molecules**

In still another aspect, the invention features an artificial polypeptide that includes: the sequence:

$CX_{(2-5)}CXXXBXRDXHJXTHX_{(3-5)}HX_{(1-6)}BXCX_{(2-5)}CXXXBXRXSHJXRHX_{(3-5)}HX_{(1-6)}BXCX_{(2-5)}CXXXBXQXSHJXRHX_{(3-5)}H$  (SEQ ID NO:65),

where B is any amino acid, or optionally phenylalanine or tyrosine; and J is any amino acid, or optionally, a hydrophobic amino acid. This array is also abbreviated as: RDHT-RSHR-QSHR. Other exemplary artificial polypeptides include:

$CX_{(2-5)}CXXXBXRXSHJXRHX_{(3-5)}HX_{(1-6)}BXCX_{(2-5)}CXXXBXQXSHJXRHX_{(3-5)}H$  (SEQ ID NO:66); and

$CX_{(2-5)}CXXXBXRDXHJXTHX_{(3-5)}HX_{(1-6)}BXCX_{(2-5)}CXXXBXRXSHJXRHX_{(3-5)}H$  (SEQ ID NO:67).

For example, the isolated polypeptide can include an amino acid sequence that is identical to the zinc finger array within SEQ ID NO:18 or that differs by no more than 8, 6, 4, 3, or 2 substitutions within the zinc finger domains present in SEQ ID NO:18. The substitutions can be conservative substitutions. The isolated polypeptide can have a sequence that is at least 80, 85, 90, 95, or 97% identical to the zinc finger array within SEQ ID NO:18. In one embodiment, the polypeptide can specifically bind to a target DNA site. For example, the polypeptide can compete with the F104\_p65 chimeric ZFP

(SEQ ID NO:18) for binding to a target DNA site, e.g., a site bound with a  $K_d$  of less than 10 nM. The polypeptide can further include a transcriptional regulatory domain, e.g., an activation or repression domain. The polypeptide can include one, two, or three or more additional zinc finger domains.

5 Also featured are nucleic acids encoding the above polypeptides. For example, the isolated polypeptide that includes the amino acid of SEQ ID NO:18 can be encoded by a nucleic acid sequence that includes the sequence of SEQ ID NO:17. Featured nucleic acids can include operably linked regulatory sequences, e.g., a promoter sequence, an enhancer sequence, an insulator sequence, untranslated regulatory regions, a polyA  
10 addition site, and so forth. In one embodiment, the coding nucleic acid is operably linked to a conditional promoter such as an inducible promoter or a cell-type specific promoter. The nucleic acid can be included in a vector or integrated into a chromosome.

In addition, the invention features host cells (e.g., mammalian host cells) that include a nucleic acid described above. The host cell can include a nucleic acid described  
15 above and express the nucleic acid.

### **11. F121\_p65 and Related Molecules**

In still another aspect, the invention features an artificial polypeptide that includes: the sequence:

20  $CX_{(2-5)}CXXXBXQXSHJXTHX_{(3-5)}HX_{(1-6)}BXCX_{(2-5)}CXXXBXRXSHJXRHX_{(3-5)}HX_{(1-6)}BXCX_{(2-5)}CXXXBXRDXHJXTHX_{(3-5)}H$  (SEQ ID NO:68),

where B is any amino acid, or optionally phenylalanine or tyrosine; and J is any amino acid, or optionally, a hydrophobic amino acid. This array is also abbreviated as: QSHT-RSHR-RDHT. Other exemplary polypeptides include:

25  $CX_{(2-5)}CXXXBXRXSHJXRHX_{(3-5)}HX_{(1-6)}BXCX_{(2-5)}CXXXBXRDXHJXTHX_{(3-5)}H$  (SEQ ID NO:69); and

$CX_{(2-5)}CXXXBXQXSHJXTHX_{(3-5)}HX_{(1-6)}BXCX_{(2-5)}CXXXBXRXSHJXRHX_{(3-5)}H$  (SEQ ID NO:70).

For example, the isolated polypeptide can include an amino acid sequence that is  
30 identical to the zinc finger array within SEQ ID NO:20 or that differs by no more than 8, 6, 4, 3, or 2 substitutions within the zinc finger domains present in SEQ ID NO:20. The

substitutions can be conservative substitutions. The isolated polypeptide can have a sequence that is at least 80, 85, 90, 95, or 97% identical to the zinc finger array within SEQ ID NO:20. In one embodiment, the polypeptide can specifically bind to a target DNA site. For example, the polypeptide can compete with the F121\_p65 chimeric ZFP (SEQ ID NO:20) for binding to a target DNA site, e.g., a site bound with a  $K_d$  of less than 10 nM. The polypeptide can further include a transcriptional regulatory domain, e.g., an activation or repression domain. The polypeptide can include one, two, or three or more additional zinc finger domains. The polypeptide can be used, for example, to regulate expression of insulin-like growth factor 2.

Also featured are nucleic acids encoding the above polypeptides. For example, the isolated polypeptide that includes the amino acid of SEQ ID NO:20 can be encoded by a nucleic acid sequence that includes the sequence of SEQ ID NO:19. Featured nucleic acids can include operably linked regulatory sequences, e.g., a promoter sequence, an enhancer sequence, an insulator sequence, untranslated regulatory regions, a polyA addition site, and so forth. In one embodiment, the coding nucleic acid is operably linked to a conditional promoter such as an inducible promoter or a cell-type specific promoter. The nucleic acid can be included in a vector or integrated into a chromosome.

In addition, the invention features host cells (e.g., mammalian host cells) that include a nucleic acid described above. The host cell can include a nucleic acid described above and express the nucleic acid.

## **12. K44-11-D01 and K44-11-G12 and Related Molecules**

In still another aspect, the invention features an artificial polypeptide that includes: the sequence:

$CX_{(2-5)}CXXXBXQXSHJXVHX_{(3-5)}HX_{(1-6)}BXCX_{(2-5)}CXXXBXQXSNJXIHX_{(3-5)}HX_{(1-6)}BXCX_{(2-5)}CXXXBXQXTHJXRHX_{(3-5)}HX_{(1-6)}BXCX_{(2-5)}CXXXBXCXSNJXRHX_{(3-5)}H$  (SEQ ID NO:265),  
 $CX_{(2-5)}CXXXBXQXSHJXVHX_{(3-5)}HX_{(1-6)}BXCX_{(2-5)}CXXXBXVXSTJXRHX_{(3-5)}HX_{(1-6)}BXCX_{(2-5)}CXXXBXRDXDNJXQHXX_{(3-5)}HX_{(1-6)}BXCX_{(2-5)}CXXXBXQXTHJXRHX_{(3-5)}H$  (SEQ ID NO:266),

where B is any amino acid, or optionally phenylalanine or tyrosine; and J is any amino acid, or optionally, a hydrophobic amino acid. These arrays are also

abbreviated as: QSHV-SQNI-QTHR-CSNR and QSHV-VSTR-RDNQ-QTHR.

For example, the isolated polypeptide can include an amino acid sequence that is identical to the zinc finger array within SEQ ID NO:14 or 16 or that differs by no more than 8, 6, 4, 3, or 2 substitutions within the zinc finger domains present in SEQ ID NO:20.

5 The substitutions can be conservative substitutions. The isolated polypeptide can have a sequence that is at least 80, 85, 90, 95, or 97% identical to the zinc finger array within SEQ ID NO:14 or 16. In one embodiment, the polypeptide can specifically bind to a target DNA site. For example, the polypeptide can compete with the F121\_p65 chimeric ZFP (SEQ ID NO:14 or 16) for binding to a target DNA site, e.g., a site bound with a  $K_d$   
10 of less than 10 nM. The polypeptide can further include a transcriptional regulatory domain, e.g., an activation or repression domain. The polypeptide can include one, two, or three or more additional zinc finger domains. The polypeptide can be used, for example, to regulate protein production.

Also featured are nucleic acids encoding the above polypeptides. For example,  
15 the isolated polypeptide that includes the amino acid of SEQ ID NO:14 or 16 can be encoded by a nucleic acid sequence that includes the sequence of SEQ ID NO:13 or 15. Featured nucleic acids can include operably linked regulatory sequences, e.g., a promoter sequence, an enhancer sequence, an insulator sequence, untranslated regulatory regions, a polyA addition site, and so forth. In one embodiment, the coding nucleic acid is operably  
20 linked to a conditional promoter such as an inducible promoter or a cell-type specific promoter. The nucleic acid can be included in a vector or integrated into a chromosome.

In addition, the invention features host cells (e.g., mammalian host cells) that include a nucleic acid described above. The host cell can include a nucleic acid described above and express the nucleic acid.

25 \* \* \*

As used herein, the “dissociation constant” refers to the equilibrium dissociation constant of a polypeptide for binding to a 28-basepair double-stranded DNA that includes one 9-basepair target site. The dissociation constant is determined by gel shift analysis using a purified protein that is bound in 20 mM Tris pH 7.7, 120 mM NaCl, 5 mM  $MgCl_2$ ,  
30 20  $\mu M$   $ZnSO_4$ , 10% glycerol, 0.1% Nonidet P-40, 5 mM DTT, and 0.10 mg/mL BSA (bovine serum albumin) at room temperature. Additional details are provided in Example 10 and Rebar and Pabo (1994) *Science* 263:671-673.

As used herein, the term “screen” refers to a process for evaluating members of a library to find one or more particular members that have a given property. In a direct screen, each member of the library is evaluated. For example, each cell is evaluated to determine if it is extending neurites. In another type of screen, termed a “selection,” each member is not directly evaluated. Rather the evaluation is made by subjecting the members of the library to conditions in which only members having a particular property are retained. Selections may be mediated by survival (e.g., drug resistance) or binding to a surface (e.g., adhesion to a substrate). Such selective processes are encompassed by the term “screening.”

The term “base contacting positions,” “DNA contacting positions,” or “nucleic acid contacting positions” refers to the four amino acid positions of zinc finger domains that structurally correspond to the positions of amino acids arginine 73, aspartic acid 75, glutamic acid 76, and arginine 79 of ZIF268.

15	Glu	Arg	Pro	Tyr	Ala	Cys	Pro	Val	Glu	Ser	Cys	Asp	Arg	Arg	Phe	Ser
	1				5					10					15	
	Arg	Ser	Asp	Glu	Leu	Thr	Arg	His	Ile	Arg	Ile	His	Thr	Gly	Gln	Lys
				20					25					30		
	Pro	Phe	Gln	Cys	Arg	Ile	Cys	Met	Arg	Asn	Phe	Ser	Arg	Ser	Asp	His
20			35					40					45			
	Leu	Thr	Thr	His	Ile	Arg	Thr	His	Thr	Gly	Glu	Lys	Pro	Phe	Ala	Cys
			50				55					60				
	Asp	Ile	Cys	Gly	Arg	Lys	Phe	Ala	Arg	Ser	Asp	Glu	Arg	Lys	Arg	His
	65					70					75				80	
25	Thr	Lys	Ile	His	Leu	Arg	Gln	Lys	Asp	(SEQ ID NO:71)						
					85											

These positions are also referred to as positions -1, 2, 3, and 6, respectively. To identify positions in a query sequence that correspond to the base contacting positions, the query sequence is aligned to the zinc finger domain of interest such that the cysteine and histidine residues of the query sequence are aligned with those of finger 3 of Zif268. The ClustalW WWW Service at the European Bioinformatics Institute (Thompson *et al.* (1994) *Nucleic Acids Res.* 22:4673-4680) provides one convenient method of aligning sequences.

Conservative amino acid substitutions refer to the interchangeability of residues having similar side chains. For example, a group of amino acids having aliphatic side chains is glycine, alanine, valine, leucine, and isoleucine; a group of amino acids having aliphatic-hydroxyl side chains is serine and threonine; a group of amino acids having



amide-containing side chains is asparagine and glutamine; a group of amino acids having aromatic side chains is phenylalanine, tyrosine, and tryptophan; a group of amino acids having basic side chains is lysine, arginine, and histidine; a group of amino acids having acidic side chains is aspartic acid and glutamic acid; and a group of amino acids having sulfur-containing side chains is cysteine and methionine. Depending on circumstances, amino acids within the same group may be interchangeable. Some additional conservative amino acids substitution groups are: valine-leucine-isoleucine; phenylalanine-tyrosine; lysine-arginine; alanine-valine; aspartic acid-glutamic acid; and asparagine-glutamine.

10       The term “heterologous polypeptide” refers either to a polypeptide with a non-naturally occurring sequence (e.g., a hybrid polypeptide) or a polypeptide with a sequence identical to a naturally occurring polypeptide but present in a milieu in which it does not naturally occur.

15       The terms “hybrid” and “chimera” refer to a non-naturally occurring polypeptide that comprises amino acid sequences derived from either (i) at least two different naturally occurring sequences, or non-contiguous regions of the same naturally occurring sequence, wherein the non-contiguous regions are made contiguous in the hybrid; (ii) at least one artificial sequence (i.e., a sequence that does not occur naturally) and at least one naturally occurring sequence; or (iii) at least two artificial sequences (same or different). Examples of artificial sequences include mutants of a naturally occurring sequence and *de novo* designed sequences. An “artificial sequence” is not present among naturally occurring sequences. With respect to any artificial sequence (e.g., protein or nucleic acid) described herein, the invention also refers to a sequence with the same elements, but which is not presenting each of the following organisms whose genomes are sequenced: *Homo sapiens*, *Mus musculus*, *Arabidopsis thaliana*, *Drosophila melanogaster*, *Escherichia coli*, *Saccharomyces cerevisiae*, and *Oryza sativa*. A molecule with such a sequence can be expressed as a heterologous molecule in a cell of one of the aforementioned organisms.

25       The invention also includes sequences (not necessarily termed “artificial”) which are made by a method described herein, e.g., a method of joining nucleic acid sequences encoding different zinc finger domains or a method of phenotypic screening. The invention also features a cell that includes such a sequence.

As used herein, the term "hybridizes under stringent conditions" refers to conditions for hybridization in 6X sodium chloride/sodium citrate (SSC) at 45°C, followed by two washes in 0.2 X SSC, 0.1% SDS at 65°C.

The term "binding preference" refers to the discriminative property of a polypeptide for selecting one nucleic acid binding site relative to another. For example, when the polypeptide is limiting in quantity relative to two different nucleic acid binding sites, a greater amount of the polypeptide will bind the preferred site relative to the other site in an *in vivo* or *in vitro* assay described herein.

A "reference cell" refers to any standard cell. In one example, the reference cell is a parental cell for a cell that expresses a zinc finger protein, e.g., a cell that is substantially identical to the zinc finger protein expressing cell, but which does not produce the zinc finger protein.

Among other advantages, many of the methods and compositions relate to the identification and use of new and useful chimeric proteins, e.g., chimeric transcription factors. Some embodiments may include one or more of the following advantages:

- i) Endogenous genes can be either up- or down-regulated. Any given artificial chimeric transcription factor can be converted to transcriptional activator by fusing to appropriate transcriptional activation domains or to transcriptional repressor by fusing to repression domains. Moreover, even without a transcriptional regulatory domain, chimeric transcription factors can be potent repressors, e.g., when they bind to sites near the TATA box and the initiator element. Moreover, it is possible to screen a library that includes both activators and repressors with different DNA binding specificity.
- ii) Gene expression can be finely regulated. Depending on the DNA-binding affinity, chimeric transcription factors can cause a range of effects, e.g., moderate to strong activation and repression. This may lead to diverse phenotypes that are not necessarily obtained by completely inactivation or high level over-expressed of a particular target gene. For example, in some cases, broad specificity may be an advantage where the coordinated action of several genes is required to drive a desired phenotype. In other cases, narrow specificity is desired. One method for flexibly controlling specificity is by adding or removing zinc finger domains. 3-finger ZFPs theoretically regulate more genes than 6-finger ZFPs.
- iii) ZFP library approach is universally applicable. Since transcriptional regulatory mechanisms are highly conserved and because all known organism use DNA

and transcription for life, chimeric proteins that bind to DNA can be used to regulate any desired cell. Further, as described herein, many methods do not require a priori information (e.g., genome sequence) of the cell in order to identify useful chimeric proteins. iv) Artificial chimeric proteins can be used as a tool to dissect pathways within  
5 a cell. For example, target genes responsible for the phenotypic changes in selected clones can be identified, e.g., as described herein. v) A ZFP-TF may mimic the function of a master regulatory protein, such as a master regulatory transcription factor. For example, the ZFP-TF may bind to the same site as the master regulatory, or to an overlapping site. vi) The level of gene expression change, thus the extent of the  
10 phenotype generated by ZFP-TF, can be precisely controlled by altering the expression level of ZFP-TF in cells.

All patents, patent applications, and references cited herein are incorporated by reference in their entirety. The following patent applications: WO 01/60970 (Kim *et al.*); U.S. Serial No. 60/338,441, filed December 7, 2001; U.S. Serial No. 60/313,402, filed  
15 August 17, 2001; U.S. Serial No. 60/374,355, filed April 22, 2002; U.S. Serial No. 60/376,053, filed April 26, 2002; U.S. Serial No. 60/400,904, filed August 2, 2002; U.S. Serial No. 60/401,089, filed August 5, 2002; and U.S. Serial No. 10/223,765, filed August 19, 2002, are expressly incorporated by reference in their entirety for all purposes. The details of one or more embodiments of the invention are set forth in the accompa-  
20 nying drawings and the description below. Any feature described herein can be used in combination with another compatible feature also described herein. Other features, objects, and advantages of the invention will be apparent from the description and drawings, and from the claims.

25

## DESCRIPTION OF THE DRAWINGS

**FIG. 1** is a diagram of a region of the yeast plasmid pYTC-Lib.

**FIG. 2** is a schematic of an exemplary target-driven approach.

**FIG. 3A** is a schematic of a method for preparing an exemplary zinc finger  
protein library.

30

**FIG. 3B** is a schematic of an exemplary phenotype-driven approach.

**FIG. 4** depicts an expression profile of transiently transfected ZFPs. In the left panel, a cell expressing p65 activation domain alone is compared to a control. In the right panel, a cell expressing the zinc finger protein F121\_p65 is compared to a control. Each dot displaced from the diagonal represents a gene whose expression is substantially altered.

**FIG. 5** depicts expression profiles of stably transfected ZFPs.

**FIG. 6A** depicts the effects of DNA-binding domain mutants and effector domain alterations to the K5 ZFP on drug resistance.

**FIG. 6B** depicts the effects of K5 and YLL053C overexpression.

**FIG. 7** depicts one method of constructing a diverse three finger library.

**FIG. 8** is a photograph of control and ZFP-expressing cells in which neurite formation is induced. **FIG. 8A.** pcDNA3(empty vector)-transfected Neuro2A cells without retinoic acid (RA) treatment. **FIG. 8B.** Neuro1-p65 (also called 08\_D01-65) expression without RA treatment. **FIG. 8C.** pcDNA3(empty vector)-transfected Neuro2A cells with 10  $\mu$ M RA. **FIG. 8D.** Neuro1-p65 expression with 10  $\mu$ M RA.

**FIG. 9** depicts comparative microarray data for cells in which the insulin gene is over-expressed. The chimeric ZFP is 08\_D04-p65. The sequence of which is listed in FIG. 16.

**FIG. 10A** is a truncated table listing ZFP DNA binding specificities.

**FIG. 10B** is a schematic illustrating the correspondence between zinc finger domains and the recognition site sequence.

**FIG. 11** is a flowchart for a method of identifying targets of artificial ZFPs.

**FIG. 12** is a schematic of a method of identifying ZFPs that induce differentiation.

**FIG. 13** depicts comparative microarray data at various time points for cells in which the F104-p65 ZFP is present.

**FIG. 14** lists the coding nucleic acid (SEQ ID NO:1) and amino acid (SEQ ID NO:2) sequences for Neuro1-p65, a protein that can induce neurites. Neuro1-p65 includes the zinc finger domains QSNR1-QSNK-CSNR1 and the p65 activation domain. Other artificial proteins with at least two or three consecutive zinc finger domains that have the same pattern of DNA contacting residues as domains in QSNR1-QSNK-CSNR1-p65 may also induce neurites.

**FIG. 15** lists the coding nucleic acid (SEQ ID NO:3) and amino acid (SEQ ID NO:4) sequences for Osteo1-p65, a protein that can induce osteocytes. Osteo1-p65 includes the zinc finger domains RDKR-QTHR1-VSTR-RDKR and the p65 activation domain. Other artificial proteins with at least two or three consecutive zinc finger domains that have the same pattern of DNA contacting residues as domains in RDKR-QTHR1-VSTR-RDKR-p65 may also induce osteocytes.

**FIG. 16** lists the coding nucleic acid (SEQ ID NO:5) and amino acid (SEQ ID NO:6) sequences for 08\_D04\_p65, a protein that can enhance insulin production (See FIG. 9). 08\_D04\_p65 includes the zinc finger domains RSHR-RDHT-VSSR and the p65 activation domain. Other artificial proteins with at least two or three consecutive zinc finger domains that have the same pattern of DNA contacting residues as domains in RSHR-RDHT-VSSR may also enhance insulin production.

**FIG. 17** lists the coding nucleic acid (SEQ ID NO:7) and amino acid (SEQ ID NO:8) sequences for P\_B08, a protein that can enhance SV40-SEAP. P\_B08 includes the zinc finger domains QSNR1-DSNR-DSNR and the p65 activation domain. Other artificial proteins with at least two or three consecutive zinc finger domains that have the same pattern of DNA contacting residues as domains in QSNR1-DSNR-DSNR may also enhance SV40-SEAP.

**FIG. 18** lists the coding nucleic acid (SEQ ID NO:9) and amino acid (SEQ ID NO:10) sequences for K\_D10, a protein that can decrease cell proliferation. K\_D10 includes the zinc finger domains QSHV-WSNR-WSNR-RDNQ and the kid repression domain. Other artificial proteins with at least two or three consecutive zinc finger domains that have the same pattern of DNA contacting residues as domains in QSHV-WSNR-WSNR-RDNQ may also decrease cell proliferation.

**FIG. 19** lists the coding nucleic acid (SEQ ID NO:11) and amino acid (SEQ ID NO:12) sequences for K\_F02, a protein that can enhance cell proliferation. K\_F02 includes the zinc finger domains DSAR2-RDKR-RDER1-QHR1 and the kid repression domain. Other artificial proteins with at least two or three consecutive zinc finger domains that have the same pattern of DNA contacting residues as domains in DSAR2-RDKR-RDER1-QHR1-kid may also enhance cell proliferation.

**FIG. 20** lists the coding nucleic acid (SEQ ID NO:13) and amino acid (SEQ ID NO:14) sequences for K44\_11\_D01, a protein that can enhance protein expression.

K44\_11\_D01 includes the zinc finger domains QSHV-QSNI-QTHR1-CSNR1 and the kid repression domain. Other artificial proteins with at least two or three consecutive zinc finger domains that have the same pattern of DNA contacting residues as domains in QSHV-QSNI-QTHR1-CSNR1 may also enhance protein expression.

5       **FIG. 21** lists the coding nucleic acid (SEQ ID NO:15) and amino acid (SEQ ID NO:16) sequences for K44-11-G12, a protein that can enhance protein expression. K44-11-G12 includes the zinc finger domains QSHV-VSTR-RDNQ-QTHR1 and the kid repression domain. Other artificial proteins with at least two or three consecutive zinc finger domains that have the same pattern of DNA contacting residues as domains in  
10       QSHV-VSTR-RDNQ-QTHR1 may also enhance protein expression.

**FIG. 22** lists the coding nucleic acid (SEQ ID NO:17) and amino acid (SEQ ID NO:18) sequences for F104\_p65. F104\_p65 includes the zinc finger domains RDHT-RSHR-QSHR2-p65.

**FIG. 23** lists the coding nucleic acid (SEQ ID NO:19) and amino acid (SEQ ID  
15       NO:20) sequences for F121\_p65. F121\_p65 includes the zinc finger domains QSHT-RSHR-RDHT-p65. Other artificial proteins with at least two or three consecutive zinc finger domains that have the same pattern of DNA contacting residues as domains in QSHT-RSHR-RDHT may also increase transcription of insulin-like growth factor 2

**FIG. 24** lists the coding nucleic acid (SEQ ID NO:259) and amino acid (SEQ ID  
20       NO:260) sequences for K12\_A11, which includes the zinc finger domains RDHT-QSNV2-QTHR1-QFNR-kid.

**FIG. 25** lists the coding nucleic acid (SEQ ID NO:261) and amino acid (SEQ ID NO:262) sequences for K44-16-E12, which includes the zinc finger domains QSHV-QSSR1-QTHR1-kid.

25       **FIG. 26** lists the coding nucleic acid (SEQ ID NO:263) and amino acid (SEQ ID NO:264) sequences for K13\_B08, which includes the zinc finger domains QSNR1-QSSR1-QTHR1-RDKR-KID.

      DNA sequences in the FIGs. 14 to 26 can include a sequence encoding a HA tag (gray underlined), and a sequence encoding a nuclear localization signal (boxed). The  
30       initiation and stop codons are underlined. The shaded letters indicate sequences encoding a regulatory domain, e.g., a p65 or kid domain. The small letters indicated the linker sequences. With respect to the amino acid sequences, italicized and shaded letters

indicate zinc finger domains and shaded letters, not italicized indicate a regulatory domain, e.g., a Kid or p65 domain.

DNA sequences in the FIGs. 14 to 24 include a sequence encoding a HA tag (gray underlined), and a sequence encoding a nuclear localization signal (boxed). The initiation and stop codons are underlined. The shaded letters indicate sequences encoding a regulatory domain, e.g., a p65 or kid domain. The small letters indicated the linker sequences. With respect to the amino acid sequences, italicized and shaded letters indicate zinc finger domains and shaded letters, not italicized indicate a regulatory domain, e.g., a Kid or p65 domain.

10

## DETAILED DESCRIPTION

In one aspect of the invention, a library of nucleic acids that encode different artificial, chimeric proteins is screened to identify a chimeric protein that alters a phenotypic trait of a cell or organism. The chimeric protein can be identified without *a priori* knowledge of a particular target gene or pathway.

In one example, each nucleic acid of the library encodes an artificial polypeptide that includes a plurality of zinc finger domains. A nucleic acid library that encodes different chimeric proteins can be prepared, for example, as described in the sections below. Members of the library are introduced into cells in culture or cells in an organism. After an interval to allow for expression of the encoded polypeptides, cells or organisms which have an altered phenotypic trait are identified. The library nucleic acid in at least one of these phenotypically altered cells is recovered, thus identifying an artificial chimeric polypeptide that produces the phenotypic effect.

Although this method is generally described below in the context of chimeras of zinc finger domains, it is easily adapted to other structural domains, including other DNA binding domains and cell signaling domains.

### **Library Construction: 1. Exemplary Structural Domains**

The nucleic acid library is constructed so that it includes nucleic acids that each encode and can express an artificial protein that is a chimera of one or more structural domains. In some aspects, the structural domains are nucleic acid binding domains that

30

vary in specificity such that the library encodes a population of proteins with different binding specificities.

A variety of structural domains are known to bind nucleic acids with high affinity and high specificity. For reviews of structural motifs which recognize double stranded  
 5 DNA, see, e.g., Pabo and Sauer (1992) *Annu. Rev. Biochem.* 61:1053-95; Patikoglou and Burley (1997) *Annu. Rev. Biophys. Biomol. Struct.* 26:289-325; Nelson (1995) *Curr Opin Genet Dev.* 5:180-9. A few non-limiting examples of nucleic acid binding domains include:

**Zinc fingers.** Zinc fingers are small polypeptide domains of approximately  
 10 30 amino acid residues in which there are four amino acids, either cysteine or histidine, appropriately spaced such that they can coordinate a zinc ion (For reviews, see, e.g., Klug and Rhodes, (1987) *Trends Biochem. Sci.* 12:464-469(1987); Evans and Hollenberg, (1988) *Cell* 52:1-3; Payre and Vincent, (1988) *FEBS Lett.* 234:245-250; Miller *et al.*, (1985) *EMBO J.* 4:1609-1614; Berg, (1988) *Proc. Natl. Acad. Sci. U.S.A.* 85:99-102;  
 15 Rosenfeld and Margalit, (1993) *J. Biomol. Struct. Dyn.* 11:557-570). Hence, zinc finger domains can be categorized according to the identity of the residues that coordinate the zinc ion, e.g., as the Cys<sub>2</sub>-His<sub>2</sub> class, the Cys<sub>2</sub>-Cys<sub>2</sub> class, the Cys<sub>2</sub>-CysHis class, and so forth. The zinc coordinating residues of Cys<sub>2</sub>-His<sub>2</sub> zinc fingers are typically spaced as follows: X<sub>a</sub>-X-C-X<sub>2-5</sub>-C-X<sub>3</sub>-X<sub>a</sub>-X<sub>5</sub>-ψ-X<sub>2</sub>-H-X<sub>3-5</sub>-H (SEQ ID NO:72), where ψ (psi) is a  
 20 hydrophobic residue (Wolfe *et al.*, (1999) *Annu. Rev. Biophys. Biomol. Struct.* 3:183-212), wherein "X" represents any amino acid, wherein X<sub>a</sub> is phenylalanine or tyrosine, the subscript indicates the number of amino acids, and a subscript with two hyphenated numbers indicates a typical range of intervening amino acids. Typically, the intervening amino acids fold to form an anti-parallel β-sheet that packs against an α-helix, although  
 25 the anti-parallel β-sheets can be short, non-ideal, or non-existent. The fold positions the zinc-coordinating side chains so they are in a tetrahedral conformation appropriate for coordinating the zinc ion. The base contacting residues are at the N-terminus of the finger and in the preceding loop region.

For convenience, the primary DNA contacting residues of a zinc finger domain  
 30 are numbered: -1, 2, 3, and 6 based on the following example:



-1 1 2 3 4 5 6

$X_a-X-C-X_{2-5}-C-X_3-X_a-X-C-X-S-N-X_b-X-R-H-X_{3-5}-H$  (SEQ ID NO: 73) ,

where  $X_a$  is typically phenylalanine or tyrosine, and  $X_b$  is typically a hydrophobic residue. As noted in the example above, the DNA contacting residues are Cys (C), Ser (S), Asn (N), and Arg (R). The above motif can be abbreviated CSNR. As used herein, such abbreviation refers to a class of sequences which include a domain corresponding to the motif. The class also includes a species whose sequence includes a particular polypeptide sequence, typically a sequence listed in Table 1 or 2 which corresponds to the motif. Where two sequences have the same motif, a number may be used to indicate the sequence.

A zinc finger protein typically consists of a tandem array of three or more zinc finger domains. For example, zinc finger domains whose motifs are listed consecutively are not interspersed with other folded domains, but may include a linker, e.g., a flexible linker described herein between domains.

The zinc finger domain (or "ZFD") is one of the most common eukaryotic DNA-binding motifs, found in species from yeast to higher plants and to humans. By one estimate, there are at least several thousand zinc finger domains in the human genome alone, possibly at least 4,500. Zinc finger domains can be isolated from zinc finger proteins. Non-limiting examples of zinc finger proteins include CF2-II, Kruppel, WT1, basonuclin, BCL-6/LAZ-3, erythroid Kruppel-like transcription factor, Sp1, Sp2, Sp3, Sp4, transcriptional repressor YY1, EGR1/Krox24, EGR2/Krox20, EGR3/Pilot, EGR4/AT133, Evi-1, GLI1, GLI2, GLI3, HIV-EP1/ZNF40, HIV-EP2, KR1, ZfX, ZfY, and ZNF7.

Computational methods described below can be used to identify all zinc finger domains encoded in a sequenced genome or in a nucleic acid database. Any such zinc finger domain can be utilized. In addition, artificial zinc finger domains have been designed, e.g., using computational methods (e.g., Dahiyat and Mayo, (1997) *Science* 278:82-7).

It is also noteworthy that at least some zinc finger domains bind to ligands other than DNA, e.g., RNA or protein. Thus, a chimera of zinc finger domains or of a zinc finger domain and another type of domain can be used to recognize a variety of target

compounds, not just DNA.

WO 01/60970, U.S. Serial No. 60/374,355, filed April 22, 2002, and U.S. Serial No. 10/223,765, filed August 19, 2002, describe exemplary zinc finger domains which can be used to construct an artificial zinc finger protein. See also the Table 1, below.

- 5       **Homeodomains.** Homeodomains are eukaryotic domains that consist of a N-terminal arm that contacts the DNA minor groove, followed by three  $\alpha$ -helices that contact the major groove (for a review, see, e.g., Laughon, (1991) *Biochemistry* 30:11357-67). The third  $\alpha$ -helix is positioned in the major groove and contains critical DNA-contacting side chains. Homeodomains have a characteristic highly-conserved motif
- 10       present at the turn leading into the third  $\alpha$ -helix. The motif includes an invariant tryptophan that packs into the hydrophobic core of the domain. This motif is represented in the Prosite database as PDOC00027 ([L/I/V/M/F/Y/G]-[A/S/L/V/R]-X(2)-[L/I/V/M/S/T/A/C/N]-X-[L/I/V/M]-X(4)-[L/I/V]-[R/K/N/Q/E/S/T/A/I/Y]-[L/I/V/F/S/T/N/K/H]-W-[F/Y/V/C]-X-[N/D/Q/T/A/H]-X(5)-[R/K/N/A/I/M/W].
- 15       Homeodomains are commonly found in transcription factors that determine cell identity and provide positional information during organismal development. Such classical homeodomains can be found in the genome in clusters such that the order of the homeodomains in the cluster approximately corresponds to their expression pattern along a body axis. Homeodomains can be identified by alignment with a homeodomain, e.g.,
- 20       Hox-1, or by alignment with a homeodomain profile or a homeodomain hidden Markov Model (HMM; see below), e.g., PF00046 of the Pfam database or "HOX" of the SMART database, or by the Prosite motif PDOC00027 as mentioned above.

- Helix-turn-helix proteins.** This DNA binding motif is common among many prokaryotic transcription factors. There are many subfamilies, e.g., the LacI family, the
- 25       AraC family, to name but a few. The two helices in the name refer to a first  $\alpha$ -helix that packs against and positions a second  $\alpha$ -helix in the major groove of DNA. These domains can be identified by alignment with a HMM, e.g., HTH\_ARAC, HTH\_ARSR, HTH\_ASNC, HTH\_CRP, HTH\_DEOR, HTH\_DTXR, HTH\_GNTR, HTH\_ICLR, HTH\_LACI, HTH\_LUXR, HTH\_MARR, HTH\_MERR, and HTH\_XRE profiles
- 30       available in the SMART database.

**Library Construction: 2. Identification of Structural Domains**

A variety of methods can be used to identify structural domains. Nucleic acids encoding identified domains are used to construct the nucleic acid library. Further, nucleic acid encoding these domains can also be varied (e.g., mutated) to provide additional domains that are encoded by the library.

**Computational Methods.** To identify additional naturally-occurring structural domains, the amino acid sequence of a known structural domain can be compared to a database of known sequences, e.g., an annotated database of protein or nucleic acid sequences. In another implementation, databases of uncharacterized sequences, e.g., unannotated genomic, EST or full-length cDNA sequence; of characterized sequences, e.g., SwissProt or PDB; and of domains, e.g., Pfam, ProDom (Corpet *et al.* (2000) *Nucleic Acids Res.* 28:267-269), and SMART (Simple Modular Architecture Research Tool, Letunic *et al.* (2002) *Nucleic Acids Res* 30, 242-244) can provide a source of structural domain sequences. Nucleic acid sequence databases can be translated in all six reading frames for the purpose of comparison to a query amino acid sequence. Nucleic acid sequences that are flagged as encoding candidate nucleic acid binding domains can be amplified from an appropriate nucleic acid source, e.g., genomic DNA or cellular RNA. Such nucleic acid sequences can be cloned into an expression vector. The procedures for computer-based domain identification can be interfaced with an oligonucleotide synthesizer and robotic systems to produce nucleic acids encoding the domains in a high-throughput platform. Cloned nucleic acids encoding the candidate domains can also be stored in a host expression vector and shuttled easily into an expression vector, e.g., into a translational fusion vector with other domains (of a similar or different type), either by restriction enzyme mediated subcloning or by site-specific, recombinase mediated subcloning (see U.S. Patent No. 5,888,732). The high-throughput platform can be used to generate multiple microtitre plates containing nucleic acids encoding different candidate chimeras.

Detailed methods for the identification of domains from a starting sequence or a profile are well known in the art. See, for example, Prosite (Hofmann *et al.*, (1999) *Nucleic Acids Res.* 27:215-219), FASTA, BLAST (Altschul *et al.*, (1990) *J. Mol. Biol.* 215:403-10.), etc. A simple string search can be done to find amino acid sequences with identity to a query sequence or a query profile, e.g., using Perl to scan text files.

Sequences so identified can be about 30%, 40%, 50%, 60%, 70%, 80%, 90%, or greater identical to an initial input sequence.

Domains similar to a query domain can be identified from a public database, e.g., using the XBLAST programs (version 2.0) of Altschul *et al.*, (1990) *J. Mol. Biol.*

5 215:403-10. For example, BLAST protein searches can be performed with the XBLAST parameters as follows: score = 50, wordlength = 3. Gaps can be introduced into the query or searched sequence as described in Altschul *et al.*, (1997) *Nucleic Acids Res.* 25(17):3389-3402. Default parameters for XBLAST and Gapped BLAST programs are available at National Center for Biotechnology Information (NCBI), National Institutes of Health, Bethesda MD.

The Prosite profiles PS00028 and PS50157 can be used to identify zinc finger domains. In a SWISSPROT release of 80,000 protein sequences, these profiles detected 3189 and 2316 zinc finger domains, respectively. Profiles can be constructed from a multiple sequence alignment of related proteins by a variety of different techniques.

15 Gribskov and co-workers (Gribskov *et al.*, (1990) *Meth. Enzymol.* 183:146-159) utilized a symbol comparison table to convert a multiple sequence alignment supplied with residue frequency distributions into weights for each position. See, for example, the PROSITE database and the work of Luethy *et al.*, (1994) *Protein Sci.* 3:139-1465.

Hidden Markov Models (HMM's) representing a DNA binding domain of interest  
20 can be generated or obtained from a database of such models, e.g., the Pfam database, release 2.1. A database can be searched, e.g., using the default parameters, with the HMM in order to find additional domains (see, e.g., Bateman *et al.* (2002) *Nucleic Acids Research* 30:276-280). Alternatively, the user can optimize the parameters. A threshold score can be selected to filter the database of sequences such that sequences that score  
25 above the threshold are displayed as candidate domains. A description of the Pfam database can be found in Sonhammer *et al.*, (1997) *Proteins* 28(3):405-420, and a detailed description of HMMs can be found, for example, in Gribskov *et al.*, (1990) *Meth. Enzymol.* 183:146-159; Gribskov *et al.*, (1987) *Proc. Natl. Acad. Sci. USA* 84:4355-4358; Krogh *et al.*, (1994) *J. Mol. Biol.* 235:1501-1531; and Stultz *et al.*, (1993) *Protein Sci.*  
30 2:305-314.

The SMART database of HMM's (Simple Modular Architecture Research Tool, Schultz *et al.*, (1998) *Proc. Natl. Acad. Sci. USA* 95:5857 and Schultz *et al.*, (2000) *Nucl.*

*Acids Res* 28:231) provides a catalog of zinc finger domains (ZnF\_C2H2; ZnF\_C2C2; ZnF\_C2HC; ZnF\_C3H1; ZnF\_C4; ZnF\_CHCC; ZnF\_GATA; and ZnF\_NFX) identified by profiling with the hidden Markov models of the HMMer2 search program (Durbin *et al.*, (1998) *Biological sequence analysis: probabilistic models of proteins and nucleic acids*. Cambridge University Press).

**Hybridization-based Methods.** A collection of nucleic acids encoding various forms of a structural domain can be analyzed to profile sequences encoding conserved amino- and carboxy-terminal boundary sequences. Degenerate oligonucleotides can be designed to hybridize to sequences encoding such conserved boundary sequences. Moreover, the efficacy of such degenerate oligonucleotides can be estimated by comparing their composition to the frequency of possible annealing sites in known genomic sequences. If desired, multiple rounds of design can be used to optimize the degenerate oligonucleotides.

Comparison of known Cys<sub>2</sub>-His<sub>2</sub> zinc fingers, for example, revealed a common sequence in the linker region between adjacent fingers in natural sequence (Agata *et al.*, (1998) *Gene* 213:55-64). Degenerate oligonucleotides that anneal to nucleic acid encoding the conserved linker region were used to amplify a plurality of zinc finger domains. The amplified nucleic acid encoding the domains can be used to construct nucleic acids that encode a chimeric array of zinc fingers.

### **Library Construction: 3. Nucleic Acids Encoding Structural Domains**

Nucleic acids that are used to assemble the library can be obtained by a variety of methods. Some component nucleic acids of the library can encode naturally occurring domains. In addition, some component nucleic acids are variants that are obtained by mutation or other randomization methods. The component nucleic acids, typically encoding just a single domain, can be joined to each other to produce nucleic acids encoding a fusion of the different domains.

**Isolation of a natural repertoire of domains.** A library of domains can be constructed by isolation of nucleic acid sequences encoding domains from genomic DNA or cDNA of eukaryotic organisms such as humans. Multiple methods are available for doing this. For example, a computer search of available amino acid sequences can be used to identify the domains, as described above. A nucleic acid encoding each domain

can be isolated and inserted into a vector appropriate for the expression in cells, e.g., a vector containing a promoter, an activation domain, and a selectable marker. In another example, degenerate oligonucleotides that hybridize to a conserved motif are used to amplify, e.g., by PCR, a large number of related domains containing the motif. For example, Kruppel-like Cys<sub>2</sub>His<sub>2</sub> zinc fingers can be amplified by the method of Agata *et al.*, (1998) *Gene* 213:55-64. This method also maintains the naturally occurring zinc finger domain linker peptide sequences, e.g., sequences with the pattern: Thr-Gly-(Glu/Gln)-(Lys/Arg)-Pro-(Tyr/Phe) (SEQ ID NO:74). Moreover, screening a collection limited to domains of interest, unlike screening a library of unselected genomic or cDNA sequences, significantly decreases library complexity and reduces the likelihood of missing a desirable sequence due to the inherent difficulty of completely screening large libraries.

The human genome contains numerous zinc finger domains, many of which are uncharacterized and unidentified. It is estimated that there are thousands of genes encoding proteins with zinc finger domains (Pellegrino and Berg, (1991) *Proc. Natl. Acad. Sci. USA* 88:671-675). These human zinc finger domains represent an extensive collection of diverse domains from which novel DNA-binding proteins can be constructed. Many exemplary human zinc finger domains are described in WO 01/60970, U.S. Serial No. 60/374,355, filed April 22, 2002, and U.S. Serial No. 10/223,765, filed August 19, 2002. See also Table 1 below.

Table 1.

ZFD	Amino acid sequence	SEQ ID NO:	Target subsite(s)
CSNR1	YKCKQCGKAFGCPSNLRRHGRTH	75	GAA>GAC>GAG
CSNR2	YQCNICGKCFSCNSNLHRHQORTH	76	GAA>GAC>GAG
DSAR	YSCGICGKSFSDDSSAKRRHCILH	77	GTC
DSCR	YTCSDCGKAFRDKSCLNRHRRTH	78	GCC
HSNK	YKCKECGKAFFNHSSNFNKHHRTH	79	GAC
HSSR	FKCPVCGKAFFRHSSSLVRHQORTH	80	GTT
ISNR	YRCKYCDRSFSISSNLQRHVNRTH	81	GAA>GAT>GAC
ISNV	YECDDHCGKAFFSIGSNLNVHRRTH	82	AAT
KSNR	YGCHLCGKAFFSKSSNLRRHEMTH	83	GAG
QAHR	YKCKECGQAFFRQRAHLIRHHKLH	84	GGA
QFNR	YKCHQCGKAFFIQSFNLRRHERTH	85	GAG
QGNR	FQCNQCGASFTQKGNLLRHIKLH	86	GAA

QSHR1	YACHLCGKAFTQSSHLRRHEKTH	87	GGA>GAA>AGA
QSHR2	YKCGQCGKFYSQVSHLTRHQKIH	88	GGA
QSHR3	YACHLCGKAFTQCSHLRRHEKTH	89	GGA>GAA
QSHR4	YACHLCAKAFIQCSHLRRHEKTH	90	GGA>GAA
QSHR5	YVCRECGRGFRQSHSLVRHKRTH	91	GGA>AGA>GAA>CGA
QSHT	YKCEECGKAFTQSSHLTTHKIIH	92	AGA, CGA>TGA>GGA
QSHV	YECDHCGKSFSQSSHLNVHKRTH	93	CGA>AGA>TGA
QSN1	YMCSECGRGFSQKSNLIIHQRT	94	AAA, CAA
QSNK	YKCEECGKAFTQSSNLTTHKKIH	95	GAA>TAA>AAA
QSNR1	FECKDCGKAFTQKSNLIRHQRT	96	GAA
QSNR2	YVCRECRRGFSQKSNLIRHQRT	97	GAA
QSNR3	YECEKCGKAFNQSSNLTTRHKKSH	98	GAA
QSNV1	YECNTCRKTFQKSNLIVHQRT	99	AAA>CAA
QSNV2	YVCSKCGKAFTQSSNLTVHQKIH	100	AAA>CAA
QSNV3	YKCDECGKNFTQSSNLTIVHKRIH	101	AAA
QSNV4	YECDVCGKTFTQKSNLGVHQRT	102	AAA
QSNT	YECVQCGKGFTQSSNLTIVHQRVH	103	AAA
QSSR1	YKCPDCGKSFSQSSSLIRHQRT	104	GTA>GCA
QSSR2	YECQDCGRAFNQSSSLGRHKRTH	105	GTA
QSSR3	YECNECGKFFSQSSSLIRHRRSH	106	GTA>GCA
QSTR	YKCEECGKAFTQSSSLTRHKIVH	107	GTA>GCA
QSTV	YECNECGKAFAQNSTLRVHQRIH	108	ACA
QTHQ	YECDHCGKSFRQSTHLTQHRRIH	109	AGA>CGA, TGA
QTHR1	YECDHCGKSFRQSTHLTRHRRIH	110	GGA>AGA, GAA
QTHR2	HKCLECGKCFQNTHLTRHQRT	111	GGA
RDER1	YVCDVEGCTWKFARSDENRHKKRH	112	GCG>GTG, GAC
RDER2	YHCDWDGCGWKFARSDENRHKKRH	113	GCG>GTG
RDER3	YRCSWEGCEWRFARSDENRHKKRH	114	GCG>GTG
RDER4	FSCSWKGCERRFARSDENRHKKRH	115	GCG>GTG
RDER5	FACSWQDCNKKFARSDENRHKKRH	116	GCG
RDER6	YHCNWDGCGWKFARSDENRHKKRH	117	GCG>GTG
RDHR1	FLCQYCAQRFGRKDHLTRHMKKSH	118	GAG, GGG
RDHT	FQCKTCQRKFSRSDHLKTHTRTH	119	AGG, CGG, GGG, TGG
RDK1	FACEVCGVRFTRNDKLKIHMRKH	120	GGG
RDKR	YVCDVEGCTWKFARSDENRHKKRH	121	GGG>AGG
RSHR	YKMECGKAFNRSHLTRHQRIH	122	GGG
RSNR	YICRKCGRGFSRKSNIIRHQRT	123	GAG>GTG
RTNR	YLCSECDKCFSRSTNIIRHRRTH	124	GAG
SSNR	YECKECGKAFTSSGSNFTRHQRIH	125	GAG>GAC
VSNV	YECDHCGKAFTSVSSNLTNVHRRIH	126	AAT>CAT>TAT
VSSR	YTCKQCGKAFTSVSSSLRRHETTH	127	GTT>GTG>GTA
VSTR	YECNYCGKTFVSSTLIRHQRIH	128	GCT>GCG
WSNR	YRCEECGKAFTWPSNLTTRHKRIH	129	GGT>GGA

If each zinc finger domain recognizes a unique 3- to 4-bp sequence, the total number of domains required to bind every possible 3- to 4-bp sequence is only 64 to 256

(4<sup>3</sup> to 4<sup>4</sup>). It is possible that the natural repertoire of the human genome contains a sufficient number of unique zinc finger domains to span all possible recognition sites. These zinc finger domains are a valuable resource for constructing artificial chimeric DNA-binding proteins. A nucleic acid library can include nucleic acids encoding proteins  
5 that include naturally occurring zinc finger domains, artificial mutants of such domains, and combinations thereof.

**Mutated Domains.** In one implementation, the library includes nucleic acids encoding at least one structural domain that is an artificial variant of a naturally-occurring sequence. In one embodiment, such variant domains are assembled from a degenerate  
10 patterned library. In the case of a nucleic acid binding domains, positions in close proximity to the nucleic acid binding interface or adjacent to a position so located can be targeted for mutagenesis. A mutated test zinc finger domain, for example, can be constrained at any mutated position to a subset of possible amino acids by using a patterned degenerate library. Degenerate codon sets can be used to encode the profile at  
15 each position. For example, codon sets are available that encode only hydrophobic residues, aliphatic residues, or hydrophilic residues. The library can be selected for full-length clones that encode folded polypeptides. Cho *et al.* ((2000) *J. Mol. Biol.* 297(2):309-19) provides a method for producing such degenerate libraries using degenerate oligonucleotides, and also provides a method of selecting library nucleic acids  
20 that encode full-length polypeptides. Such nucleic acids can be easily inserted into an expression plasmid, e.g., using convenient restriction enzyme cleavage sites.

Selection of the appropriate codons and the relative proportions of each nucleotide at a given position can be determined by simple examination of a table representing the genetic code, or by computational algorithms. For example, Cho *et al.*,  
25 *supra*, describe a computer program that accepts a desired profile of protein sequence and outputs a preferred oligonucleotide design that encodes the sequence.

See also Zhang *et al.*, (2000) *J. Biol. Chem.* 275:33850-33860; Rebar and Pabo (1994) *Science* 263:671-673; Segal (1999) *Proc. Natl. Acad. Sci. USA* 96:2758; Gogus *et al.*, (1996) *Proc. Natl. Acad. Sci. USA*. 93:2159-2164; Drier *et al.*, (2001) *J. Biol. Chem.*  
30 276: 29466-29478; Liu *et al.* (2001) *J. Biol. Chem.* 276(14):11323-11334; and Hsu *et al.*, (1992) *Science* 257:1946-50 for some available zinc finger domains.



**Library Construction: 4. A Library of Chimeric Zinc Finger Proteins**

A library of nucleic acids encoding diverse chimeric zinc finger proteins can be formed by serial ligation, e.g., as described in Example 1. The library can be constructed such that each nucleic acid encodes a protein that has at least three, four, or five zinc finger domains. In some implementations, particularly for large libraries, each zinc finger coding segment can be designed to randomly encode any one of a set of zinc finger domains. The set of zinc finger domains can be selected to represent domains with a range of specificities, e.g., covering 30, 40, 50 or more of the 64 possible 3-basepair subsites. The set can include at least about 12, 15, 20, 25, 30, 40 or 50 different zinc finger domains. Some or all of these domains can be domains isolated from naturally occurring proteins. Moreover, because there may be little or no need for more than one zinc finger domain for a given 3-basepair subsite, it may be possible to generate a library using a small number of component domains, e.g., less than 500, 200, 100, or even less than 64 total component domains.

One exemplary library includes nucleic acids that encode a chimeric zinc finger protein having three fingers and 30 possible domains at each finger position. In its fully represented form, this library includes 27,000 sequences (i.e., the result of  $30^3$ ). The library can be constructed by serial ligation in which a nucleic acid from a pool of nucleic acids encoding all 30 possible domains is added at each step.

In one embodiment, the library can be stored as a random collection. In another embodiment, individual members can be isolated, stored at an addressable location (e.g., arrayed), and sequenced. After high throughput sequencing of 40 to 50 thousand constructed library members, missing chimeric combinations can be individually assembled in order to obtain complete coverage. Once arrayed, e.g., in microtitre plates, each individual member can be recovered later for further analysis, e.g., for a phenotypic screen. For example, equal amounts of each arrayed member can be pooled and then transformed into a cell. Cells with a desired phenotype are selected and characterized. In another example, each member is individually transformed into a cell, and the cell is characterized, e.g., using a nucleic acid microarray to determine if the transcription of endogenous genes is altered (see "Profiling Regulatory Properties of a Chimeric Zinc Finger Protein," below).

### Introducing Nucleic Acid Libraries into Cells

Library nucleic acids can be introduced into cells by a variety of methods. In one example, the library is stored as a random pool including multiple replicates of each library nucleic acid. An aliquot of the pool is transformed into cells. In another  
5 embodiment, individual library members are stored separately (e.g., in separate wells of a microtitre plate or at separate addresses of an array) and are individually introduced into cells.

In still another embodiment, the library members are stored in pools that have a reduced complexity relative to the library as a whole. For example, each pool can include  
10  $10^3$  different library members from a library of  $10^5$  or  $10^6$  different members. When a pool is identified as having a member that causes a particular effect, the pool is deconvolved to identify the individual library member that mediates the phenotypic effect. This approach is useful when recovery of the altered cell is difficult, e.g., in a screen for chimeric proteins that cause apoptosis.

15 Library nucleic acids can be introduced into cells by a variety of methods. Exemplary methods include electroporation (see, e.g., U.S. 5,384,253); microprojectile bombardment techniques (see, e.g., U.S. 5,550,318; 5,538,880; and 5,610,042; and WO 94/09699); liposome-mediated transfection (e.g., using LIPOFECTAMINE™ (Invitrogen) or SUPERFECT™ (QIAGEN GmbH); see, e.g., Nicolau *et al.*, *Methods*  
20 *Enzymol.*, 149:157-176, 1987.); calcium phosphate or DEAE-Dextran mediated transformation (see, e.g., Rippe *et al.*, (1990) *Mol. Cell Biol.*, 10:689-695); direct microinjection or sonication loading; receptor mediated transfection (see, e.g., EP 273 085); and *Agrobacterium*-mediated transformation (see, e.g., U.S. 5,563,055 and 5,591,616). The term “transform,” as used herein, encompasses any method that  
25 introduces an exogenous nucleic acid into a cell.

It is also possible to use a viral particle to deliver a library nucleic acid into a cell in vitro or in vivo. In one embodiment, viral packaging is used to deliver the library nucleic acids to cells within an organism. In another embodiment, the library nucleic acids are introduced into cells in vitro, after which the cells are transferred into an  
30 organism.

After introduction of the library nucleic acids, the library nucleic acids are expressed so that the chimeric proteins encoded by the library are produced by the cells.

Constant regions of the library nucleic acid can provide necessary regulatory and supporting sequences to enable expression. Such sequences can include transcriptional promoters, transcription terminators, splice site donors and acceptors, untranslated regulatory regions (such as polyA addition sites), bacterial origins of replication, markers  
5 for indicating the presence of the library nucleic acid or for selection of the library nucleic acid.

### **Screening Nucleic Acid Libraries Encoding Chimeric Proteins**

In a screen, the cells or organisms are evaluated to identify ones that have an  
10 altered phenotype. This process can be adapted to the phenotype of interest. As the number of possible phenotypes is vast, so too are the possibilities for screening. Numerous genetic screens and selections have been conducted to identify mutants or overexpressed naturally occurring genes that result in particular phenotypes. Any of these methods can be adapted to identify useful members of a nucleic acid library encoding  
15 chimeric proteins. A screen can include evaluating each cell or organism that includes a library nucleic acid or a selection, e.g., evaluating cells or organisms that survive or otherwise withstand a particular treatment.

Exemplary methods for evaluating cells include microscopy (e.g., light, confocal, fluorescence, scanning electron, and transmission electron), fluorescence based cell  
20 sorting, differential centrifugation, differential binding, immunoassays, enzymatic assays, growth assays, and *in vivo* assays.

Some screens involve particular environmental conditions. Cells that are sensitive or resistant to the condition are identified.

Some screens require detection of a particular behavior of a cell (e.g., chemotaxis, morphological changes, or apoptosis), or a particular behavior of an organism (e.g.,  
25 phototaxis by a plant, mating behavior by a *Drosophila*, and so forth). In one embodiment, the cells or organisms can be evaluated directly, e.g., by visual inspection, e.g., using a microscope and optionally computer software to automatically detect altered cells. In another embodiment, the cells or organisms can be evaluated using an assay or  
30 other indicator associated with the desired phenotype.

Some screens relate to cell proliferation. Cells that proliferate at a different rate relative to a reference cell (e.g., a normal cell) are identified. In addition, cells that have an altered response to a proliferative signal (e.g., a growth factors or other mitogen) can be identified. The cells may be more or less sensitive to the signal.

5       Screens that relate to cell differentiation can also be used. The screening and use of chimeric zinc finger proteins can be used to modulate the differentiative and proliferative capacity of a variety of cells, including stem cells, such as ES cells and somatic stem cells, both human and otherwise. Zinc finger proteins can be found that direct ES cells to differentiate into a restricted lineage, such as neuronal progenitor cells  
10 or hematopoietic stem cells. It should be also possible to screen for zinc finger proteins that can direct differentiation of stem cells toward a defined post-mitotic cell subtype, for example, directing differentiation of ES cells and/or neural stem cells to dopaminergic or cholinergic neurons.

Among other phenotypes to evaluate differentiation, it is possible to look at  
15 expression of marker genes and marker proteins. Examples of such markers include:

- FLK1 for endothelial cells (Cho *et al.*, (2001) *Blood* 98:3635-42; Nishikawa *et al.*, *Development* 125: 1747-1757),
- vascular smooth muscle cell-specific myosin heavy chain for smooth muscle (Drab *et al.*, (1997) *FASEB J* 11:905-15)
- 20 ▪ Bone-specific alkaline phosphatase (BAP) and osteocalci for osteoblasts, (Demers *et al.*, (2000) *Cancer* 88:2919-26)
- CD4, CD8, and CD45 for white blood cells (Ody *et al.*, (2000) *Blood* 96:3988-90, Martin *et al.*, (2000) *Blood* 96:2511-9)
- Flk-2 and CD34 for hematopoietic stem cells, (Julie *et al.*, *Proc. Natl. Acad. Sci. USA*, 2001, Vol. 98, Issue 25, 14541-14546, Woodward & Jenkinson. *Eur J Immunol* 2001 Nov;31(11):3329-38, George AA *et al.*, *Blood* 2001 Jun 15;97(12):3925-30)
- 25 ▪ CFU for hematopoietic stem cells, MSC progenitors (Frimberger *et al.*, *Exp Hematol* 2001 May;29(5):643-52)
- 30 ▪ Muc-18 (CD146) for bone marrow fibroblasts, (Filshie *et al.*, (1998) *Leukemia* 12:414-21)

- collagen type II, collagen type IV and chondrocyte expressed protein-68 for chondrocytes (Carlberg *et al.*, (2001) *Differentiation* 67:128-38, Steck *et al.*, (2001) *Biochem J* 353:169-74)
- adipocyte lipid-binding protein (ALBP) and fatty acid transporter for adipocytes (Amri, *et al.*, (1995) *J. Biol. Chem.* 270:2367-2371, Bastie *et al.*, (1999) *J Biol Chem* 274:21920-5, Frohnert *et al.*, (1999) *J. Biol. Chem.* 274, 3970-3977, Teboul *et al.*, (2001) *Biochem. J.* 360:305-312)
- CD133 for neural stem cells (Uchida N *et al.*, (2000) *Proc. Natl. Acad. Sci. USA* 97:14720-5)
- GFAP for astrocytes (Dai *et al.*, (2001) *Genes Dev* 15:1913-25)
- microtubule-associated protein-2 for neurons (Roy *et al.*, (2000) *Nat Med* 6:271-7)

It is also possible to screen mammalian cells for other properties, such as anti-tumorigenesis, altered apoptosis, and anti-viral phenotypes. For example, by selecting for cells that are resistant to viral infection or virus production, it is possible to identify artificial chimeric proteins that can be used as anti-viral agents.

Similarly changes in cell signaling pathways can be detected by the use of probes correlated with activity or inactivity of the pathway or by observable indications correlated with activity or inactivity of the pathway.

Some screens relate to production of a compound of interest, e.g., a metabolite, a secreted protein, and a post-translationally modified protein. For example, cells can be identified that produce an increased amount of a compound. In another example, cells can be identified that produce a reduced amount of a compound, e.g., an undesired byproduct. Cells of interest can be identified by a variety of means, including the use of a responder cell, microarrays, chemical detection assays, and immunoassays.

More examples of particular embodiments include:

1) Protein solubility: In *E. coli*, many heterologous proteins are expressed as inclusion bodies. We identified chimeric zinc finger proteins that increase the soluble fraction of a human protein expressed in *E. coli*. See Example 12. Accordingly, the invention features an artificial transcription factor or a chimeric zinc finger protein that alters (e.g., increases) the solubility of a heterologous protein expressed (e.g., overexpressed in a cell).

2) Glycosylation: Therapeutic proteins including antibodies are often produced in CHO cells. However, such proteins do not have optimal glycosylation pattern. In one embodiment, a library encoding chimeric proteins is screened to identify a CHO cell that is modified so that a secreted protein, e.g., an antibody, includes one or more (e.g., all) glycosylations that characterize an antibody produced by a B cell. Accordingly, the invention features an artificial transcription factor or a chimeric zinc finger protein that alters glycosylation of a secreted protein, e.g., a protein secreted by a CHO cell, e.g., an antibody secreted by a CHO cell.

3) Viral titer: In one embodiment, a library encoding chimeric proteins is screened to identify a chimeric protein that increases or decreases viral titer in a cell culture. Viruses can be used as a delivery vehicle, e.g., a gene delivery vehicle. For example, therapeutic viruses are now being developed to cure certain type of cancer (e.g. an adenovirus). Increasing the viral titer is useful for preparing viruses for therapy. On the other hand suppressing viral production in a cell culture and in vivo is useful for treating viral disease. Accordingly, the invention features an artificial transcription factor or a chimeric zinc finger protein that alters (e.g., increases or decreases) virus production in a cell, e.g., a eukaryotic or mammalian cell.

4) Transformation efficiency: Genetic engineering in many eukaryotic cell lines or prokaryotic organisms is limited by low transfection or transformation efficiency. Artificial transcription factors can be selected that modify cells so that transfection or transformation efficiency is improved. A selection for such a factor can be performed by a transformation with a reporter or marker at limiting concentrations, followed by selection of those cells that take up the reporter. Accordingly, the invention features an artificial transcription factor or a chimeric zinc finger protein that alters (e.g., increases) the DNA uptake efficiency or tolerance of DNA uptake procedures of a cell.

5) Feeder cells. It is possible to identify artificial transcription factors and other chimeras that modify the properties of a culture cell so that the culture cell can support proliferation or differentiation of a stem cells, e.g., thereby producing a feeder cell. The culture cell can be a human or mammalian cell. The cells can be screened (e.g., by pooling library members) to identify a cell which causes a stem cell cultivated in the same milieu (e.g., the same well) to proliferate or differentiation. The artificial transcription factor may activate key cytokines and growth factors, which are secreted to the media.

The media can be used to induce differentiation or proliferate (e.g., by supporting self-renewal) the stem cell. Accordingly, the invention features an artificial transcription factor or a chimeric zinc finger protein that alters (e.g., increases) the ability of a mammalian cell to condition media or otherwise alter the behavior of a stem cell, e.g.,  
5 regulate proliferation or differentiation of a stem cell.

It is also possible to screen for an artificial transcription factor using one type of cell and then to express the artificial transcription factor in a second type of cell. This process can be used to generally transfer the phenotypic change induced by the transcription factor from a first cell into a second cell. For example, we determined the  
10 expression profiles of a particular zinc finger protein in two widely different cell lines; human embryonic kidney 293 cell, which is non-cancerous, and human cervical cancer cell HeLa. We found that the profiles were strikingly similar. Similarly, in yeast we demonstrated that a phenotype induced by a ZFP in one strain can be transferred to a different strain.

## 15 Stem Cells

The approaches described here, while generally applicable to any cell, are also particularly useful for regulating the behavior of stem cells from any metazoan organism. Stem cells are cells with the capacity self-renewal and also the potential for differentiation. The self-renewal can be prolonged, and even indefinite. Stem cells can produce highly  
20 differentiated descendants (Watt and Hogan (2000) *Science* 287:1427-1430). Recent success in culturing human embryonic stem cells has provided a potential source of cells for cell-based therapies. However, maintaining, replicating, and differentiating stem cells can, at least in some cases, be difficult. ES cells, for example, have a tendency to differentiate randomly in vitro.

25 A library of chimeric transcription factors can be used to identify proteins that can control cell differentiation, e.g., stem cell differentiation. For example, one may identify chimeric transcription factors that direct the differentiation of stem cells towards a defined post-mitotic cell subtype (for example, a dopaminergic or cholinergic neuron).

Proteins can be identified that increase the potential for self-renewal, that prevent  
30 differentiation, or that direct the extent and character of differentiation. These proteins are generally identified by introducing nucleic acids encoding artificial zinc finger

proteins into stem cells or stem cell progenitors, and evaluating the phenotype of the cell.

A means to control the differentiative and proliferative potential of stem cells would enable, among other things, the provision of a large supply of undifferentiated cells, and the regulated differentiation toward a specific cell types. Such control can be tailored  
5 to a therapeutic use or other applications (e.g., development of transgenic animals, in vitro cell culture, and so forth).

In other examples, one can identify chimeric transcription factors that direct embryonic stem (ES) cells to differentiate into a restricted lineage. Thus, one may produce neuronal progenitor cells or hematopoietic stem cells from ES cells. It is also  
10 possible to identify chimeric proteins, e.g., chimeric ZFPs, that cause 1) a differentiated cell to adopt a different differentiated state or 2) a differentiated cell to adopt a non-differentiated state, e.g., thereby generating a stem cell or a pluripotent progenitor cell.

The identification method does not require information about a particular target gene. Target genes can be identified after screening, e.g., by transcript or protein  
15 profiling to identify genes whose expression or activity is altered by an identified chimeric transcription factor. The identification of genes regulated by ZFP-TFs will advance understanding of cell differentiation.

#### **Production of cellular products.**

The invention features artificial transcription factors (e.g., chimeric zinc finger  
20 proteins) that alter the ability of a cell to produce a cellular product, e.g., a protein or metabolite. A cellular product can be an endogenous or heterologous molecule. For example, it is possible to identify an artificial transcription factor that increases the ability of a cell to produce proteins, e.g., particular proteins (e.g., particular endogenous proteins), overexpressed proteins, heterologous proteins, or mis-folded proteins.

25 In one embodiment, cells are screened for their ability to produce a reporter protein, e.g., a protein that can be enzymatically or fluorescently detected. In one example, the reporter protein is insoluble when overexpressed in a reference cell. For example, bacterial cells can be screened for artificial transcription factors that reduce inclusion bodies. In another example, the reporter protein is secreted, e.g., by a  
30 prokaryotic or eukaryotic cell. Cells can be screened for higher secretory through-put, or improved post-translational modification, e.g., glycosylation, phosphorylation, or



proteolytic processing.

In one embodiment, cells are screened for their ability to alter (e.g., increase or decrease) the activity of two different reporter proteins. The reporter proteins may differ, e.g., by activity, localization (e.g., secreted/cytoplasmic/nuclear), size, solubility, isoelectric point, oligomeric state, post-translational regulation, translational regulation, and transcriptional regulation (e.g., the gene encoding them may be regulated by different regulatory sequences). The invention includes artificial transcription factors (e.g., zinc finger proteins) that alter at least two different reporter genes that differ by these properties, and zinc finger proteins that selectively regulate a reporter gene, or a class of reporter genes defined by one of these properties.

Because the phenotypic screening method can be used to isolate the artificial transcription factor, it is not necessary to know a priori how the zinc finger protein mediates increased protein production. Possible mechanisms, which can be verified, include alteration of one or more of the following: translation machinery, transcript processing, transcription, secretion, protein degradation, stress resistance, catalytic activity, e.g., metabolite production. In one example, an artificial transcription factor may modulate expression of one or more enzymes in a metabolic pathway and thereby enhance production of a cellular product such as a metabolite or a protein.

## **Iterative Design**

Once a chimeric DNA binding protein is identified, its ability to alter a phenotypic trait of a cell can be further improved by a variety of strategies. Small libraries, e.g., having about 6 to 200 or 50 to 2000 members, or large libraries can be used to optimize the properties of a particular identified chimeric protein.

In a first exemplary implementation of an iterative design, mutagenesis techniques are used to alter the original chimeric DNA binding protein. The techniques are applied to construct a second library whose members include members that are variants of an original protein, for example, a protein identified from a first library. Examples of these techniques include: error-prone PCR (Leung *et al.* (1989) *Technique* 1:11-15), recombination, DNA shuffling using random cleavage (Stemmer (1994) *Nature* 389-391), Coco *et al.* (2001) *Nature Biotech.* 19:354, site-directed mutagenesis (Zollner *et al.*

(1987) *Nucl Acids Res* 10:6487-6504), cassette mutagenesis (Reidhaar-Olson (1991) *Methods Enzymol.* 208:564-586) incorporation of degenerate oligonucleotides (Griffiths *et al.* (1994) *EMBO J* 13:3245); serial ligation, pooling specific library members from a prefabricated and arrayed library, recombination (e.g., sexual PCR and “DNA Shuffling™” (Maxygen, Inc., CA)), or by combinations of these methods.

In one embodiment, a library is constructed that mutates a set of amino acid positions. For example, for a chimeric zinc finger protein, the set of amino acid positions may be positions in the vicinity of the DNA contacting residues, but not the DNA contacting residues themselves. In another embodiment, the library varies each encoded domain in a chimeric protein, but to a more limited extent than the initial library from which the chimeric DNA binding protein was identified. For a chimeric zinc finger protein, the nucleic acids that encode a particular domain can be varied among other zinc finger domains whose recognition specificity is known to be similar to that of the domain present in the original chimeric protein.

Some techniques include generating new chimeric DNA binding proteins from nucleic acids encoding domains of at least two chimeric DNA binding proteins that are known to have a particular functional property. These techniques, which include DNA shuffling and standard domain swapping, create new combinations of domains. See, e.g., U.S. Patent No. 6,291,242. DNA shuffling can also introduce point mutations in addition to merely exchanging domains. The shuffling reaction is seeded with nucleic acid sequences encoding chimeric proteins that induces a desired phenotype. The nucleic acids are shuffled. A secondary library is produced from the shuffling products and screened for members that induce the desired phenotype, e.g., under similar or more stringent conditions. If the initial library is comprehensive such that chimeras of all possible domain combinations are screened, DNA shuffling of domains isolated from the same initial library may be of no avail. DNA shuffling may be useful in instances where coverage is comprehensive and also in instances where comprehensive screening may not be practical.

In a second exemplary implementation of an iterative design, a chimeric DNA binding protein that produces a desired phenotype is altered by varying each domain. Domains can be varied sequentially, e.g., one-by-one, or greater than one at a time.

The following example refers to an original chimeric protein that includes three zinc finger domains: fingers I, II, and III and that produces a desired phenotype. A second library is constructed such that each nucleic acid member of the second library encodes the same finger II and finger III as the initially identified protein. However, the library includes nucleic acid members whose finger I differs from finger I of the original protein. The difference may be a single nucleotide that alters the amino acid sequence of the encoded chimeric protein or may be more substantial. The second library can be constructed, e.g., such that the base-contacting residues of finger I are varied, or that the base-contacting residues of finger I are maintained but that adjacent residues are varied. The second library can also include a large enough set of zinc finger domains to recognize at least 20, 30, 40, or 60 different trinucleotide sites.

The second library is screened to identify members that alter a phenotype of a cell or organism. The extent of alteration can be similar to that produced by the original protein or greater than that produced by the original protein.

Concurrently, or subsequently, a third library can be constructed that varies finger II, and a fourth library can be constructed that varies finger III. It may not be necessary to further improve a chimeric protein by varying all domains, if the chimeric protein or already identified variants are sufficient. In other cases, it is desirable to re-optimize each domain.

If other domains are varied concurrently, improved variants from each particular library can be recombined with each other to generate still another library. This library is similarly screened.

In a third exemplary implementation of an iterative design, the method includes adding, substituting, or deleting a domain, e.g., a zinc finger domain or a regulatory domain. An additional zinc finger domain may increase the specificity of a chimeric protein and may increase its binding affinity. In some cases, increased binding affinity may enhance the phenotype that the chimeric protein produces. An additional regulatory domain, e.g., a second activation domain or a domain that recruits an accessory factor, may also enhance the phenotype that the chimeric protein produces. A deletion may improve or broaden the specificity of the activity of the chimeric protein, depending on the contribution of the domain that is deleted, and so forth.

In a fourth exemplary implementation of an iterative design, the method includes co-expressing the original chimeric protein and a second chimeric DNA binding protein in a cell. The second chimeric protein can be also identified by screening a nucleic acid library that encodes different chimeras. In one embodiment, the second chimeric protein is identified by screening the library in a cell that expresses the original chimeric protein. In another embodiment, the second chimeric protein is identified independently.

### **Profiling Regulatory Properties of a Chimeric Zinc Finger Protein**

A chimeric transcription factor that alters a phenotype of a cell can be further characterized to identify the endogenous genes that it directly or indirectly regulates. Typically, the chimeric transcription factor is produced within the cell. At an appropriate time, e.g., before, during, or after the phenotypic change occurs, the cell is analyzed to determine the levels of transcripts or proteins present in the cell or in the medium surrounding the cell. For example, mRNA can be harvested from the cell and analyzed using a nucleic acid microarray.

Nucleic acid microarrays can be fabricated by a variety of methods, e.g., photolithographic methods (see, e.g., U.S. Patent No. 5,510,270), mechanical methods (e.g., directed-flow methods as described in U.S. Patent No. 5,384,261), and pin based methods (e.g., as described in U.S. 5,288,514). The array is synthesized with a unique capture probe at each address, each capture probe being appropriate to detect a nucleic acid for a particular expressed gene.

The mRNA can be isolated by routine methods, e.g., including DNase treatment to remove genomic DNA and hybridization to an oligo-dT coupled solid substrate (e.g., as described in *Current Protocols in Molecular Biology*, John Wiley & Sons, N.Y.). The substrate is washed, and the mRNA is eluted. The isolated mRNA is then reversed transcribed and optionally amplified, e.g., by rtPCR, e.g., as described in (U.S. Patent No. 4,683,202). The nucleic acid can be labeled during amplification or reverse transcription, e.g., by the incorporation of a labeled nucleotide. Examples of preferred labels include fluorescent labels, e.g., red-fluorescent dye Cy5 (Amersham) or green-fluorescent dye Cy3 (Amersham). Alternatively, the nucleic acid can be labeled with biotin, and detected after hybridization with labeled streptavidin, e.g., streptavidin-phycoerythrin (Molecular Probes).

The labeled nucleic acid is then contacted to the array. In addition, a control nucleic acid or a reference nucleic acid can be contacted to the same array. The control nucleic acid or reference nucleic acid can be labeled with a label other than the sample nucleic acid, e.g., one with a different emission maximum. Labeled nucleic acids are  
5 contacted to an array under hybridization conditions. The array is washed, and then imaged to detect fluorescence at each address of the array.

A general scheme for producing and evaluating profiles includes detecting hybridization at each address of the array. The extent of hybridization at an address is represented by a numerical value and stored, e.g., in a vector, a one-dimensional matrix,  
10 or one-dimensional array. The vector  $x$  has a value for each address of the array. For example, a numerical value for the extent of hybridization at a particular address is stored in variable  $x_a$ . The numerical value can be adjusted, e.g., for local background levels, sample amount, and other variations. Nucleic acid is also prepared from a reference sample and hybridized to the same or a different array. The vector  $y$  is construct  
15 identically to vector  $x$ . The sample expression profile and the reference profile can be compared, e.g., using a mathematical equation that is a function of the two vectors. The comparison can be evaluated as a scalar value, e.g., a score representing similarity of the two profiles. Either or both vectors can be transformed by a matrix in order to add weighting values to different genes detected by the array.

The expression data can be stored in a database, e.g., a relational database such as a SQL database (e.g., Oracle or Sybase database environments). The database can have multiple tables. For example, raw expression data can be stored in one table, wherein each column corresponds to a gene being assayed, e.g., an address or an array, and each row corresponds to a sample. A separate table can store identifiers and sample  
20 information, e.g., the batch number of the array used, date, and other quality control information.

Genes that are similarly regulated can be identified by clustering expression data to identify coregulated genes. Such cluster may be indicative of a set of genes coordinately regulated by the chimeric zinc finger protein. Genes can be clustered using  
30 hierarchical clustering (see, e.g., Sokal and Michener (1958) *Univ. Kans. Sci. Bull.* 38:1409), Bayesian clustering, k-means clustering, and self-organizing maps (see, Tamayo *et al.* (1999) *Proc. Natl. Acad. Sci. USA* 96:2907).

The similarity of a sample expression profile to a reference expression profile (e.g., a control cell) can also be determined, e.g., by comparing the log of the expression level of the sample to the log of the predictor or reference expression value and adjusting the comparison by the weighting factor for all genes of predictive value in the profile.

5 Proteins can also be profiled in a cell that has an active chimeric protein with in it. One exemplary method for profiling proteins includes 2-D gel electrophoresis and mass spectroscopy to characterize individual protein species. Individual “spots” on the 2-D gel are proteolyzed and then analyzed on the mass spectrometer. This method can identify both the protein component and, in many cases, translational modifications.

10 The protein and nucleic acid profiling methods can not only provide information about the properties of the chimeric protein, but also information about natural mechanisms operating within the cell. For example, the proteins or nucleic acids upregulated by expression of the chimeric protein may be the natural effectors of the phenotypic change caused by expression of the chimeric protein.

15 In addition, other methods can be used to identify target genes and proteins that are directly or indirectly regulated by the artificial chimeric protein. In one example, alterations that compensate (e.g., suppress) the phenotypic effect of the artificial chimeric protein are characterized. These alterations include genetic alterations such as mutations in chromosomal genes and overexpression of a particular gene, as well as other alterations, 20 such as RNA interference (e.g., by double-stranded RNA).

In a particular example, a chimeric ZFP is isolated that causes a growth defect or lethality when conditionally expressed in a cell, e.g., a pathogenic bacteria or fungi. Such a ZFP can be identified by transforming the cell with the ZFP libraries that include nucleic acids encoding ZFPs, expression of the nucleic acids being controlled by an 25 inducible promoter. Transformants are cultured on non-inducible media and then replica-plated on both inducible and non-inducible plates. Colonies that grow normally on non-inducible plate, but show defective growth on inducible plate are identified as “conditional lethal” or “conditional growth defective” colonies.

*(a) Identification of target genes using a cDNA library*

30 A cDNA expression library is then transformed into the “conditional lethal” or “conditional growth defective” strains described above. Transformants are plated on

inducible plates. Colonies that survive, despite the presence and expression of the ZFP that causes the defect, are isolated. The nucleic acid sequences of cDNAs that complement the defect are characterized. These cDNA can be transcripts of direct or indirect target genes that are regulated by chimeric ZFP that mediates the defect.

5     ***(b) Identification of target genes using a secondary ZFP library***

A second chimeric protein that suppresses the effect of the first chimeric protein is identified. The targets of the second chimeric protein (in the presence or absence of the first chimeric protein) are identified.

For example, a ZFP library is transformed into “conditional lethal” or  
10     “conditional growth defective” colonies (which include a first chimeric ZFP that causes the defect). Transformants are plated on inducible plates. Colonies that can survive by the expression of introduced ZFP are identified as “suppressed strains”. Target genes of the second ZFPs can be characterized by DNA microarray analysis. The comparative analysis can be done between four strains: 1) no ZFP; 2) the first ZFP alone; 3) the  
15     second ZFP alone; and 4) the first and second ZFP. For example, genes that are regulated in opposing directions by the first and second chimeric ZFPs are candidates for targets that mediate the growth-defective phenotype. This method can be applied to any phenotype, not just a growth defect.

***(c) Co-regulated genes identified by expression profiling analysis***

20     A candidate target of a chimeric ZFP can be identified by expression profiling. Subsequently, to determine if the candidate target mediates the phenotype of the chimeric ZFP, the candidate target can be independently over-expressed or inhibited (e.g., by genetic deletion or RNA interference). In addition, it may be possible to apply this analysis to multiple candidate targets since in at least some cases more than one candidate  
25     may need to be perturbed to cause the phenotype. An example of this approach is provided in Example 3 (Ketoconazole resistance).

***(d) Time-Course Analysis***

The targets of a chimeric ZFP can be identified by a characterizing changes in gene expression with respect to time after a cell is exposed to the chimeric ZFP. For  
30     example, a gene encoding the chimeric ZFP can be attached to an inducible promoter. An

exemplary inducible promoter is regulated by a small molecule such as doxycycline. The gene encoding the chimeric ZFP is introduced into cells. mRNA samples are obtained from cells at various times after induction of the inducible promoter. See, e.g., FIG. 13, which depicts genes that are activated and repressed in the course of induction of the ZFP  
5 F104-p65.

*(e) Identification of primary target genes of ZFP-TFs from mammalian cells using protein transduction and cDNA microarray technologies.*

It is also possible to introduce a chimeric protein into a cell by transduction. The protein is provided to the extracellular milieu and the cell transduces the protein into itself.  
10 Thus, the cell does not have to include a gene encoding the chimeric protein. This approach may obviate concerns about exogenous nucleic acid integration, propagation, and so forth. Levels of the protein can be precisely controlled. In one embodiment, the chimeric ZFP is fused to protein transduction domain of Tat or VP22.

To analyze the effects of a transduced chimeric protein in culture cells, the  
15 chimeric protein is added to the culture media, e.g., as a fusion to a protein transduction domain. Detection of regulated target genes can be enhanced by addition of an inhibitor of protein synthesis such as cycloheximide. Thus, translation of the primary target genes is blocked, and genes that would be regulated by proteins encoded by the primary target genes would be detected. The identity of primary target genes can be found by DNA  
20 microarray analysis.

The use of cyclohexamide to identify primary target genes can also be used when the chimeric protein is encoded by a heterologous nucleic acid in the cell. For example, expression of the heterologous nucleic acid can be induced for less than 30, 20, 15, 10, or 5 minutes, and then cyclohexamide can be added.

25 *(f) Activity Analysis*

The function of a potential target gene can be evaluated by inhibiting activity of the target gene, e.g., by RNA interference (RNAi) with double-stranded RNAs (dsRNA), anti-sense technology, ribozymes, or targeted genetic mutation. A cell or organism in which activity of the target gene is reduced can be evaluated and compared to a control  
30 cell or organism that is not treated with RNAi. In another example, a cell or organism



that expresses the artificial zinc finger protein believed to regulate the target gene is treated with RNAi. The ability of the artificial zinc finger protein to induce a phenotype is evaluated in the presence and absence of RNAi. In some cases, if the potential target gene is indeed a critical target, the RNAi treatment inactivating the potential target may attenuate the phenotype induced by the artificial zinc finger protein.

dsRNA can be produced by transcribing a cassette in both directions, for example, by including a T7 promoter on either side of the cassette. The insert in the cassette is selected so that it includes a sequence complementary to the potential target gene. See also, the HiScribe™ RNAi Transcription Kit (New England Biolabs, MA) and Fire, A. (1999) *Trends Genet.* 15, 358–363. dsRNA can be digested into smaller fragments. See, e.g., US Patent Application 2002-0086356. dsRNAs can be used to silence gene expression in mammalian cells. See, e.g., Clemens, *et al.* (2000) *Proc. Natl. Sci. USA* 97, 6499–6503; Billy, E. *et al.* (2001) *Proc. Natl. Sci. USA* 98, 14428–14433; Elbashir *et al.* (2001) *Nature*. 411(6836):494–8; Yang, D. *et al.* (2002) *Proc. Natl. Acad. Sci. USA* 99, 9942–9947.

### **Target DNA Site Identification**

With respect to chimeric DNA binding proteins, a variety of methods can be used to determine the target site of a chimeric DNA binding protein that produces a phenotype of interest. Such methods can be used, alone or in combination, to find such a target site.

In one embodiment, information from expression profile is used to identify the target site recognized by a chimeric zinc finger protein. The regulatory regions of genes that are co-regulated by the chimeric zinc finger protein are compared to identify a motif that is common to all or many of the regulatory regions.

In another embodiment, biochemical means are used to determine what DNA site is bound by the chimeric zinc finger protein. For example, chromatin immunoprecipitation experiments can be used to isolate nucleic acid to which the chimeric zinc finger protein is bound. The isolated nucleic acid is PCR amplified and sequence. See, e.g., Gogus *et al.* (1996) *Proc. Natl. Acad. Sci. USA*. 93:2159-2164. The SELEX method is another exemplary method that can be used. Further, information about the binding specificity of individual zinc finger domains in the chimeric zinc finger protein can be

used to predict the target site. The prediction can be validated or can be used to guide interpretation of other results (e.g., from chromatin immunoprecipitation, in silico analysis of co-regulated genes, and SELEX).

In still another embodiment, a potential target site is inferred based on information  
 5 about the binding specificity of each component zinc finger. For example, as shown in FIG. 10A and 10B, a chimera that includes the zinc finger domains, from N- to C-terminus, : CSNR, RSNR, and QSNR is expected to recognize the target site 5'-GAAGAGGACC-3' (SEQ ID NO:130). The domains CSNR, RSNR, and QSNR have the following respective DNA binding specificities GAC, GAG, and GAA. The expected  
 10 target site is formed by considering the domains in C terminal to N-terminal order and concatenating their recognition specificities to obtain one strand of the target site in 5' to 3' order.

Although in most cases, chimeric zinc finger proteins are likely to function as transcriptional regulators, it is possible that in some cases the chimeric zinc finger  
 15 proteins mediate their phenotypic effect by binding to an RNA or protein target. Some naturally-occurring zinc finger proteins in fact bind to these macromolecules.

#### **Additional Features for Chimeric Transcription Factors**

With respect to a library encoding chimeric nucleic acid binding domains, the encoded polypeptides can also include one or more of the following features. These  
 20 features may be constant among all members of the library or may also vary. In one example, some nucleic acids encode polypeptides that include an activation domain, whereas others include a repression domain, or no transcriptional regulatory domain.

**Activation domains.** Transcriptional activation domains that may be used in the present invention include but are not limited to the Gal4 activation domain from yeast and  
 25 the VP16 domain from herpes simplex virus. The ability of a domain to activate transcription can be validated by fusing the domain to a known DNA binding domain and then determining if a reporter gene operably linked to sites recognized by the known DNA-binding domain is activated by the fusion protein.

An exemplary activation domain is the following domain from p65:  
 30 YLPDTDDRHRIEEKRKRTYETFKSIMKKSPFSGPTDPRPPRRRIAVPSRSSASVPKP  
 APQYPFTSSLSTINYDEFPTMVFP SGQISQASALAPAPPQVLPQAPAPAPAMVS  
 ALAQAPAPVPVLAPGPPQAVAPPAPKPTQAGEGTLSEALLQLQFDDDLGALLG

NSTDPAVFTDLASVDNSEFQQLLNQGIPVAPHTTEPMLMEYPEAITRLVTAQRPP  
DPAPAPLGAPGLPNGLLSGDEDFSSIADMDFSALLSQ (SEQ ID NO:131)

The sequence of an exemplary Gal4 activation domain is as follows:

5 NFNQSGNIADSSLSFTFTNSSNGPNLITTQTNSQALSQPIASSNVHDNFMNNEITAS  
KIDDGNNKPLSPGWTDQTAYNAFGITTGMFNTTTMDDVYNYLFDDDEDTPPNPK  
KEISMAYPYDVPDYAS (SEQ ID NO:132)

In bacteria, activation domain function can be emulated by a domain that recruits  
10 a wild-type RNA polymerase alpha subunit C-terminal domain or a mutant alpha subunit  
C-terminal domain, e.g., a C-terminal domain fused to a protein interaction domain.

**Repression domains.** If desired, a repression domain instead of an activation  
domain can be fused to the DNA binding domain. Examples of eukaryotic repression  
domains include repression domains from Kid, UME6, ORANGE, groucho, and WRPW  
15 (see, e.g., Dawson *et al.*, (1995) *Mol. Cell Biol.* 15:6923-31). The ability of a domain to  
repress transcription can be validated by fusing the domain to a known DNA binding  
domain and then determining if a reporter gene operably linked to sites recognized by the  
known DNA-binding domain is repressed by the fusion protein.

An exemplary repression domain is the following domain from UME6 protein:

20 NSASSSTKLDDDLGTAAAVLSNMRSSPYRTHDKPISNVNDMNNNTNALGVPASRPH  
SSSFPSKGVLRPILLRIHNSEQQPIFESNNSTACI (SEQ ID NO:133)

Another exemplary repression domain is from the Kid protein:

25 VSVTFEDVAVLFTRDEWKKLDLSQRSLYREVMLENYSNLASMAGFLFTKPKVIS  
LLQQGEDPW (SEQ ID NO:134)

Still other chimeric transcription factors include neither an activation or repression  
domain. Rather, such transcription factors may alter transcription by displacing or  
30 otherwise competing with a bound endogenous transcription factor (e.g., an activator or  
repressor).

**Peptide Linkers.** DNA binding domains can be connected by a variety of linkers.  
The utility and design of linkers are well known in the art. A particularly useful linker is  
a peptide linker that is encoded by nucleic acid. Thus, one can construct a synthetic gene  
35 that encodes a first DNA binding domain, the peptide linker, and a second DNA binding  
domain. This design can be repeated in order to construct large, synthetic, multi-domain  
DNA binding proteins. PCT WO 99/45132 and Kim and Pabo ((1998) *Proc. Natl. Acad.*

*Sci. USA* 95:2812-7) describe the design of peptide linkers suitable for joining zinc finger domains.

Additional peptide linkers are available that form random coil,  $\alpha$ -helical or  $\beta$ -pleated tertiary structures. Polypeptides that form suitable flexible linkers are well known in the art (see, e.g., Robinson and Sauer (1998) *Proc Natl Acad Sci U S A.* 95:5929-34). Flexible linkers typically include glycine, because this amino acid, which lacks a side chain, is unique in its rotational freedom. Serine or threonine can be interspersed in the linker to increase hydrophilicity. In addition, amino acids capable of interacting with the phosphate backbone of DNA can be utilized in order to increase binding affinity. Judicious use of such amino acids allows for balancing increases in affinity with loss of sequence specificity. If a rigid extension is desirable as a linker,  $\alpha$ -helical linkers, such as the helical linker described in Pantoliano *et al.* (1991) *Biochem.* 30:10117-10125, can be used. Linkers can also be designed by computer modeling (see, e.g., U.S. 4,946,778). Software for molecular modeling is commercially available (e.g., from Molecular Simulations, Inc., San Diego, CA). The linker is optionally optimized, e.g., to reduce antigenicity and/or to increase stability, using standard mutagenesis techniques and appropriate biophysical tests as practiced in the art of protein engineering, and functional assays as described herein.

For implementations utilizing zinc finger domains, the peptide that occurs naturally between zinc fingers can be used as a linker to join zinc fingers together. An example of a naturally occurring linker is: Thr-Gly-(Glu or Gln)-(Lys or Arg)-Pro-(Tyr or Phe) (SEQ ID NO:74) (Agata *et al.*, *supra*). Generally, linkers can be selected or based on the sequences that join zinc fingers in naturally occurring proteins.

**Dimerization Domains.** An alternative method of linking DNA binding domains is the use of dimerization domains, especially heterodimerization domains (see, e.g., Pomerantz *et al* (1998) *Biochemistry* 37:965-970). In this implementation, DNA binding domains are present in separate polypeptide chains. For example, a first polypeptide encodes DNA binding domain A, linker, and domain B, while a second polypeptide encodes domain C, linker, and domain D. An artisan can select a dimerization domain from the many well-characterized dimerization domains. Domains that favor heterodimerization can be used if homodimers are not desired. A particularly adaptable dimerization domain is the coiled-coil motif, e.g., a dimeric parallel or anti-parallel

coiled-coil. Coiled-coil sequences that preferentially form heterodimers are also available (Lumb and Kim, (1995) *Biochemistry* 34:8642-8648). Another species of dimerization domain is one in which dimerization is triggered by a small molecule or by a signaling event. For example, a dimeric form of FK506 can be used to dimerize two FK506  
5 binding protein (FKBP) domains. Such dimerization domains can be utilized to provide additional levels of regulation.

### **Chimeric Proteins for Non-DNA Applications**

It is also possible to modify the examples herein to make libraries of nucleic acids that encode chimeric proteins that include different combinations of non-DNA binding  
10 domains, e.g., intracellular signal transduction domains (e.g., SH2, SH3, PDZ, Che domains, or kinase domains). The chimeric proteins encoded by the library can be expressed in cells, and cells having an altered phenotypic trait are identified. For example, chimeric proteins formed of different combinations of signaling domains can be identified that decrease or increase the rate of cell proliferation.

### **Expression of Zinc Finger Proteins**

Method described herein can include use of routine techniques in the field of molecular biology, biochemistry, classical genetics, and recombinant genetics. Basic texts disclosing the general methods of use in this invention include Sambrook *et al.*,  
15 *Molecular Cloning, A Laboratory Manual* (2nd ed. 1989); Kriegler, *Gene Transfer and Expression: A Laboratory Manual* (1990); and *Current Protocols in Molecular Biology* (Ausubel *et al.*, eds., 1994)).

In addition to other methods described herein, nucleic acids encoding zinc proteins can be constructed using synthetic oligonucleotides as linkers to construct a synthetic gene. In another example, synthetic oligonucleotides are used and/or primers to  
25 amplify sequences encoding one or more zinc finger domains, e.g., from an RNA or DNA template, artificial or synthetic. See U.S. Patents 4,683,195 and 4,683,202; *PCR Protocols: A Guide to Methods and Applications* (Innis *et al.*, eds, 1990)). Methods such as polymerase chain reaction (PCR) can be used to amplify nucleic acid sequences directly from mRNA, from cDNA, from genomic, cDNA, or zinc finger protein libraries.  
30 Degenerate oligonucleotides can be designed to amplify homologs using the sequences provided herein. Restriction endonuclease sites can be incorporated into the primers.

Gene expression of zinc finger proteins can also be analyzed by techniques known in the art, e.g., reverse transcription and amplification of mRNA, isolation of total RNA or polyA<sup>+</sup> RNA, northern blotting, dot blotting, *in situ* hybridization, RNase protection, nucleic acid array technology, e.g., and the like.

5           The polynucleotide encoding an artificial zinc finger protein can be cloned into vectors before transformation into prokaryotic or eukaryotic cells for replication and/or expression. These vectors are typically prokaryote vectors, e.g., plasmids, phage or shuttle vectors, or eukaryotic vectors.

**Protein Expression.** To obtain recombinant expression (e.g., high level)  
10       expression of a polynucleotide encoding an artificial zinc finger protein, one can subclone the relevant coding nucleic acids into an expression vector that contains a strong promoter to direct transcription, a transcription/translation terminator, and a ribosome binding site for translational initiation. Suitable bacterial promoters are well known in the art and described, e.g., in Sambrook *et al.*, and Ausubel *et al.*, *supra*. Bacterial expression  
15       systems for expression are available in, e.g., *E. coli*, *Bacillus sp.*, and *Salmonella* (Palva *et al.*, (1983) *Gene* 22:229-235; Mosbach *et al.*, (1983) *Nature* 302:543-545. Kits for such expression systems are commercially available. Eukaryotic expression systems for mammalian cells, yeast (e.g., *S. cerevisiae*, *S. pombe*, *Pichia*, and *Hanseula*), and insect cells are well known in the art and are also commercially available.

20           Selection of the promoter used to direct expression of a heterologous nucleic acid depends on the particular application. The promoter is preferably positioned about the same distance from the heterologous transcription start site as it is from the transcription start site in its natural setting. As is known in the art, however, some variation in this distance can be accommodated without loss of promoter function.

25           In addition to the promoter, the expression vector typically contains a transcription unit or expression cassette that contains all the additional elements required for expression in host cells. A typical expression cassette thus contains a promoter operably linked to the coding nucleic acid sequence and signals required for efficient polyadenylation of the transcript, ribosome binding sites, and translation termination.  
30       Additional elements of the cassette may include enhancers and, if genomic DNA is used as the structural gene, introns with functional splice donor and acceptor sites.

In addition to a promoter sequence, the expression cassette should also contain a transcription termination region downstream of the structural gene to provide for efficient termination. The termination region may be obtained from the same gene as the promoter sequence or may be obtained from different genes.

5       The particular expression vector used to transport the genetic information into the cell is not particularly critical. Any of the conventional vectors used for expression in eukaryotic or prokaryotic cells may be used. Standard bacterial expression vectors include plasmids such as pBR322 based plasmids, pSKF, pET23D, and fusion expression systems such as MBP, GST, and LacZ. Epitope tags can also be added to recombinant  
10       proteins to provide convenient methods of isolation, e.g., c-myc-, or a hexa-histidine tag.

Expression vectors can contain regulatory elements from eukaryotic viruses, e.g., SV40 vectors, papilloma virus vectors, and vectors derived from Epstein-Barr virus. Other exemplary eukaryotic vectors include pMSG, pAV009/A<sup>+</sup>, pMTO10/A<sup>+</sup>, pMAMneo-5, baculovirus pDSVE, and any other vector allowing expression of proteins  
15       under the direction of the CMV promoter, SV40 early promoter, SV40 later promoter, metallothionein promoter, murine mammary tumor virus promoter, Rous sarcoma virus promoter, polyhedrin promoter, or other promoters shown effective for expression in eukaryotic cells.

Expression of proteins from eukaryotic vectors can be also be regulated using  
20       inducible promoters. With inducible promoters, expression levels are tied to the concentration of inducing agents, such as tetracycline or ecdysone, by the incorporation of response elements for these agents into the promoter. Generally, high level expression is obtained from inducible promoters only in the presence of the inducing agent; basal expression levels are minimal. Inducible expression vectors are often chosen if  
25       expression of the protein of interest is detrimental to eukaryotic cells.

Some expression systems have markers that provide gene amplification such as thymidine kinase and dihydrofolate reductase. Alternatively, high yield expression systems not involving gene amplification are also suitable, such as using a baculovirus vector in insect cells, with mitochondrial respiratory chain protein encoding sequences  
30       and glycolysis protein encoding sequence under the direction of the polyhedrin promoter or other strong baculovirus promoters

The elements that are typically included in expression vectors also include a replicon that functions in *E. coli*, a gene encoding antibiotic resistance to permit selection of bacteria that harbor recombinant plasmids, and unique restriction sites in nonessential regions of the plasmid to allow insertion of eukaryotic sequences. The prokaryotic  
5 sequences can be chosen such that they do not interfere with the replication of the DNA in eukaryotic cells.

Standard transfection methods are used to produce bacterial, mammalian, yeast or insect cell lines that express large quantities of zinc finger proteins, which are then purified using standard techniques (*see, e.g., Colley et al., J. Biol. Chem.* 264:17619-  
10 17622 (1989); *Guide to Protein Purification*, in *Methods in Enzymology*, vol. 182 (Deutscher, ed., 1990)). Transformation of eukaryotic and prokaryotic cells are performed according to standard techniques (*see, e.g., Morrison, J. Bact.* 132:349-351 (1977); Clark-Curtiss & Curtiss, *Methods in Enzymology* 101:347-362 (Wu *et al.*, eds, 1983).

Any of the well-known procedures for introducing foreign nucleotide sequences into host cells may be used. These include the use of calcium phosphate transfection, protoplast fusion, electroporation, liposomes, microinjection, plasma vectors, viral vectors and any of the other well known methods for introducing cloned genomic DNA, cDNA, synthetic DNA or other foreign genetic material into a host cell (*see, e.g., Sambrook et al., supra*).  
15 It is only necessary that the particular genetic engineering procedure used be capable of successfully introducing at least one gene into the host cell.

After the expression vector is introduced into the cells, the transfected cells are cultured under conditions favoring expression or activating expression. The protein can then be isolated from a cell extract, cell membrane component or vesicle, or media.

25 Expression vectors with appropriate regulatory sequences can also be used to express a heterologous gene encoding an artificial zinc finger in a model organism, e.g., a *Drosophila*, nematode, zebrafish, *Xenopus*, or mouse. See, e.g., Riddle *et al.*, eds., *C. elegans II*. Plainview (NY): Cold Spring Harbor Laboratory Press; 1997.

**Protein Purification.** Zinc finger protein can be purified from materials  
30 generated by any suitable expression system, e.g., those described above.

Zinc finger proteins may be purified to substantial purity by standard techniques, including selective precipitation with such substances as ammonium sulfate; column



chromatography, affinity purification, immunopurification methods, and others (*see, e.g.,* Scopes, *Protein Purification: Principles and Practice* (1982); U.S. Patent No. 4,673,641; Ausubel *et al., supra*; and Sambrook *et al., supra*). For example, zinc finger proteins can include an affinity tag that can be used for purification, e.g., in combination with other  
5 steps.

Recombinant proteins are expressed by transformed bacteria in large amounts, typically after promoter induction; but expression can be constitutive. Promoter induction with IPTG is one example of an inducible promoter system. Bacteria are grown according to standard procedures in the art. Fresh or frozen bacteria cells are used for  
10 isolation of protein. Proteins expressed in bacteria may form insoluble aggregates (“inclusion bodies”). Several protocols are suitable for purifying proteins from inclusion bodies. *See, e.g.,* Sambrook *et al., supra*; Ausubel *et al., supra*). If the proteins are soluble or exported to the periplasm, they can be obtained from cell lysates or periplasmic preparations.

Differential Precipitation. Salting-in or out can be used to selectively precipitate a zinc finger protein or a contaminating protein. An exemplary salt is ammonium sulfate. Ammonium sulfate precipitates proteins on the basis of their solubility. The more hydrophobic a protein is, the more likely it is to precipitate at lower ammonium sulfate concentrations. A typical protocol includes adding saturated ammonium sulfate to a  
20 protein solution so that the resultant ammonium sulfate concentration is between 20-30%. This concentration precipitates many of the more hydrophobic proteins. The precipitate is analyzed to determine if the protein of interest is precipitated or in the supernatant. Ammonium sulfate is added to the supernatant to a concentration known to precipitate the protein of interest. The precipitate is then solubilized in buffer and the excess salt  
25 removed if necessary, either through dialysis or diafiltration.

Column chromatography. A zinc finger protein can be separated from other proteins on the basis of its size, net surface charge, hydrophobicity, and affinity for ligands. In addition, antibodies raised against proteins can be conjugated to column matrices and the proteins immunopurified. All of these methods are well known in the art.  
30 Chromatographic techniques can be performed at any scale and using equipment from many different manufacturers (e.g., Pharmacia Biotech). *See, generally, Scopes, Protein Purification: Principles and Practice* (1982).

Similarly general protein purification procedures can be used to recover a protein whose production is altered (e.g., enhanced) by expression of an artificial zinc finger protein in a producing cell.

## 5 **Gene and Cell-based Therapeutics**

One aspect of the invention, described above, provides for isolated DNA molecules which encode an artificial zinc finger protein. These isolated DNA molecules can be inserted into a variety of DNA constructs and vectors for the purposes of gene therapy. As used herein, a “vector” is a nucleic acid molecule competent to transport  
10 another nucleic acid molecule to which it has been covalently linked. Vectors include plasmids, cosmids, artificial chromosomes, and viral elements. The vector can be competent to replicate in a host cell or to integrate into a host DNA. Viral vectors include, e.g., replication defective retroviruses, adenoviruses and adeno-associated viruses. A gene therapy vector is a vector designed for administration to a subject, e.g., a mammal,  
15 such that a cell of the subject is able to express a therapeutic gene contained in the vector.

The gene therapy vector can contain regulatory elements, e.g., a 5' regulatory element, an enhancer, a promoter, a 5' untranslated region, a signal sequence, a 3' untranslated region, a polyadenylation site, and a 3' regulatory region. For example, the 5' regulatory element, enhancer or promoter can regulate transcription of the DNA  
20 encoding the therapeutic polypeptide. The regulation can be tissue specific. For example, the regulation can restrict transcription of the desired gene to brain cells, e.g., cortical neurons or glial cells; hematopoietic cells; or endothelial cells. Alternatively, regulatory elements can be included that respond to an exogenous drug, e.g., a steroid, tetracycline, or the like. Thus, the level and timing of expression of the therapeutic zinc finger  
25 polypeptide (e.g., a polypeptide that regulates VEGF) can be controlled.

Gene therapy vectors can be prepared for delivery as naked nucleic acid, as a component of a virus, or of an inactivated virus, or as the contents of a liposome or other delivery vehicle. Alternatively, where the gene delivery agent, e.g., a viral vector, can be produced from recombinant cells which produce the gene delivery system. Appropriate  
30 viral vectors include retroviruses, e.g., Moloney retrovirus, adenoviruses, adeno-associated viruses, and lentiviruses, e.g., Herpes simplex viruses (HSV). HSV is

potentially useful for infecting nervous system cells.

A gene therapy vector can be administered to a subject, for example, by intravenous injection, by local administration (see U.S. Patent 5,328,470) or by stereotactic injection (see e.g., Chen et al. (1994) *Proc. Natl. Acad. Sci. USA* 91:3054-  
5 3057). The gene therapy agent can be further formulated, for example, to delay or prolong the release of the agent by means of a slow release matrix. One method of providing a recombinant therapeutic tri-domain polypeptide, is by inserting a gene therapy vector into bone marrow cells harvested from a subject. The cells are infected, for example, with a retroviral gene therapy vector, and grown in culture. Meanwhile, the  
10 subject is irradiated to deplete the subject of bone marrow cells. The bone marrow of the subject is then replenished with the infected culture cells. The subject is monitored for recovery and for production of the therapeutic polypeptide.

Cell based-therapeutic methods include introducing a nucleic acid that encoding the artificial zinc finger protein operably linked to a promoter into a cell in culture. The  
15 artificial zinc finger protein can be selected to regulate an endogenous gene in the culture cell or to produce a desired phenotype in the cultured cell. Further, it is also possible to modify cells, e.g., stem cells, using nucleic acid recombination, e.g., to insert a transgene, e.g., a transgene encoding an artificial zinc finger protein that regulates an endogenous gene. The modified stem cell can be administered to a subject. Methods for cultivating  
20 stem cells in vitro are described, e.g., in US Application 2002-0081724. In some examples, the stem cells can be induced to differentiate in the subject and express the transgene. For example, the stem cells can be differentiated into liver, adipose, or skeletal muscle cells. The stem cells can be derived from a lineage that produces cells of the desired tissue type, e.g., liver, adipose, or skeletal muscle cells.

25 In another embodiment, recombinant cells that express or can express an artificial zinc finger protein, e.g., as described herein, can be used for replacement therapy in a subject. For example, a nucleic acid encoding the artificial zinc finger protein operably linked to a promoter (e.g., an inducible promoter, e.g., a steroid hormone receptor-regulated promoter) is introduced into a human or nonhuman, e.g., mammalian, e.g.,  
30 porcine recombinant cell. The cell is cultivated and encapsulated in a biocompatible material, such as poly-lysine alginate, and subsequently implanted into the subject. See, e.g., Lanza (1996) *Nat. Biotechnol.* 14:1107; Joki et al. (2001) *Nat. Biotechnol.* 19:35;

and U.S. Patent No. 5,876,742. In implementations where the artificial zinc finger protein regulates an endogenous gene that encodes a secreted protein, production of the secreted polypeptide can be regulated in the subject by administering an agent (e.g., a steroid hormone) to the subject.

5           In still another embodiment, the recombinant cells that express or can express an artificial zinc finger protein are cultivated in vitro. A protein produced by the recombinant cells can be recovered (e.g., purified) from the cells or from media surrounding the cells.

#### 10    **Target for Altered Protein Production**

          In one embodiment, a nucleic acid library is screened to identify an artificial zinc finger protein that alters production, synthesis or activity of one or more particular target proteins. The alteration can increase or decrease activity or abundance of the target protein. The phenotype screened for can be associated with altered production or activity  
15   of one or more target proteins or can be the level of production or activity itself. For example, it is possible to screen a nucleic acid library for artificial transcription factors that activate or suppress expression of a reporter gene (such as those encoding luciferase, LacZ, or GFP) under the control of a regulatory sequence (e.g., the promoter) of an endogenous target gene.

20           Some exemplary target proteins include: cell surface proteins (e.g., glycosylated surface proteins), cancer-associated proteins, cytokines, chemokines, peptide hormones, neurotransmitters, cell surface receptors (e.g., cell surface receptor kinases, seven transmembrane receptors, virus receptors and co-receptors, extracellular matrix binding proteins, cell-binding proteins, antigens of pathogens (e.g., bacterial antigens, malarial  
25   antigens, and so forth). Additional protein targets include enzymes such as enolases, cytochrome P450s, acyltransferases, methylases, TIM barrel enzymes, isomerases, acyl transferases, and so forth.

          More specific examples include: integrins, cell attachment molecules or "CAMs" such as cadherins, selections, N-CAM, E-CAM, U-CAM, I-CAM and so forth); proteases  
30   (e.g., subtilisin, trypsin, chymotrypsin; a plasminogen activator, such as urokinase or human tissue-type plasminogen activator); bombesin; factor IX, thrombin; CD-4; platelet-

derived growth factor; insulin-like growth factor-I and -II; nerve growth factor; fibroblast growth factor (e.g., aFGF and bFGF); epidermal growth factor (EGF); VEGFa; transforming growth factor (TGF, e.g., TGF- $\alpha$  and TGF- $\beta$ ); insulin-like growth factor binding proteins; erythropoietin; thrombopoietin; mucins; human serum albumin; growth hormone (e.g., human growth hormone); proinsulin, insulin A-chain insulin B-chain; parathyroid hormone; thyroid stimulating hormone; thyroxine; follicle stimulating hormone; calcitonin; atrial natriuretic peptides A, B or C; leutinizing hormone; glucagon; factor VIII; hemopoietic growth factor; tumor necrosis factor (e.g., TNF- $\alpha$  and TNF- $\beta$ ); enkephalinase; Mullerian-inhibiting substance; gonadotropin-associated peptide; tissue factor protein; inhibin; activin; vascular endothelial growth factor; receptors for hormones or growth factors; rheumatoid factors; osteoinductive factors; an interferon, e.g., interferon- $\alpha$ , $\beta$ , $\gamma$ ; colony stimulating factors (CSFs), e.g., M-CSF, GM-CSF, and G-CSF; interleukins (ILs), e.g., IL-1, IL-2, IL-3, IL-4, etc.; decay accelerating factor; and immunoglobulins. In some embodiments, the target is associated with a disease, e.g., cancer.

The present invention will be described in more detail through the following examples. However, it should be noted that these examples are not intended to limit the scope of the present invention.

#### EXAMPLE 1: CONSTRUCTION OF ZFP LIBRARIES

In one example, various phenotypes of *Saccharomyces cerevisiae* are altered by regulating gene expression using zinc finger protein (ZFP) expression libraries. The zinc finger proteins in these exemplary libraries consist of three or four zinc finger domains (ZFDs) and recognize 9- to 12-bp DNA sequences respectively. The chimeric zinc finger protein is identified without *a priori* knowledge of the target genes. Three different class of transcription factors are produced from the ZFPs in the libraries: isolated ZFPs themselves function as efficient transcriptional repressors when they bind to a site near the promoter region; ZFPs are also expressed as fusion proteins to a transcriptional activation domain or to a repression domain to yield transcriptional activators or repressors, respectively.

We used 40 different zinc finger domains as modular building blocks to construct 3-finger or 4-finger zinc finger protein. At their upper limits, a 3-finger ZFP library consists of 64,000 ( $= 40^3$ ) sequences and a 4-finger library consists of 2.6 million ( $= 40^4$ ) sequences.

5        These libraries of ZFP expression plasmids were then transformed into yeast cells. In each transformed cell, a different ZFP transcription factor would be expressed and regulate unspecified target genes in the genome. This alteration of gene expression pattern can lead to phenotypic changes. By screening a large number of transformed cells, one can isolate clones with desired phenotypes. In addition, the regulated target genes  
10       can be identified by genome-wide analyses of gene expression profile (e.g., via DNA microarray analysis) or in silico prediction of target DNA sequences after identifying zinc finger proteins introduced to the transformants.

#### (1) Yeast Strains

15       The *S. cerevisiae* strain used for this experiment was YPH499a (*MATa*, *ade2-101*, *ura3-52*, *lys2-801*, *trp1-63*, *his3-200*, *leu2-1*, *GAL+*). Transformation of yeast cells was carried out by using the lithium acetate transformation method (see, e.g., Gietz *et al.*, (1992) *Nucl. Acids Res* 20:1245).

#### 20       (2) Construction of plasmid p3

The parental vector that we used to construct libraries of zinc finger proteins is the plasmid p3. p3 was constructed by modifying the pcDNA3 vector (Invitrogen, San Diego CA) as follows. The pcDNA3 vector was digested with HindIII and XhoI. A synthetic oligonucleotide duplex with compatible overhangs was ligated into the digested pcDNA3.  
25       The duplex contains nucleic acid that encodes the hemagglutinin (HA) tag and a nuclear localization signal. The duplex also includes: restriction sites for BamHI, EcoRI, NotI, and BglII; and a stop codon. The XmaI site in SV40 origin of the vector was destroyed by digestion with XmaI, filling in the overhanging ends of the digested XmaI restriction site, and religation of the ends.

30

#### (3) Construction of plasmid pYCT-Lib

We used pYCT-Lib as the parental vector for conditional expression of zinc finger

proteins in yeast. pYCT-Lib is a yeast shuttle vector that includes the inducible GAL1 promoter (FIG. 1). Other features can include (i) a sequence encoding a nuclear localization signal (NLS) and a hemagglutinin tag (HA) and (ii) a sequence including the *TRP1* gene for selection of plasmid containing cells on synthetic minimal media lacking tryptophan.

The polylinker from the T7 primer site to the SphI site region can include:

TAATACGACTCACTATAGGGAATATTAAGCTAAGCTCACCATGGGTAAGCCT  
ATCCCTAACCCTCTCCTCGGTCTCGATTCTACACAAGCTATGGGTGCTCCTCC  
AAAAAAGAAGAGAAAGGTAGCTGGATCCACTAGTAACGGCCGCCAGTGTGCT  
GGAATTCTGCAGATATCCATCACACTGGCGGCGCTCGAGGCATGCATCTA  
(SEQ ID NO:135)

p-YCT-Lib was constructed as follows. The yeast expression plasmid pYESTrp2 (Invitrogen, San Diego CA) was digested with NgoM4 and then was partially digested with PstI to remove the 2 $\mu$  ori fragment from the vector. The 5.0 kb DNA fragment from the NgoM4-PstI digested vector was purified after gel electrophoresis and ligated with a CEN-ARS fragment that was amplified from pRS313 (forward primer: 5'-CGATCTGCAGGG TCCTTTTCATCACGTGCT-3' (SEQ ID NO:136), reverse primer: 5'-CGATCGATGCCG GCGGACGGATCGCTTGCCT (SEQ ID NO:137)).

The DNA segment that encodes the B42 activation domain was removed by digestion with NcoI and BamHI and replaced with a DNA fragment encoding the V5 epitope tag and the nuclear localization signal. The latter DNA fragment was PCR-amplified from pYESTrp2 (forward primer: 5'-AATTCCATGGGTAAGCCTATCCCTAACC-3' (SEQ ID NO:138), reverse primer: 5'-AATTGGATCCAGCTACCTTTCTCTTCTT-3' (SEQ ID NO:139)) and ligated into the NcoI and BamHI sites. The resulting plasmid was named as pYTC-Lib (FIG. 1).

#### (4) Construction of plasmid pYCT-Lib-Gal4

To generate pYCT-Lib-Gal4, the Gal4 activation domain was PCR-amplified from yeast genomic DNA (forward primer: 5'-AAGGAAGGAAGGAAGCGGC CGCAGCCAATTTTAATCAAAGTGG-3' (SEQ ID NO:140), reverse primer: 5'-ACATACATGCATGCGCCGTTACTAGTGGATCC-3' sequence (SEQ ID NO:141)) and inserted between the NotI and SphI recognition sites of pYTC-Lib to generate

pYTC-Lib-Gal4. An exemplary sequence encoding the Gal4 activation domain and linking sequences includes:

GGCCGCCAGTGTGCTGGAATTCTGCAGATATCCATCACACTGGCGGCCGCAG  
 CCAATTTTAATCAAAGTGGGAATATTGCTGATAGCTCATTGTCCTTCACTTTC  
 5 ACTAACAGTAGCAACGGTCCGAACCTCATAACAACTCAAACAAATTCTCAAG  
 CGCTTTCACAACCAATTGCCTCCTCTAACGTTTCATGATAACTTCATGAATAAT  
 GAAATCACGGCTAGTAAAATTGATGATGGTAATAATTCAAACCACTGTCAC  
 CTGGTTGGACGGACCAAACTGCGTATAACGCGTTTGGAATCACTACAGGGAT  
 GTTTAATACCACTACAATGGATGATGTATATAACTATCTATTTCGATGATGAAG  
 10 ATACCCCAACCAACCCAAAAAAGAGATCTCTATGGCTTACCCATACGATGT  
 TCCAGATTACGCTAGCTAAGGATCCACTAGTAACGGCGCATGCATCTAGAGG  
 GCC (SEQ ID NO:142)

(5) Construction of plasmid pYCT-Lib-Ume6

15 To generate pYCT-Lib-Ume6, a DNA fragment encoding amino acids 508 to 594 of *S. cerevisiae* Ume6 was amplified from yeast genomic DNA (forward primer: 5'-AAGGAAGGAAGGAAGCGGCCGCAAATTCTGCATCTTCATCTACC-3' (SEQ ID NO:143), reverse primer: 5'-ACATACATGCATGCTGTAGAATTGTTGCTTTTCG-3' (SEQ ID NO:144)) and inserted between the NotI and SphI recognition sites of pYTC-Lib. This 87-amino acid region functions as a transcriptional repression domain (Kadosh and Struhl (1997) *Cell* 89:365-371). An exemplary sequence encoding the Ume6 repression domain and linking sequences includes:

GGCCGCCAGTGTGCTGGAATTCTGCAGATATCCATCACACTGGCGGCCGCAA  
 25 ATTCTGCATCTTCATCTACCAAACTAGACGACGACTTGGGTACAGCAGCAGCA  
 GTGCTATCAAACATGAGATCATCCCCATATAGAACTCATGATAAACCCATTTC  
 CAATGTCAATGACATGAATAACACAAATGCGCTCGGTGTGCCGGCTAGTAGG  
 CCTCATTCGTCATCTTTTCCATCAAAGGGTGTCTTAAGACCAATTCTGTTACGT  
 ATCCATAATTCCGAACAACAACCCATTTTCGAAAGCAACAATTCTACAGCATG  
 30 CATCTAGAGGGCC (SEQ ID NO:145)

(6) Library construction

A three-fingered protein library (the "3-F library"), encoding zinc finger proteins that have an array of three ZFDs, was constructed from nucleic acids encoding  
 35 40 different ZFDs or "fingers." A four-fingered protein library (the "4-F library") was constructed from nucleic acids encoding 27 different ZFDs (Table 2, below).



Table 2: Zinc finger domains for construction of 3-finger or 4-finger ZFP libraries.

Domain Name	Source	Target Sites	Amino acid sequences	SEQ ID NO:	Library
DSAR	Mutated <sup>1</sup>	GTC	FMCTWSYCGKRFTDRSALARHKRTH	146	3F
DSHR	Mutated <sup>1</sup>	GGC	HICHIQCGCKVYGDRSHLTRHLRWH	147	3F
DSKR	Mutated <sup>1</sup>	GGT	FACPECCKRFMDSSKLSRHIKTH	148	3F
DSNR	Mutated <sup>2</sup>	GAC	YACPVESCDRRFSDSSNLTRHIRH	149	3F
DSSR	Mutated <sup>3</sup>	GCC	HICHIQCGCKVYGDRSSLTRHLRWH	150	3F
HSNK	Human	GAC	YKCKECGKAFNHSSNFNKHHRH	151	3F
HSSR	Human	GTT	FKCPVCGKAFRHSSSLVRHQRT	152	3F
ISNR	Human	GAA>GAT>GAC	YRCKYCDRSFSSISNLQRHVRNIH	153	3F
KSNR	Human	GAG	YGCHLCGKAFSKSSNLRRHEMIH	154	3F
QAGR	Human	GGA	YKCECGQAFRQRAHLIRHHKLH	155	3F
QFNR	Human	GAG	YKCHQCGKAFIQSFNLRRHERTH	156	3F
QGNR	Human	GAA	FQCNQCGASFTQKGNLLRHIKTH	157	3F
QNTQ	Drosophila <sup>4</sup>	ATA	YTCSYCGKSFTQSNLTQKHTRI	158	3F
QSHR5	Human	GGA>AGA>GAA>CGA	YVCRECGRGFRQHSNLRVHKKRTH	159	3F-
QSHV	Human	CGA>AGA>TGA	YECDHCGKSFSQSSHLNVHKKRTH	160	3F
QSN1	Human	AAA, CAA	YMCSECGRGFSQKSNLIIHQRT	161	3F
QSNK	Human	GAA>TAA>AAA	YKCEECGKAFTQSSNLTKHKKIH	162	3F
QSTR	Human	GTA>GCA	YKCEECGKAFNQSSLTTRHKIVH	163	3F
QTHR1	Human	GGA>AGA,GAA>TGA,CGA	YECDHCGKSFRQSTHLTRHRIH	164	3F
RDHR1	Human	GAG, GGG	FLCQYCAQRFGRKDHLTRHMKKSH	165	3F
RDKR	Human	GGG>AGG	YVCDVEGCTWKFARSDKLNHRHKKRH	166	3F
RDNQ	Mutated <sup>6</sup>	AAG	FACPECCKRFMRSDNLTQHIKTH	167	3F
SADR	Mutated <sup>3</sup>	AGA	FQCRICMRNFSSPADLTRHIRTH	168	3F
SSNR	Human	GAG>GAC	YECKECGKAFSSGSNFTRHQRIH	169	3F
TIDR	Mutated <sup>5</sup>	ACT	FQCRICMRNFSTHIDLIRHIRTH	170	3F
VSNV	Human	AAT>CAT>TAT	YECDHCGKAFSVSSNLNVHRRH	171	3F
VSTR	Human	GCT>GCG	YECNYCGKTFSVSSTLIRHQRIH	172	3F
CSNR1	Human	GAA>GAC>GAG	YKCKQCGKAFGCPNLRHGRTH	173	3F-,4F-
DGNV	Mutated <sup>5</sup>	AAC	FQCRICMRNFSDSGNLRVHIRTH	174	3F-,4F-
QSHR3	Human	GGA>GAA	YACHLCGKAFTQCSHLRRHEKTH	175	3F-
QSHT	Human	AGA,CGA>TGA>GGA	YKCEECGKAFRQSSHLTTHKIIH	176	3F-,4F-
QSNR1	Human	GAA	FECKDCGKAFIQKSNLIRHQRT	177	3F-,4F-
QSNV2	Human	AAA,CAA	YVCSKCGKAFTQSSNLTVHQKI	178	3F-,4F-
QSSR1	Human	GTA>GCA	YKCPDCGKSFSQSSSLIRHQRT	179	3F-,4F-
QTHQ	Human	CGA>TGA,AGA	YECDHCGKSFRQSTHLTQHRRH	180	3F-,4F-
RDER1	Human	GCG>GTG, GAG	YVCDVEGCTWKFARSDENLRHKKRH	181	3F-,4F-
RDHT	Human	TGG,AGG, CGG,GGG	FQCKTCQRFKRSRDLKTHTRTH	182	3F-,4F-
RSHR	Human	GGG	YKCMCEGKAFNRRSHLTRHQRIH	183	3F-,4F-
RSNR	Human	GAG>GTG	YICRKCGRGFSRKSNIIRHQRT	184	3F-,4F-
VDYK	Drosophila <sup>7</sup>	TAT, GAT	FHCYCEKSFVSKDYLTKIRTH	185	3F-,4F-
VSSR	Human	GTT>GCT>GTG>GTA	YTCKQCGKAFSVSSSLRRHETTH	186	3F-,4F-
DGAR	Mutated <sup>3</sup>	GTC	FQCRICMRNFSDPGALVRHIRTH	187	4F-
DGHR	Mutated <sup>3</sup>	GGC	FQCRICMRNFSDPGHLVRHIRTH	188	4F-
DGNR	Mutated <sup>3</sup>	GAC	FQCRICMRNFSDPGNLKRHIRTH	189	4F-
DRDR	Mutated <sup>3</sup>	GCC	FQCRICMRNFSDCDLARHIRTH	190	4F-
MHHE	Mutated <sup>8</sup>	TGT	YACPVESCDRRFSMSHHLKEHIRTH	191	4F-
QASA	Mutated <sup>8</sup>	ATA	FQCRICMRNFSSQASLNARHIRTH	192	4F-
QGDR	Mutated <sup>3</sup>	GCA, GCC	FQCRICMRNFSSQSDLRRHIRTH	193	4F-
QSDR	Mutated <sup>9</sup>	GCT	FQCRICMRNFSSQSDLVRHIRTH	194	4F-
QGTR	Mutated <sup>8</sup>	ACA	FQCRICMRNFSSQSGTLTRHIRTH	195	4F-
RDTN	Mutated <sup>5</sup>	AAG	FQCRICMRNFSSDTLSNHIRTH	196	4F-
TDKR	Mutated <sup>3</sup>	GGG, GGT	FQCRICMRNFSTADKLSRHIRTH	197	4F-
TGNR	Mutated <sup>3</sup>	GAT>GAA	FQCRICMRNFSTSGNLVRHIRTH	198	4F-
TIDR	Mutated <sup>5</sup>	ACT	FQCRICMRNFSTHIDLIRHIRTH	199	4F-

Superscripts in column 2 of Table 2 refer to 1) Zhang *et al.*, (2000) *J. Biol. Chem.* 275:33850-33860; 2) Rebar and Pabo (1994) *Science* 263:671-673; 3) Segal (1999) *Proc. Natl. Acad. Sci. USA* 96:2758 ; 4) Gogus *et al.*, (1996) *Proc. Natl. Acad. Sci. USA*.

93:2159-2164; 5) Drier *et al.*, (2001) *J. Biol. Chem.* 276: 29466-29478; 6) Liu *et al.* (2001) *J. Biol. Chem.* 276(14):11323-11334; 7) Hsu *et al.*, (1992) *Science* 257:1946-50.

FIG. 7 depicts a method of constructing a diverse three finger library. Nucleic acid fragments encoding each ZFD were individually cloned into the p3 vector to form "single fingered" vectors. Equal amounts of each "single fingered" vector were combined to form a pool. One aliquot of the pool was digested with AgeI and XhoI to obtain digested vector fragments. These vector fragments were treated with phosphatase for 30 minutes. Another aliquot of the pool was digested with XmaI and XhoI to obtain segments encoding single fingers. The digested vector nucleic acids from the AgeI and XhoI digested pool were ligated to the nucleic acid segments released from the vector by the XmaI and XhoI digestion. The ligation generated vectors that each encodes two zinc finger domains. After transformation into *E. coli*, approximately  $1.4 \times 10^4$  independent transformants were obtained, thereby forming a two-fingered library. The size of the insert region of the two-fingered library was verified by PCR analysis of 40 colonies. The correct size insert was present in 95% of the library members.

To prepare a three-fingered library, DNA segments encoding one finger were inserted into plasmids encoding two fingers. The 2-fingered library was digested with AgeI and XhoI. The digested plasmids, which retain nucleic acid sequences encoding two zinc finger domains, were ligated to the pool of nucleic acid segments encoding a single finger (prepared as described above by digestion with XmaI and XhoI). The products of this ligation were transformed into *E. coli* to obtain about  $2.4 \times 10^5$  independent transformants. Verification of the insert region confirmed that library members predominantly included sequences encoding three zinc finger domains.

To prepare a four-fingered library, DNA segments encoding two fingers were inserted into plasmids encoding two fingers. The two-fingered library was digested with XmaI and XhoI to obtain nucleic acid segments that encode two zinc finger domains. The two-fingered library was also digested with AgeI and XhoI to obtain a pool of digested plasmids. The digested plasmids, which retain nucleic acid sequences encoding two zinc finger domains, were ligated to the nucleic acid segments encoding two zinc finger domains to produce a population of plasmids encoding different combination of four fingered proteins. The products of this ligation were transformed into *E. coli* and yielded about  $7 \times 10^6$  independent transformants.

(7) *Construction of libraries for expression in yeast*

The three-fingered (3-F) and four-fingered (4-F) libraries were subcloned into the EcoRI and NotI sites of pYTC-Lib, pYTC-Gal4, and pYTC-Ume6. These subcloning procedures produced six different libraries encoding three and four fingered ZFPs with and without transcriptional regulatory domains. After amplification in *E. coli*, each library was transformed into the yeast strain YPH499a using lithium acetate. The transformation yielded approximately  $1.5 \times 10^7$  colonies. The size of the insert region of the library was verified by PCR analysis of 50 colonies. 95% of the library members included the correct insert size. The transformants were resuspended in TE buffer and stored in glycerol at -80°C.

EXAMPLE 2: GROWTH-DEFECTIVE TRANSFORMANTS ON GALACTOSE MEDIA

The 3-F libraries were screened to identify chimeric zinc finger proteins that impair the growth of yeast cells. This screen uses the GAL promoter to conditionally express the chimeric zinc finger proteins. Previous studies have used the GAL promoter to yeast cDNA and genomic DNA sequences to identify genes whose overexpression is lethal (Liu *et al.*, (1992) *Genetics* 132:665-673; Ramer *et al.* (1992) *Proc. Natl. Acad. Sci. USA* 89:11589-11593; Espinet *et al.*, (1995) *Yeast* 11:25-32; Akada *et al.*, (1997) *Mol. Gen. Genet* 254:267-274; Stevenson *et al.*, (2001) *Proc. Natl. Acad. Sci. USA* 98:3946-3951).

Yeast strain YPH499a was transformed with nucleic acid from the 3-F libraries. Transformants were grown for two days at 30°C on plates containing synthetic minimal medium that lack tryptophan and that include glucose. Each of these glucose plates was replica-plated onto a galactose plate and a second glucose plate. The replica plates were grown overnight at 30°C. Then, each galactose plate was compared to its corresponding glucose replica plate. Colonies were identified that did not grow on galactose, but grew on glucose. These colonies were recovered from the glucose plate and retested by streaking selected colonies on galactose media. Library plasmids were rescued from each colony that retested. The plasmids were retransformed into YPH499a to confirm that the growth defect is caused by expression of the zinc finger protein. The vector plasmids

pYTC and pYTC-Gal4, both of which do not encode any zinc finger domains, were analyzed as controls.

As shown in Table 3, 0.7% to 2.8% of transformants from the 3-F and 4-F libraries were unable to grow on galactose media. These percentages are significantly greater than the similar values obtained with the pYTC-Lib vector control (0.1%) and pYTC-Lib-Gal4 vector control (0.2%).

Table 3. Ratio of growth-defective transformants on galactose media

<i>Library</i>	<i>No. of colonies on glucose media (A)</i>	<i>No. of growth-defective colonies on galactose media (B)</i>	<i>Ratio of growth-defective mutants (B/A x 100)</i>
3-finger	5,820	42	0.7
3-finger + Gal4AD	7,428	206	2.8
3-finger + Ume6RD	8,400	78	0.93
PYTC-Lib vector	2,690	3	0.1
PYTC-Lib-Gal4 vector	2,750	6	0.2

Plasmids were recovered from ten colonies that were growth-defective on galactose. The plasmids (L1 to L10) were retransformed into yeast cells. All ten plasmids retested. Cells transformed with the recovered plasmids were unable to grow on galactose media but were able to grow on glucose media. The zinc finger proteins encoded by these ten plasmids were characterized by DNA sequencing (Table 4). The potential target DNA binding sites for these proteins were inferred from information about the binding specificities of the component zinc finger domains.

Table 4: ZFPs encoded in plasmids isolated from growth-defective transformants

No	Name of ZFD (N to C)			Potential target sequence
	1	2	3	
L1	RSHR	CSNR1	RDHT	5'-NGG GAV GGG-3' (SEQ ID NO:200)
L2	RSNR	RDHT	TDKR	5'-GGK NGG GAG-3' (SEQ ID NO:201)
L3	RDHT	QSHR3	RDHT	5'-NGG GRA NTT-3' (SEQ ID NO:202)
L4	QSDR	RDHT	RSNR	5'-GAANGG GCT-3' (SEQ ID NO:203)
L5	CSNR1	RDTN	VSSR	5'-GTD AAG GAV-3' (SEQ ID NO:204)

L6	RDHT	RDHT	RDER1	5'-GHG NGG KGG-3' (SEQ ID NO:205)
L7	QSNR1	RDTN	QTHQ	5'-HGA AAG GAA-3' (SEQ ID NO:206)
L8	TGNR	RDER1	RDHT	5'-NGG GHG GAW-3' (SEQ ID NO:207)
L9	QSSR1	RDHT	QTHQ	5'-HGA NGG GYA-3' (SEQ ID NO:208)
L10	QSSR1	RDHT	QSNR1	5'-GAA NGG GYA-3' (SEQ ID NO:209)

### EXAMPLE 3: ANTI-FUNGAL DRUG RESISTANCE

Ketoconazole is an orally absorbed antimycotic imidazole drug. It can be administered for the treatment of certain mucoses. Ketoconazole blocks the biosynthesis of ergosterol in yeasts and other fungi (Burden *et al.*, (1989) *Phytochemistry* 28:1791-1804) and has additional effects on cellular metabolism (Kelly *et al.*, (1992) In Fernandes, P.B. (Ed.) *New Approaches for Antifungal Drug*, Birkhäuser, Boston, pp.155-187).

To check the fungistatic response of the tester strain YPH499a to ketoconazole, 10<sup>7</sup> cells of the YPH499a strain were plated onto synthetic media containing different concentrations of the drug. We found that 35 µM ketoconazole inhibited growth of YPH499a cells and used this concentration to screen for ketoconazole-resistant yeast colonies.

1 x 10<sup>7</sup> yeast cells containing plasmids from the 3-finger and 4-finger libraries were cultivated in synthetic liquid medium with 2% galactose for 3 hours at 30°C to induce zinc finger protein expression and then were plated onto synthetic galactose agar plates containing 35 µM ketoconazole (ICN Biomedicals). After four days of incubation at 30°C, about 120 clones formed colonies on galactose media containing 35 µM ketoconazole. These ketoconazole resistant yeast colonies were picked and streaked on fresh synthetic galactose agar plates containing 35 µM ketoconazole. 23 clones were randomly selected from the 120 resistant clones. For each of these 23 clones, the resistant phenotype was verified by plasmid rescue. The plasmids were isolated, transformed into *E. coli* for amplification, and retransformed into yeast strain YPH499a (Ausubel, *et al.* (Eds) (1995) *Current Protocols in Molecular Biology* John Wiley and Sons Ltd, New York). Equal numbers of retransformants were spotted onto synthetic galactose agar

plates with or without 35  $\mu$ M ketoconazole. The retransformants were also spotted onto synthetic glucose agar plates with or without ketoconazole to verify that the drug resistance was induced by galactose-inducible expression of zinc finger protein.

In one experiment,  $5 \times 10^4$  cells from each transformant were serially diluted ( $10^{-1}$ ,  
5  $10^{-2}$ , and  $10^{-3}$  fold) and spotted on galactose or glucose media supplemented without or with 35  $\mu$ M ketoconazole. Growth of the cells was monitored after four days at 30°C and compared to controls on the same plate. Controls included a plasmid encoding a zinc finger protein that does not confer ketoconazole resistance and the pYTC-Lib plasmid without an insert encoding a zinc finger protein. In all 23 cases, recovered plasmids  
10 retested. In addition, ketoconazole resistance was observed only when the cells were plated on galactose media, confirming that expression of the zinc finger protein confers ketoconazole resistance.

The plasmids isolated from ketoconazole resistant transformants were sequenced and their expected target sequences in yeast genome were predicted (Table 5). Eleven  
15 unique clones were identified (Table 5).

Table 5: ZFPs that confer ketoconazole resistance

No.	Name of ZFD (N to C)				Functional domain	Potential target sequence	Number of isolates <sup>(1)</sup>
	#1	#2	#3	#4			
K1	QSHV	QFNR	RSHR	-	UME6	5'-GGG GAG HGA-3' (SEQ ID NO:210)	3
K2	RSNR	RSNR	QSSR1	QSHT	UME6	5'-HGA GYA GAG GAG-3' (SEQ ID NO:211)	1
K3	RSNR	RSNR	QGTR	QSHR5	UME6	5'-GRA ACA GAG GAG-3' (SEQ ID NO:212)	2
K4	RSNR	RSNR	QGTR	QTHQ	UME6	5'-HGA ACA GAG GAG-3' (SEQ ID NO:213)	1
K5	VSSR	DGNV	VSSR	VDYK	GAL4	5'-KAT GTD AAC GTD-3' (SEQ ID NO:214)	2
K6	MHHE	QSNR1	VSSR	QGDR	GAL4	5'-GCA GTD GAA TGT-3' (SEQ ID NO:215)	3
K7	DGNV	QSHT	QSSR1	DGHR	GAL4	5'-GGC GYA HGA AAC-3' (SEQ ID NO:216)	3
K8	DGAR	RDTN	QTHQ	RDTN	-	5'-AAG HGA AAG GTG-3' (SEQ ID NO:217)	1
K9	RDHT	QTHQ	QSHT	DGNV	-	5'-AAC HGA HGA NGG-3' (SEQ ID NO:218)	1
K10	RDHT	QTHQ	QSHT	-	-	5'-HGA HGA NGG-3' (SEQ ID NO:219)	5
K11	RDHT	QSHV	QSHV	-	-	5'-HGA HGA NGG-3' (SEQ ID NO:220)	1

<sup>(1)</sup> The number of isolates of the ZFP among the 23 isolated ketoconazole-resistant transformants.

The amino acid sequences of these proteins are listed below (zinc finger domains are underscored and transcriptional regulatory domains are bolded). K1:QSHV-QFNR-RSHR-Ume6 includes the following amino acid sequence:

5 MGKPIPNPLLGLNSTQAMGAPPKKRKGIRIPGEKPYECDHCGKSFSQSSHLNVHKRTHHTGEKP  
YKCHQCGKAFTQSFNLRHERHTHTGEKPYKMECGKAFNRRSHLTRHQRTHAAAAANSASSSTKLD  
 DDLGTAAAVLSNMRSSPYRTHDKPISNVNDMNTNALGVPASRPHSSSFPSKGVLRPILLRIHNS  
 EQQPIFESNNSTACI (SEQ ID NO:221)

10 K2: RSNR-RSNR-QSSR1-QSHT-Ume6 includes the following amino acid  
 sequence:

MGKPIPNPLLGLNSTQAMGAPPKKRKGIRIPGEKPYICRKCGRGFSRKSNIIRHQRTHHTGEKP  
 YICRKCGRGFSRKSNIIRHQRTHHTGEKPYKCPDCGKSFSQSSSLIRHQRTHHTGEKPYKCEECGKA  
FROSSHLTTHKLIHAAAAANSASSSTKLDDDLTGTAAAVLSNMRSSPYRTHDKPISNVNDMNTNAL  
 15 GVPASRPHSSSFPSKGVLRPILLRIHNSQQPIFESNNSTACI (SEQ ID NO:222)

K3: RSNR-RSNR-QGTR-QSHR5-Ume6 includes the following amino acid  
 sequence:

MGKPIPNPLLGLNSTQAMGAPPKKRKGIRIPGEKPYICRKCGRGFSRKSNIIRHQRTHHTGEKP  
YICRKCGRGFSRKSNIIRHQRTHHTGEKPFQCRICMRNFSQRGTLTRHIRTHHTGEKPYVCRECGRG  
 20 FRQSHLVRHKRTHAAAAANSASSSTKLDDDLTGTAAAVLSNMRSSPYRTHDKPISNVNDMNTNAL  
 GVPASRPHSSSFPSKGVLRPILLRIHNSQQPIFESNNSTACI (SEQ ID NO:223)

K4: RSNR-RSNR-QGTR-QTHQ-Ume6 includes the following amino acid  
 sequence:

25 MGKPIPNPLLGLNSTQAMGAPPKKRKGIRIPGEKPYICRKCGRGFSRKSNIIRHQRTHHTGEKP  
YICRKCGRGFSRKSNIIRHQRTHHTGEKPFQCRICMRNFSQRGTLTRHIRTHHTGEKPYECHDCGKS  
FRQSTHLTQHRRIHAAAAANSASSSTKLDDDLTGTAAAVLSNMRSSPYRTHDKPISNVNDMNTNAL  
 GVPASRPHSSSFPSKGVLRPILLRIHNSQQPIFESNNSTACI (SEQ ID NO:224)

30 K5: VSSR-DGNV-VSSR-VDYK-Gal4 includes the following amino acid  
 sequence:

MGKPIPNPLLGLNSTQAMGAPPKKRKGIRIPGEKPYTCKQCGKAFSVSSSLRRHETHTHTGEKP  
FQCRICMRNFSDSGNLRVHIRTHHTGEKPYTCKQCGKAFSVSSSLRRHETHTHTGEKPFHCGYCEKS  
FSVKDYLTKIRTHAAAAANFNQSGNIADSSLSFTFTNSSNGPNLITTTQNSQALSQPIASSNVHDNFMNNEITAS  
 35 KIDDGNNKPLSPGWIDQTAYNAFGITTGMENTTMDDVYNLYFDDDETTPNPKEISMAYPYDVPDYAS (SEQ  
 ID NO:225)

K6: MHHE-QSNR1-VSSR-QGDR-Gal4 includes the following amino acid  
 sequence:

40 MGKPIPNPLLGLNSTQAMGAPPKKRKGIRIPGEKPYACPVESCDRRFSMSHHLKEHIRTHHTGE  
 KPFECCKDCGKAFTQKSNLIIRHQRTHHTGEKPYTCKQCGKAFSVSSSLRRHETHTHTGEKPFQCRICM  
RNFSQSGDLRRHIRTHAAAAANFNQSGNIADSSLSFTFTNSSNGPNLITTTQNSQALSQPIASSNVHDNFMNNE



ITASKIDDGNNKPLSPGWIDQTAYNAFGITTCMFNTITMDDVYNLYFDDDETPPNPKKEISMAYPYDVPDYAS  
(SEQ ID NO:226)

K7: DGNV-QSHT-QSSR1-DGHR-Gal4 includes the following amino acid

5 sequence:

MGKPIPNPLLGLNSTQAMGAPPKKRKRKVGIRIPGEKPFQCRICMRNFSDSGNLRVHIRTHHTGEKP  
YKCEECGKA~~FRQSSHLTTHKIIHT~~GEKP YKCPDCGKSFSQSSSLIRHQRTHHTGEKP FQCRICMRN  
FSDPGHLVRHIRTHAAAANFNQSGNIADSSLSFTFNSSNGPNLITQTNSQALSQPIASSNVHDNFMNNEITA  
SKIDDGNNKPLSPGWIDQTAYNAFGITTCMFNTITMDDVYNLYFDDDETPPNPKKEISMAYPYDVPDYAS (SEQ  
10 ID NO:227)

K8: DGAR-RDTN-QTHQ-RDTN includes the following amino acid sequence:

MGKPIPNPLLGLNSTQAMGAPPKKRKRKVGIRIPGEKPFQCRICMRNFSDPGALVRHIRTHHTGEKP  
FQCRICMRNFSRSDTL~~SNHIRTHTGEKPYECHDCGKSFRQSTHLTQHRRIHT~~GEKPFQCRICMRN  
15 FSRSDTL~~SNHIRTHT~~AAAARGMHLEGRIM (SEQ ID NO:228)

K9: RDHT-QTHQ-QSHT-DGNV includes the following amino acid sequence:

MGKPIPNPLLGLNSTQAMGAPPKKRKRKVGIRIPGEKPFQCKTCQKFSRSDHLKTHTRTHHTGEKP  
YECDCGKSFRQSTHLTQHRRIHTGEKPYKCEECGKA~~FRQSSHLTTHKIIHT~~GEKPFQCRICMRN  
20 FSDSGNLRVHIRTHAAAARGMHLEGRIM (SEQ ID NO:229)

K10: RDHT-QTHQ-QSHT includes the following amino acid sequence:

MGKPIPNPLLGLNSTQAMGAPPKKRKRKVGIRIPGEKPFQCKTCQKFSRSDHLKTHTRTHHTGEKP  
YECDCGKSFRQSTHLTQHRRIHTGEKPYKCEECGKA~~FRQSSHLTTHKIIH~~AAAARGMHLEGRIM  
25 (SEQ ID NO:230)

K11: RDHT-QSHV-QSHV includes the following amino acid sequence:

MGKPIPNPLLGLNSTQAMGAPPKKRKRKVGIRIPGEKPFQCKTCQKFSRSDHLKTHTRTHHTGEKP  
YECDCGKSFSQSSHLNVHKRTHHTGEKPYECDCGKSFSQSSHLNVHKRTHAAAARGMHLEGRIM  
30 (SEQ ID NO:231)

Other zinc finger proteins that include two, three, or more zinc finger domains that  
have the same general motifs (i.e., set of four DNA contacting residues) and that are  
arranged in the same consecutive order as any of the proteins described above may also  
35 confer drug resistance to a fungal cell.

Some of clones had included a similar configuration of zinc finger domains. The  
first and second fingers of K2, K3, and K4 are identical to one another. In these clones,  
three out of four fingers are identical to those in corresponding positions in the other  
proteins. It is extremely unlikely that these ZFPs are related only by chance ( $P < 1.6 \times 10^{-}$

<sup>5</sup>). Accordingly, the K2, K3, and K4 ZFPs may bind to the same target site *in vivo* and regulate the same target genes.

In addition, the zinc finger protein encoded by the K10 clone is closely related to those encoded in the K9 and K11 clones. The QTHQ, QSHT, and QSHV fingers found in  
5 K9, K10, and K11 can recognize the same 3-bp DNA site: 5'-HGA-3'. Given their structural similarity, the K9, K10, and K11 ZFPs may bind to the same target site *in vivo* and regulate the same target genes. Within each of the two groups of related clones (i.e., K2, K3, and K4; and K9, K10, and K11), all the ZFPs include the same type of regulatory features. The K2, K3, and K4 clones each include the Ume6 repression domain. The K9,  
10 K10, and K11 clones each function without a dedicated transcriptional regulatory domain.

Synergistic or additive effects may result when two or more ZFPs are cotransformed into cells. For example, when the K4 and K5 ZFPs were co-expressed, yeast cells became completely resistant to ketoconazole. The combination produced an approximately 1,000-fold enhancement of the phenotype.

15 ZFP mutants were constructed that alter a DNA contacting residue or that remove or replace a regulatory domain. In one mutant (VSSR-DGAV-VSSR-VDYK-GAL4AD), the asparagine DNA contacting residue of the second zinc finger of K5 was mutated to alanine. Gel shift assays demonstrated that this mutated ZFP had at least 10-fold decrease in DNA-binding affinity for its expected DNA site. This mutant K5 protein does not  
20 confer drug resistance to yeast cells. In another mutant, the Gal4 activation domain of the K5 zinc finger protein was deleted by inserting a stop codon in front of the DNA sequence encoding the activation domain. This protein also does not confer resistance to ketoconazole. Similar results were obtained for the other ketoconazole resistance ZFPs.

When the activation domain fused to the K5 ZFP was replaced with the Ume6  
25 repression domain, expression of the Ume6-form of the protein reversed the ketoconazole resistance phenotype. The cells that express the Ume6-form were more sensitive to ketoconazole relative to control cells. This result indicates that transcription factors can be selected by selecting for transcription factors that exacerbate a phenotype and then altering the attached regulatory domain (e.g., by switching the directionality of its  
30 function) to produce a transcription factor that has the desired phenotypic effect. Screening for opposite phenotype opposite to the desired phenotype can be more amenable than screening for the desired phenotype itself. Examples of replacements that

switch functional directionality include replacing one type of regulatory domain with another type or regulatory domain and removing a regulatory domain. In the case of the K5 ZFP, a protein that increases drug sensitivity was obtained by screening for a protein that increased drug resistance and replacing its transcriptional activation domain with a transcriptional repression domain.

Table 6:

Ketoconazole conc. (uM)	control		K5		YLL053C	
	average	st. dev.	average	st. dev.	average	st. dev.
0	100	0	100	0	100	0
5	82.7	4.1569	89.9	15.544	84.167	16.003
10	0.031	0.0044	90.6	5.8207	28.433	7.0002
15	0.0123	0.0021	82.467	7.7106	15.7	11.95
20	0.001	0	50.367	4.7014	2.4	0.1
25			4.2	3.1193	0.0233	0.0058
30			0.0433	0.0058	0.0033	0.0006
35			0.0167	0.0058	0.0013	0.0006

DNA microarray analysis was used to identify genes associated with the drug resistance phenotype. We reasoned that different ZFPs conferring the identical phenotype may regulate identical gene sets whose differential expression is directly or indirectly associated with the phenotype. Three ZFPs -- K5, K6, and K7 -- were chosen for expression profiling analyses. All three transcription factors contain the Gal4 activation domain. Out of 6,400 yeast open reading frames, ten were activated over 2 fold by at least two different ZFP transcription factors, and four open reading frames were activated by all three tested ZFP transcription factors. The four activated open reading frames are: YLL053C, YJR147W, YLL052C, and YPL091W.

Table 7 lists the number of genes that are regulated by more than one chimeric ZFP.

Table 7: Coordinately Regulated Genes

K5	K6	K7	Number of Commonly Regulated Genes
+	-	-	39
+	+	-	1
+	-	+	2
+	+	+	4
-	+	-	95
-	+	+	3
-	-	+	126

*PDR5*, a gene known to pump out ketoconazole, was activated by two ZFPs, K6 and K7, but not by K5. This result suggests that K5 confers ketoconazole resistance by a  
5 *PDR5*-independent mechanism and that at least two different pathways can confer ketoconazole resistance in yeast. One pathway depends on activation of *PDR*, and the other is independent of *PDR5*.

To identify new genes associated with the drug resistant phenotype, we evaluated the drug resistance phenotype of cells overexpressing one of the four genes activated by  
10 all three tested ZFP transcription factors. We found that one of the genes -- YLL053C -- induced ketoconazole resistance when overexpressed on its own. See Table 6, above. YLL053C is homologous to plasma membrane and water channel proteins from *Candida albicans*. The amino acid sequence of YLL053C is as follows:

15 MWFPQIIAGMAAGGAASAMTPGKVLFTNALGLGCSRSRGLFLEMFGTAVLCLTVLMTAVE  
KRETNFMAALPIGISLFMAHMALTYGTGTGVNPARSLGAAVAARYFPHYHWIYWISPLLGA  
AFLAWSVWQLLQILDYTTYVNAEKAAGQKKED (SEQ ID NO:232)

The amino acid sequence of an exemplary homologous channel protein (AQY1) from *Candida albicans* is as follows:

20 MVAESSSIDNTPNDVEAQRFPVYEPKYDDSVNVSPLKNHMI AFLGEEFFGTFFIFLWVAFVIA  
QIANQDPTIPDKGSDPMQLIMISFGFGFGVMMGVFMFFRVSGGNLNPVTLTLVLAQAVP  
PIRGLFMMVAQMIAGMAAAGAASAMTPGPPIAFTNGLGGGASKARGVFLEAFGTCILCLTV  
LMMAVEKSRATFMAPFVIGISLFLGHLICVYYTGAGLNPARSFGPCVAARSFPVYHWIYW  
25 VGPILGSVIAFAIWKIFKILKYETCNPGQSDA (SEQ ID NO:233)

The YLL053C gene product may confer resistance by pumping out ketoconazole as does the *PDR5* gene product. These data demonstrate that genes associated with phenotypic changes can be identified by the analysis of gene expression profiles of cells. Gene identification is further assisted by the use of different chimeric ZFPs that cause the  
30 same phenotype (in this example, ketoconazole resistance).

EXAMPLE 4: THERMOTOLERANT TRANSFORMANTS SCREENING

We screened libraries encoding chimeric zinc fingers for nucleic acids that encode proteins that confer thermotolerance to yeast cells.

1 x 10<sup>7</sup> yeast cells containing nucleic acids from the 3-fingered libraries were  
5 cultivated on SD synthetic liquid medium with 2% galactose for 3 hrs at 30°C and then  
incubated at 52°C (air temperature) with slow gyration for 2 hrs. After heat treatment, the  
culture were plated on galactose media and incubated for 5 days at 30°C. Growing yeast  
colonies were suspended in galactose liquid media and incubated at 52°C for 2 hrs to  
confirm the thermotolerant phenotype. Plasmids were isolated from these cells and  
10 retransformed into yeast as describe above. The retransformants were cultivated in  
galactose liquid media for 3 hrs at 30°C and incubated at 52°C for 2hrs. The incubated  
retransformants were spotted in four dilution onto SD galactose agar plates. To verify  
that the thermotolerance is induced by the expression of zinc finger protein in the mutants,  
retransformants were cultivated in SD glucose liquid media with the same condition  
15 described above and then spotted onto SD glucose agar plates. The transformants with  
pYTC vector and plasmid encoding randomly-picked 3-fingered proteins were used as  
controls for the procedure.

Thermotolerant yeast cells were identified from the cells transformed with zinc  
finger protein expression plasmids. Wild-type cells carrying the pYTC-Lib plasmid or  
20 plasmid encoding a randomly-selected zinc finger protein were used as negative controls.  
A total of 10<sup>7</sup> cells were grown in galactose liquid media. Galactose induces zinc finger  
protein expression. Cells were heat treated at 52°C for 2hrs and then plated on galactose  
minimal agar plates. After five days of incubation at 30°C, 26 colonies grew on the plates.  
We rescued plasmids from these colonies and retransformed them into YPH499a. We  
25 isolated nine clones that induced varying degrees of thermotolerance. Typically,  
expression of the zinc finger proteins from these clones caused up to 10% of the cells to  
survive heat treatment, when cultured in galactose media but not in glucose media. Only  
about 0.3% of cells transformed with control plasmid survived under the same conditions.  
Freshly-growing retransformed cells survive better under the experimental conditions  
30 than frozen cell stocks. These results demonstrate that the expression of particular zinc  
finger proteins can induce thermotolerance in yeast cells. ZFPs were characterized by  
DNA sequencing of the recovered library plasmids (Table 8).

Table 8: ZFPs encoded in plasmids isolated from thermotolerant transformants

No.	Name of ZFD Motif (N to C)			Functional domain	Potential target sequence
	1	2	3		
H1	ISNR	QSNI	RDNQ	UME6	5'-AAG MAA GAH-3'
H2	QNTQ	QNTQ	HSNK	UME6	5'-GAC ATA ATA-3'
H3	QSHR5	DSHR	DSKR	GAL4	5'-GGT GGC GRA-3'
H4	RDKR	QSTR	QSHR5	GAL4	5'-GRA GYA RGG-3'
H5	RDHR1	QSSR1	QSHR5	UME6	5'-GRA GYA GRG-3'
H6	QAHR	RSHR	RSHR	UME6	5'-GGG GGG GGA-3'
H7	DSNR	RDHT	QNTQ	-	5'-ATA NGG GAC-3'
H8	ISNR	RSNR	RSNR	-	5'-GAG GAG GAH-3'
H9	RDHT	QSNK	QSTR	-	5'-GYA DAA NGG-3'

EXAMPLE 5: NEURITE FORMATION

5 We screened our nucleic acid libraries for nucleic acids encoding zinc finger proteins that induce neuritogenesis in the mouse neuroblastoma cell line Neuro2A, a cell line capable of differentiating into a neuronal cell type. We identified a novel chimeric ZFP that induces neuronal differentiation, as evidenced by alterations in cell morphology and the expression of neuronal marker genes.

10

Materials and Methods*Library Construction*

See Example 1, above. As described, a three- finger and four-finger ZFP-Tf libraries were constructed using 40 and 25 zinc finger domains, respectively. The three-  
15 finger and four-finger libraries recognize approximately 9- and 12-bp DNA binding sites, respectively. ZFPs were expressed as fusion proteins to the p65 transcriptional activation domain and to the KRAB repression domain.

*Cell culture and neuronal differentiation of Neuro2A cells*

Mouse neuroblastoma Neuro2a cells were maintained in MEM-a media with 10%  
20 FBS and antibiotics at 37°C, in a humidified atmosphere containing 95% air and 5% CO<sub>2</sub>.

Cells were seeded at  $8.0 \times 10^3$  cells per 96-well culture plate and then were transfected using LIPOFECTAMINE PLUS™ reagent (Invitrogen, CA) according to the manufacturer's protocol, with 50 ng of ZFP, together with 20 ng of LacZ reporter plasmid. In vitro differentiation was carried out with or without retinoic acid (RA) (10  $\mu$ M) respectively, and G418 (1 mg/ml) was treated 24 hours after transfection to reduce the number of untransfected cells. Cells were then cultured for 96 hours and then fixed, stained for  $\beta$ -galactosidase activity, and photographed. Among  $\beta$ -galactosidase-positive cells, cells were regarded as differentiated if the length of neurite extension was at least two times the diameter of the cell body.

## Result and Discussion

### *Screening ZFP-TFs inducing neuritogenesis*

To screen for ZFP-TFs that can induce neuronal differentiation, Neuro2A cells were transiently transfected with library plasmids and a reporter plasmid that includes the LacZ gene. LacZ expression was used to visualize the morphology of transfected cells. Because the differentiating cells grow slower than non-differentiating cells and the latter will dominate the cell population, we treated the cell culture with G418 24hr after transfection to reduce the number of untransfected cells. After five days, cells were fixed and LacZ-stained. We then characterized the cells by their morphological characteristics. In particular, we identified cells with increased neurite length and thickness.

We identified several ZFP-TFs that alter neuritogenesis. These ZFP-TFs affect neuritogenesis to varying degrees. The ZFP-TF, named Neuro1-p65, had the most prominent effect on differentiation, as measured by the length and thickness of neurites that it produced. A marked acceleration of neuritogenesis in the Neuro1-p65-transfected Neuro2A cell was also observed when cells were treated with 10  $\mu$ M RA (retinoic acid).

The nucleic acid sequence encoding Neuro1-p65 and its amino acid sequence is shown in FIG. 14. The Neuro1-p65 nucleic acid encodes a chimeric ZFP that includes the zinc finger domains QSNR1-QSNK-CSNR1. Other ZFPs with the same motifs and/or ZFPs that binding to a site that at least partially overlaps the Neuro1-p65 binding site are also expected to modulate differentiation. Based on the zinc finger-DNA binding site directory (see Table 6), the predicted binding site for Neuro1 is 5'-GACGAAGAA-3'.

Neuro1-p65 requires the p65 activation domain to induce neurite formation. The same zinc finger domains fused to the KRAB transcriptional repression domain or without any effector domain do not drive neuritogenesis. See FIG. 8 and Table 9. Also the DNA binding ability of Neuro1-p65 is critical, since mutations that are predicted to  
 5 disable its DNA binding ability of the zinc finger domains of Neuro1-p65 (Neuro1-p65mut) abolished its ability to support neuritogenesis.

Real-time PCR is used to characterize the expression level of neuronal marker genes during the course of Neuro1-p65 expression in cells. Similarly, nucleic acid microarrays are used to compare the pattern of gene expression between RA-treated cells  
 10 and ZFP-TF treated cells at various time points during differentiation. Neuro1-p65 may activate a pathway that is required for neuroblastoma cell differentiation at least in vitro.

Table 9: Percentage of neurite bearing cells

Construct	No RA	RA 10uM
pCDNA3 (vector)	5.77 ± 1.99	14.93 ± 7.69
08_D1-p65	42.39 ± 5.56	41.59 ± 6.46
08_D1mut-p65	5.25 ± 0.71	NA
08_D1 alone	5.85 ± 4.44	NA
08_D1-KRAB	4.46 ± 0.57	NA

#### 15 EXAMPLE 6: OSTEOGENESIS

The C2C12 cell line is derived from the myoblast lineage, but can differentiate into osteoblasts upon the addition of bone morphogenic protein-2 (BMP-2) (Katagiri, T. *et al.*, (1994) *J. Cell. Biol.* 127, 1755). Several naturally-occurring transcription factors have been identified as candidates for controlling this process (Lee, K.-S. *et al.*, (2000)  
 20 *Mol. Cell. Biol.* 20:8783; Nakashima, K. *et al.*, (2002) *Cell* 108:17).

We screened for chimeric zinc finger proteins that induce transdifferentiation of C2C12 myoblasts to osteoblasts in the absence of BMP-2. We transiently transfected a nucleic acid library encoding chimeric zinc finger proteins into C2C12 cells and screened for cells that undergo transdifferentiation in the absence of BMP-2. Seven days after  
 25 transfection, the transformed cells were stained for alkaline phosphatase (ALP), a marker for osteoblasts (Katagiri, T. *et al.*, (1994) *J. Cell. Biol.* 127:1755).



From a screen of about 2,000 ZFP-TFs, we identified one activator, Osteo1-p65, that induced strong ALP staining in about 30 % of cells. The percentage of cells stained with ALP was similar to the percentage of transfected cells detected by LacZ staining. From these results, we conclude that the Osteo1-p65 transcription factor can trigger the transdifferentiation of C2C12 myoblasts to osteoblasts in the absence of BMP-2.

As a positive control, cells were treated with 1 µg/ml of BMP-2. Nearly 100% of the positive control cells strongly stained for ALP upon BMP-2 treatment. Without BMP-2 treatment, negative control cells that were transfected with a control vector had only background staining. Osteo1-p65 is a four-finger protein composed of the RDKR-QTHR1-VSTR-RDKR zinc finger domains (from N- to C-terminus). See FIG. 15. This protein is predicted to recognize the DNA element 5'-GGGGCWRGAGGG-3' (SEQ ID NO:234).

For these experiments, the mouse myoblast cell line, C2C12, was maintained in Dulbecco's Modified Eagle's Medium (DMEM) with 4.5g/L glucose, 10% FBS, and antibiotics, at 37°C, in a humidified atmosphere containing 95% air and 5% CO<sub>2</sub>. Cells were seeded at  $1.0 \times 10^4$  cells per 96-well culture plates. The cells were transfected with 50 ng of library nucleic acid using LIPOFECTAMINE PLUS™ (Invitrogen) according to the manufacturer's protocol. Twenty-four hours after transfection, the growth medium was replaced with DMEM containing 2% FBS, and the cells were cultured for an additional six days.

To examine the differentiation of C2C12 cells to osteoblasts, ALP staining was performed as described in Katagiri, T. *et al.*, (1994) *J. Cell. Biol.* 127:1755.

In summary (referring to Examples 5 and 6), we have screened artificial transcription factor libraries for proteins that can induce two different cell differentiation processes, neurogenesis and osteogenesis. Again, the method does not require prior knowledge of the biology of particular stem cells.

#### EXAMPLE 7: INSULIN REGULATION

We stably transfected nucleic acids encoding chimeric zinc finger proteins in human 293 cell lines, and analyzed transformed cells using DNA microarray experiments to characterize genes regulated by each chimeric zinc finger protein (see FIGs. 4, 5, and 9). We have identified a chimeric zinc finger protein (08\_D04-p65) that increases the

expression of human insulin gene more than 60 fold.

To test whether 08\_D04-p65 can induce insulin gene expression in different human cell lines, we transiently transfected a nucleic acid encoding 08\_D04-p65 into HeLa cells. Expression of the nucleic acid in HeLa cells caused a 80 fold increase in  
5 expression of the insulin gene.

Accordingly, 08\_D04-p65, its derivatives, and similarly functional zinc finger proteins can be used as therapeutics for diabetes. DNA encoding 08\_D04-p65 or a similarly functional zinc finger protein can be delivered into diabetic patients by viral delivery or in encapsulated form (e.g., a liposome). Once DNA is delivered into cells, the  
10 zinc finger protein can be expressed to induce the production of insulin. In some implementations, the nucleic acid encoding the zinc finger protein can be operably linked to an inducible promoter, e.g., a Tet-inducible promoter. The use of doxycycline as an inducer enables the level of insulin production to be regulated by a small chemical. Because insulin-inducing zinc finger proteins, such as 08\_D04-p65, can function in  
15 different human cell lines, it may work in both pancreatic cells (e.g., beta cells and non-beta cells) and non-pancreatic cells.

It is also possible to identify an artificial transcription factor that induces expression of insulin processing enzymes. Cells can be engineered to express such a transcription factor and a transcription factor that induces the insulin gene, e.g., 08\_D04-  
20 p65. In addition, insulin-inducing zinc finger proteins can be also used for ex vivo cell therapy. In one example, cells from a patient are modified *in vitro* by the introduction of a nucleic acid encoding an insulin-inducing zinc finger protein. The modified cells are then transplanted back into patients or into another subject.

## 25 Materials and Methods.

### *DNA microarray analysis of cell lines expressing ZFP-TFs*

Nucleic acids encoding zinc finger proteins were stably introduced into FlpTRex-  
293 cell lines (Invitrogen) essentially as described in the manufacturer's protocols. Briefly, the HindIII-XhoI fragment from the pLFD-p65 or pLFD-Kid vectors was  
30 subcloned into pCDNA5/FRT/TO (Invitrogen CA). This fragment includes a sequence encoding the zinc finger proteins. Resulting plasmids were cotransfected into FlpTRex-

293 cells with pOG44 (Invitrogen). Stable integrants that express ZFP-TFs upon doxycycline induction were obtained.

DNA microarrays containing 7458 human EST clones were obtained from Genomictree (Korea). FlpTRex-293 cells stably expressing ZFP-TFs were grown with (+Dox) or without (-Dox) 1 µg/ml Doxycycline for 48 hours. Total RNA was prepared from each sample. RNA from the -Dox sample was used as a reference (Cy3), and +Dox as the experimental sample (Cy5). Microarray analysis was performed according to the manufacturer's protocols. Spots with sum of median less than 500 were colored red and not analyzed.

Nucleic acids encoding certain zinc finger proteins were also expressed in HeLa cells. pLFD-p65 containing 08\_D04 ZFP was transiently transfected into HeLa cells using LIPOFECTAMINE™ 2000 (Invitrogen). The pLFD-p65 vector, which does not encode a zinc finger protein, was also transfected into cells in parallel as a control.

#### EXAMPLE 8

We screened libraries encoding chimeric zinc fingers to identify nucleic acids that encode proteins that alter reporter gene expression in a mammalian cell.

##### *Construction of libraries*

Two ZFP libraries were constructed as four finger proteins and three finger proteins in P3, a modified pcDNA3 vector. Construction of these libraries is described above.

##### *Transfection of ZFP plasmids*

Human embryonic kidney 293 cells were cultured with 100 µl of DMEM with 10 % of FBS in a humidified atmosphere containing 95% air and 5% CO<sub>2</sub> and seeded in wells of a 96 well plates 1 day ahead of transfection. The plasmids were isolated from individual colonies of each library separately and transfected into 293 cells LIPOFECTAMINE PLUS™ (Invitrogen) as recommended by the manufacturer. For MTT assay, 50 ng of plasmids containing zinc finger protein gene fused to the functional domains were transfected into cells cultured at 5 x 10<sup>3</sup> cells/well. For the SEAP assay, 10 ng of pSEAP2-control (Clontech) plasmid was co-transfected with 50 ng of plasmids

containing zinc finger protein gene fused to the functional domains into cells cultured at  $1 \times 10^4$  cells/well. The transfected cells were incubated at 37°C for three days before assays.

5 *SEAP assay*

Three days after transfection, medium was transferred to the new tubes and heated for 30 minutes at 65°C to inactivate the endogenous alkaline phosphatase. 25 µl of medium was mixed with the same volume of 2 X SEAP assay buffer (2 M Diethanolamine (pH 9.8) 10 ml, 1 M  $\text{MgCl}_2$  10 µl, 1M homoarginine 200 µl, pNitro phenyl phosphate 44.52 mg). Absorbance at 405 nm was measured after the indicated incubation times at 37°C.

*Luciferase assay*

For the luciferase assay, 5 ng of both CMV-luciferase and pRL-SV40 plasmid were co-transfected with 50 ng of ZFP coding plasmids to 293 cells seeded in wells of a 96 well plate. After 3 days of incubation, cells were harvested and the luciferase assay was done by a Dual Luciferase reporter assay system (Promega) as recommended by the manufacturer.

20 *MTT assay*

MTT assay is used to measure cell growth. Tetrazolium MTT reduced by metabolically active cells changes to a yellow color. Measurement of light absorbance by the yellow color indicates the number of viable cells. MTT assay was done using a MTT assay kit (Trevigen). The MTT assay was done at three days after transfection. Briefly, 10 µl of MTT solution was added directly to the culture medium and incubated for two hours in a  $\text{CO}_2$  incubator. Then, 100 µl of detergent solution from the MTT assay kit was added and incubated in the dark for two hours before measurement of absorbance at 570 nm was measured using a Power-Wave 340x (Bio-Tek Instrument).

To count cell numbers, 293 cells were seeded at  $1.5 \times 10^4$  cells/well in a 24 well plate one day before transfection. Three days after transfection with 200 ng of ZFP-coding nucleic acid or control vector plasmids, cells were washed with PBS once and suspended in 30 µl of TE (10 mM Tris 1 mM EDTA, pH 8.0) buffer and counted by the

hematocytometer.

## Results

### *Change of protein productivity*

5 We tested whether library nucleic acids could alter expression of a heterologous nucleic acid. SEAP (secretory alkaline phosphatase) was used as a reporter protein to test whether a ZFP can affect amount of foreign protein produced intracellularly. Table 10 shows representative results obtained from 81 wells, each well containing cells transfected with a nucleic acid encoding a random chimeric ZFP from the library and  
10 three wells containing reference cells transfected with a control vector. Several wells exhibited increased absorbance relative to other wells that contain cells transfected with nucleic acid encoding other random ZFPs and relative to the wells that contain cells transfected with a control vector.

Table 10: Reporter activity in the presence of 81 random ZFPs.

ZFP	Absorbance(405nm)	ZFP	Absorbance(405nm)	ZFP	Absorbance(405nm)
A01	0.29	C07	0.12	F01	0.15
A02	0.14	C08	0.16	F02	0.13
A03	0.14	C09	0.18	F03	0.13
A04	0.13	C10	0.17	F04	0.12
A05	0.19	C11	0.18	F05	0.13
A06	0.13	C12	0.15	F06	0.12
A07	0.12	D01	0.17	F07	0.12
A08	0.13	D02	0.15	F08	0.14
A09	0.11	D03	0.14	F09	0.19
A10	0.15	D04	0.14	F10	0.12
A11	0.15	D05	0.12	F11	0.20
A12	0.12	D06	0.13	F12	0.12
B01	0.15	D07	0.21	G01	0.15
B02	0.78	D08	0.12	G02	0.16
B03	0.15	D09	0.14	G03	0.14
B04	0.19	D10	0.15	G04	0.49
B05	0.13	D11	0.20	G05	0.26
B06	0.15	D12	0.12	G06	0.15
B07	0.14	E01	0.16	G07	0.22
B08	2.40	E02	0.13	G08	0.65
B09	0.11	E03	0.12	G09	0.18
B10	0.12	E04	0.41	vector	0.37

B11	0.13	E05	0.12	vector	0.39
B12	0.11	E06	0.15	vector	0.34
C01	0.20	E07	0.12		
C02	0.14	E08	0.12		
C03	0.31	E09	0.13		
C04	0.13	E10	0.34		
C05	0.13	E11	0.22		
C06	0.13	E12	0.11		

The P\_B08, a zinc finger protein fused to the p65 domain showing the highest SEAP activity. This ZFP was retested by transfection with the SEAP plasmid in three separate transfections. Table 11 illustrates one such retesting. The P value for P\_B08 in this assay is 0.008. P\_B08 exhibited approximately 16-fold increase of SEAP activity compared to that of the parental plasmid.

Table 11: SV40-SEAP reporter in 293 cells.

Expression Plasmid	average	st. dev.
P_B08	16.51	0.54
Vector(HANLS)	1	0.17

Since the SEAP assay was used to assay the production of foreign proteins, reasons for the observed increased SEAP activity could be various, for example, the direct or indirect activation of a SV40 promoter used for the SEAP gene expression in pSEAP2-Control plasmid. Other reasons include: increased activity of proteins functioning in secretion pathway or activation of the general machinery for the protein production. The mechanism of enhanced activity of SEAP can be elucidated by determining the effect of P\_B08 on the production of other proteins, e.g., using other reporter proteins (e.g., unsecreted reporters) and reporters linked to other promoters.

To investigate this point, an extensive screening had been carried out using the SEAP reporter under the control of CMV promoter (CMV-SEAP) in 293F cells. Two ZFPs, K44\_11\_D01 and K44\_11\_G12, that increase activity of the SEAP protein were isolated. These two ZFPs were further tested using two other reporter plasmids, SV40-SEAP and the luciferase reporter under the control of CMV promoter (CMV-Luc). Table 12 lists some of the results. K44\_11\_D01 and K44\_11\_G12 exhibited approximately 3-fold increase of SEAP activity compared to that of the parental plasmid (vector).

K44\_11\_D01 showed activation of SV40-SEAP but not the CMV-Luciferase, suggesting that the activation may be related to mechanisms specific to SEAP such as secretion. In contrast, K44\_11\_G12 showed approximately 2-3 fold activation for both CMV-luciferase and SV40-SEAP, suggesting that the mechanism is specific to neither promoter nor reporter. Thus, K44\_11\_G12 may be used increase the production of proteins generally in cells, e.g., eukaryotic cells.

Table 12: CMV-SEAP, CMV-Luc and SV40-SEAP reporter in 293F cells.

Expression plasmid	CMV-SEAP	average CMV-Luc	SV40-SEAP	CMV-SEAP	st.dev. CMV-Luc	SV40-SEAP
K44_11_D01	3.49	0.87	3.66	0.46	0.26	0.28
K44_11_G12	2.82	2.75	2.14	0.50	0.38	0.15
Vector (HA-NLS)	1	1	1	0.22	0.19	0.17

Zinc finger proteins K44-16-E12 (FIG. 25) and K12\_A11 (FIG. 24) may also alter protein production, e.g., as indicated by CMV-SEAP and SMV-Luc expression.

As an analogous example, the overexpression of cyclin D1 has been reported to cause to increase production of some proteins (US patent No. 6,210,924 B1). A zinc finger protein that can directly or indirectly activate the cyclin D1 expression may up-regulate protein production, although the effects of a zinc finger protein may be different, far more broad ranging, or more potent. Other zinc finger proteins resulting in a physiological effect similar to cyclin D1 overexpression can be isolated by this assay. Such zinc finger proteins can be used to enhance production of the protein of interest.

#### *Change of cellular growth rate*

Two ZFPs fused to the kid domain, K\_D10 and K\_F02, were selected as representatives of the ZFPs regulating cell growth since they exhibited the maximum variations compared to the controls based on the MTT assay results. To confirm the MTT assay, the cell numbers were counted after transfection of K\_D10 and K\_F02 in 293 cells. The result was compared to the cell number of the well transfected with the parental vector, converted to relative percentages and shown in Table 13. Compared to the parental vector, K\_D10 exhibited approximately 3-fold inhibition and K\_F02 showed 2.7-

fold activation of cell growth compared to the control. The P values for K\_D10 and K\_F02 are 0.001 and 0.01, respectively. For sequence information, see FIGs. 18 and 19.

Table: 13: MTT assay results for two ZFPs.

	relative cell number	
	average	st. dev.
K_F02	279.3	6.9
K_D10	27.4	4.3
Vector	99.99	3.4

#### 5 *Change of cellular growth rate*

We have identified zinc finger proteins that can alter the rate of cell growth and proliferation. These important phenotypes are linked to diseases such as cancer and viral infection and to developmental processes. The ability to use zinc finger protein to control cell growth and proliferation can include, for example, controlling apoptosis, cell  
10 differentiation, host cell defenses (e.g., against viral infection), and p53-mediated signaling

A zinc finger protein that produces one or more of these phenotypes may directly or indirectly regulate a gene that regulates cell growth or signaling. The specific zinc finger proteins describe here produce detectable effects to cellular growth as detected by  
15 the MTT assay. For example, two zinc finger proteins showed at least a two-fold difference of cell growth compared to the controls. Considering that this assay was based on observations of transiently transfected cells three days after transfection, the two-fold difference is significant. In addition, the change in the cell number confirms that that the difference detected using the MTT assay is not particular to the assay.

20 Since cell growth is such an important parameter of cell physiology, this experiment can be extended to a large screening to isolate sufficient numbers of zinc finger proteins regulating cellular growth. The cDNA microarrays can be used profile the gene expression patterns of cells that expressing each of these zinc finger proteins. The profiles can identify novel genes and pathways that participate in cell proliferation or  
25 apoptosis.

These experiments indicate that the zinc finger proteins are able to induce various phenotypes in mammalian cells, e.g., in this case altering cell proliferation.



EXAMPLE 9: SOLVENT TOLERANT BACTERIAL CELLS

We screened for bacterial cells that express artificial chimeric zinc finger proteins for cells that were resistant to an organic solvent as a result of the artificial chimeric zinc finger protein. Three different zinc finger proteins were identified for their ability to confer hexane tolerance to *E. coli* cells (Table 13). Hexane tolerance was evaluated by comparing the survival rate of transformants expressing one of the zinc finger proteins -- HT-1, HT-2, and HT-3 -- to the survival rate control cells. The control cells either included an empty vector (C1) or ZFP-1. The ZFP-1 construct encodes a zinc finger protein that does not confer hexane resistance and that includes the fingers RDER-QSSR-DSKR. Bacterial cells that express hexane resistance-conferring zinc finger proteins exhibited as much as a 200-fold increase in hexane tolerance.

Table 13: Hexane Resistant Zinc Finger Proteins.

Expression Construct	Name	Survival Rate (%)
Control	C1	0.14
Control	ZFP-1	0.05
Hexane resistance ZFP	HT-1	21.4
Hexane resistance ZFP	HT-2	1.85
Hexane resistance ZFP	HT-3	28.6

The expression plasmids for these zinc finger proteins include an IPTG-inducible promoter. Transformants that express each of the hexane resistance inducing ZFPs were characterized in the presence and absence of IPTG. Transformants expressing HT-2 showed higher hexane tolerance in the presence of IPTG, whereas HT-1 or HT-3 expressing cells were hexane tolerant even in the absence of IPTG.

Table 14: Zinc finger proteins that confer hexane tolerance in *E. coli*

Name	F1	F2	F3	F4	putative DNA target	No. of occurrences(##)
HT-1	RSHR	HSSR	ISNR		GAH GTT GGG	5
HT-2	ISNR	RDHT	QTHR	VSTR	GCT GRA NGG GAH (SEQ ID NO:235)	3
HT-3	QNTQ	CSNR	ISNR		GAH GAV ATA	1

(##) Occurrence of the ZFP in nine colonies that could grow after third round of hexane tolerant screening

**Construction of a nucleic acid library that encodes ZFPs for *E. coli***

**expression.** To express zinc finger proteins conditionally in *E. coli*, we subcloned the zinc finger proteins cloned in pYTC-Lib yeast vector into a pZL1. pZL1 was constructed by the modification of pBT-LGF2 (Clontech, Palo Alto, CA). Plac-UV5 was amplified  
5 from pBT-LGF2 by PCR (forward primer: 5'-GACA ACC GGT CAT CGA TAA GCT AAT TCT CAC-3' (SEQ ID NO:236); reverse primer: 5'-TTG TCC ATG GAC GCT GTT TCC TG GTG AAA-3' (SEQ ID NO:237)). The PCR product was cloned into the pYTC Lib vector between AgeI and NcoI site. The vector was named as pYTC-lac. pYTC-lac was digested with ClaI and NotI to subclone the DNA fragment containing the  
10 following elements: Plac promoter-V5 epitope-MCS. The digested DNA fragment was purified after gel-electrophoresis and subcloned into the ClaI and NotI sites of pBT-LGF2. The resulting vector was named as pZL1. The 3F- or 4F- ZFP library constructed in pYTC-Lib was digested with EcoRI and NotI. The digested DNA fragments were gel-purified and subcloned into EcoRI and NotI site of pZL1, thus providing a library for *E.*  
15 *coli* expression.

**Screening for Solvent Tolerance.** The *E. coli* strain DH5 $\alpha$  was transformed with the 3-finger or 4-finger ZFP nucleic acid library formatted for prokaryotic expression. Transformants were cultured overnight in LB with chloramphenicol (34  $\mu$ g/ml). The  
20 overnight-culture was diluted to 1:500 in 1 ml fresh LB media with 1mM IPTG and chloramphenicol to induce ZFP expression. After a three hour incubation at 30°C, hexane was added to 1.5% and rapidly vortexed to make emulsion of hexane and *E. coli* culture. The mixture was incubated for three hours with shaking (250 rpm) at 37°C and plated on LB plates with chloramphenicol  $\mu$ g/ml(34  $\mu$ g/ml). Plasmids were purified from the pool  
25 of growing colonies and transformed into DH5 $\alpha$ . The transformants were treated with hexane as described above. Selection for hexane tolerance was repeated two additional times. Plasmids were recovered from 20 individual colonies that could grow on LB plates with chloramphenicol (34  $\mu$ g/ml) after the third round of selection. These plasmids were retransformed into DH5 $\alpha$ . Each transformant was retested for hexane-tolerance as  
30 described above. Plasmids that induce hexane tolerance were sequenced to characterize the encoded zinc finger protein.

EXAMPLE 10: THERMO-TOLERANT BACTERIAL CELLS

We screened for zinc finger proteins that conferred heat resistance to cells. The nucleic acid library encoding different zinc finger proteins was transformed into *E. coli* cells. The cells were exposed to heat, and heat-resistant cells were recovered. Plasmids  
5 were purified from 23 individual colonies that were selected after the third round of phenotypic screening. Ten different zinc finger proteins were identified (Table 15) and the improvement of thermo-tolerance was analyzed by comparing survival rate of ZFP transformants and control cells, C1 or ZFP-2 upon heat treatment. C1 or ZFP-2 represent the transformants of empty vector or irrelevant ZFP (QTHQ-RSHR-QTHR1),  
10 respectively. More than 99.99% of wild type cells died upon heat treatment at 50°C for 2 hours. In contrast, about 6% of cells transformed with certain ZFP-TFs survived under these extreme conditions, a 700 fold increase in the thermotolerance phenotype -- that is, the percentage of cells expressing ZFP-TFs that survive under stress conditions (6.3%) divided by the percentage of C1 that survived under the same conditions (0.0085%).  
15 Since the expression of ZFP is induced by IPTG, transformants of ZFPs that induce thermo-tolerance were analyzed for their phenotype in the presence or absence of IPTG. Transformants of T-1 or T-10 showed higher thermo-tolerance in the presence of IPTG.

Table 15: ZFPs that confer thermotolerance.

Name	F1	F2	F3	F4	putative DNA target	Occurrences
T-1	QSHV	VSNV	QSNK	QSNK	5' DAA DAA AAT HGA 3' (SEQ ID NO:238)	6
T-2	RDHT	QSHV	QTHR1	QSSR1	5' GYA GRA HGA NGG K 3' (SEQ ID NO:239)	3
T-3	WSNR	QSHV	VSNV	QSHV	5' HGA AAT HGA GGT 3' (SEQ ID NO:240)	1
T-4	QTHR1	RSHR	QTHR1	QTHR1	5' GRA GRA GGG GRA 3' (SEQ ID NO:241)	1
T-5	DSAR	RDHT	QSHV	QTHR1	5' GRA HGA NGG GTC 3' (SEQ ID NO:242)	2
T-6	QTHQ	RSHR	QTHR1	QTHR1	5' GRA GRA GGG HGA 3' (SEQ ID NO:243)	1
T-7	QSHV	VSNV	QSNR1	CSNR1	5' GAV GAA AAT HGA 3' (SEQ ID NO:244)	3
T-8	VSNV	QTHR1	QSSR1	RDHT	5' NGG GYA GRA AAT 3' (SEQ ID NO:245)	2
T-9	RDHT	QSHV	QTHR1	QSNR1	5' GAA GRA HGA NGG K 3' (SEQ ID NO:246)	2
T-10	DSAR	RDHT	QSNK	QTHR1	5' GRA DAA NGG GTC 3' (SEQ ID NO:247)	2

**Screening for thermotolerance.** Libraries for prokaryotic expression were prepared as described in Example 9. *E. coli* strain DH5 $\alpha$  was transformed with 3-finger or 4-finger ZFP library and cultured overnight in LB with chloramphenicol (34  $\mu$ g/ml). The overnight-culture was diluted to 1:500 in 1 ml fresh LB media with 1  $\mu$ M IPTG and chloramphenicol (34  $\mu$ g/ml) to induce ZFP expression. After a 3 hour incubation at 30°C, 100ul culture was transferred to micro-centrifuge tube and incubated in water bath at 50°C for 2 hrs. The culture was plated on LB plate with chloramphenicol (34  $\mu$ g/ml). Plasmids were purified from the pool of growing colonies and transformed into DH5 $\alpha$ . Selection for thermotolerance was repeated with retransformants. Plasmid was purified from 30 individual colonies that could grow on LB + chloramphenicol plate (34  $\mu$ g/ml) after third round of selection and retransformed into DH5 $\alpha$ . Each transformant was analyzed for thermo-tolerance as described above. Plasmids that could induce thermo-tolerance were sequenced to identify ZFP.

#### EXAMPLE 11: GENES REGULATED BY ZFP F121-P65

The zinc finger protein F121\_p65 was expressed in human embryonic kidney 293 cells. Transcripts from the cells were profiled and compared transcripts profiled from a

corresponding control cell that does not express F121\_p65. Examples of transcripts up-regulated by F121\_p65 are listed in Table 16. F121\_p65 increases transcription of insulin-like growth factor 2, among other genes.

Table 16: Genes up-regulated by F121\_p65

Name	ID	Norm ratio of medians(ROM)
insulin-like growth factor 2 (somatomed	H59614	17.71
insulin-like growth factor 2 (somatomed	H59614	16.88
protein tyrosine phosphatase, receptor t	R45941	16.45
insulin-like growth factor 2 (somatomed	N54596	14.40
Putative gene product	H09111	12.35
jun B proto-oncogene	N94468	11.61
Cellular retinoic acid-binding protein 2	AA598508	10.30
protein phosphatase 2, regulatory subuni	R59165	9.89
Nuclear factor of activated T-cells, cyt	AA679278	9.64
FK506-binding protein 8 (38kD)	N95418	8.66
protein phosphatase 2, regulatory subuni	R59165	8.60
Cadherin 13, H-cadherin (heart)	R41787	7.34
Cysteine-rich protein 2	AA485427	6.71
zinc finger protein homologous to Zfp-36	R38383	6.46
tumor necrosis factor (ligand) superfami	AI347622	6.15
Cadherin 13, H-cadherin (heart)	R41787	5.90
brain-specific protein p25 alpha	AA133959	5.71
growth arrest and DNA-damage-inducible,	AA404666	5.55
lymphocyte antigen 6 complex, locus H	AI929550	5.50
ketohehexokinase (fructokinase)	T61256	5.28
cyclin D1 (PRAD1: parathyroid adenomatos	AA487486	5.27
-	AA045731	5.27
Fn14 for type I transmembrane protein	AI221536	5.06

5

#### Example 12: Change of foreign protein solubility in *E. coli*

We screened for zinc finger proteins that conferred enhanced solubility of the recombinant protein, Akt1 expressed in *E. coli*. The mammalian Akt1 gene was cloned in pET21b vector and GFP was ligated to the C-terminal of the Akt1 ORF. The nucleic acid library encoding different zinc finger proteins was transformed into *E. coli* cells. The Akt1:GFP construct was introduced into ZFP transformants. Increased solubility of Akt1 was analyzed by FACS sorting, since soluble Akt1 expressing cells produce more fluorescent GFP. After the eighth round of phenotypic screening, individual colonies

were selected and the improvement of solubility was analyzed by comparing the amount of Akt1 in soluble fraction between ZFP expressed and C1 expressed cell by western blot analysis. The western blot result was quantified by image analysis software, QUANTITY ONE (*Bio-Rad*, Hercules, CA). C1 represent the transformants of empty vector, pZL1.

- 5 Two different zinc finger proteins were identified that increase the solubility to a recombinant Akt1 protein expressed in *E. coli*.

The ratio of the amount of Akt1 protein between soluble and insoluble fraction in C1 was 32.5:67.5. In contrast, cells transformed with certain zinc finger proteins showed a 2 fold increase of the ratio of Akt1 in soluble fraction -- that is, the percentage of the  
10 amount of Akt1 protein in soluble fraction of cells expressing ZFP-TFs (66.1%) divided by the amount in C1 (32.5%).

Table 19. ZFPs that improve solubility of Akt1 protein in *E. coli*.

Expression Construct	Name	Ratio of the amount of Akt1 protein (%)	
		Soluble fraction	Insoluble fraction
Control	C1	32.5	67.5
Solubility increasing ZFP	S-1	66.1	33.9
Solubility increasing ZFP	S-2	45.7	54.3

- 15 Table 20 : ZFPs that confer increased solubility to Akt1 protein in *E. coli*.

Name	F1	F2	F3	F4	putative DNA target
S-1	QSTR	DSAR	RDHT	WSNR	GGT NGG GTC GYA (SEQ ID NO:248)
S-2	VSTR	DGNV	QSNR	QSNK	DAA GAA AAC GCT (SEQ ID NO:249)

### Screening for enhanced solubility of recombinant proteins.

- Libraries for prokaryotic expression were prepared as described in Example 9. *E. coli* strain DH5 $\alpha$  was co-transformed with ZFP library and Akt1 expression vector and  
20 cultured overnight in LB with chloramphenicol (34  $\mu$ g/ml) and ampicillin (50  $\mu$ g/ml). The overnight-culture was diluted to 1:500 in 1 ml fresh LB media with 1 mM IPTG and chloramphenicol (34  $\mu$ g/ml) and ampicillin (50  $\mu$ g/ml) to induce ZFP expression. After three hour incubation at 30°C, 10<sup>6</sup> cells were analyzed with FACS on a FACS Vantage

flow cytometer and sorted for 5 to 10 % of cells that expressed higher fluorescence. The GFP expressing or pET21b empty vector transformed cells were used as a positive or negative control to set the background fluorescence.

Sorted cell were overnight cultured in LB media with chloramphenicol (34 µg/ml) and ampicillin (50 µg/ml). Plasmids were purified from the culture and transformed into DH5α. Screening for enhanced solubility of recombinant protein was repeated with retransformants. Plasmid was purified from individual colonies that could grow on LB + chloramphenicol (34 µg/ml) + ampicillin (50 µg/ml) plate after eighth round of selection and retransformed into DH5α. Each transformant was analyzed for enhanced solubility of Akt1 with western blot analysis. Plasmids that could increase solubility of Akt1 were sequenced to identify ZFP.

A number of embodiments of the invention have been described. Nevertheless, it will be understood that various modifications may be made without departing from the spirit and scope of the invention. Accordingly, other embodiments are within the scope of the following claims.

**WHAT IS CLAIMED IS:**

1. A modified cell comprising a heterologous nucleic acid encoding an artificial transcription factor that confers stress resistance to the modified cell relative to a  
5 reference cell that is substantially identical to the modified cell and that lacks the heterologous nucleic acid and the artificial transcription factor.
2. The modified cell of claim 1 wherein the artificial transcription factor comprises two zinc finger domains.  
10
3. The modified cell of claim 1 wherein the cell is bacterial cell.
4. The modified cell of claim 1 wherein the cell is a eukaryotic cell.
- 15 5. The modified cell of claim 2 wherein the stress resistance includes one or more the following traits: heat resistance, solvent resistance, heavy metal resistance, osmolarity resistance, resistance to extreme pH, chemical resistance, cold resistance, and resistance to a genotoxic agent, resistance to radioactivity.
- 20 6. The modified cell of claim 1 wherein the cell expresses the artificial transcription factor and resists stress to a greater extent than a substantially identical culture cell that lacks the artificial transcription factor
7. A method of producing a cellular product, the method comprising:  
25       providing the modified cell of claim 1;  
          maintaining the modified cell under conditions in which the artificial transcription factor is produced; and  
          recovering a product produced by the cultured cell, wherein the product is other than the artificial transcription factor.  
30
8. The method of claim 7 wherein the modified cell includes a nucleic acid encoding a heterologous protein, other than the artificial transcription factor, and the



product is the heterologous protein.

9. The method of claim 7 wherein the product is a metabolite or an endogenous protein.

5

10. The method of claim 8 wherein the modified cell further includes a second nucleic acid encoding a heterologous protein, and the heterologous protein participates in production of the metabolite.

10

11. The method of claim 7 wherein the modified cell is maintained at a temperature between 20°C and 40°C.

15

12. The method of claim 7 wherein the modified cell is maintained under conditions which would inhibit the growth of a substantially identical cell that lacks the artificial transcription factor.

13. The method of claim 7 wherein the artificial transcription factor comprises a zinc finger domain.

20

14. The method of claim 13 wherein the zinc finger domain comprises a set of DNA contacting residues that correspond to DNA contacting residues of a zinc finger domain listed in Table 15.

25

15. The method of claim 14 wherein the artificial transcription factor comprises an array of at least three zinc finger domains, wherein the DNA contacting residues of each of the zinc finger domains of the array correspond respectively to DNA contacting residues of any three consecutive zinc finger domains listed in a row of Table 15.

30

16. The method of claim 7 wherein the stress resistance includes one or more the following traits: heat resistance, solvent resistance, heavy metal resistance, osmolarity resistance, resistance to extreme pH, chemical resistance, cold resistance, and resistance to radioactivity.

17. A cell that contains a gene encoding a target protein and a heterologous nucleic acid that comprises a sequence encoding an artificial protein chimera that (1) increases the amount of the protein produced by the cell relative to a cell that does not include the heterologous nucleic acid, and (2) does not bind to a transcriptional regulatory region that directly regulates transcription of the gene encoding the target protein.

18. The cell of claim 17 wherein the artificial protein chimera comprises two zinc finger domains and binds to DNA.

19. The cell of claim 17 wherein the cell is a eukaryotic cell, and the artificial protein chimera competes with PB08, K\_F02, or K\_D10 for binding to a genomic DNA site.

20. The cell of claim 17 wherein the artificial protein chimera alters the rate of cell cycle progression by the cell.

21. The cell of claim 17 wherein the gene is an endogenous gene.

22. An artificial transcription factor that (1) increases the amount of a target protein produced by a eukaryotic cell relative to a cell that does not include artificial transcription factor, and (2) does not bind to a transcriptional regulatory region that directly regulates transcription of the gene encoding the target protein.

23. An artificial transcription factor comprising a plurality of zinc finger domains, wherein the artificial transcription factor alters the rate of cell cycle progression in a eukaryotic cell.

24. A method of producing a protein, the method comprising:  
providing the cell of claim 17, and  
maintaining the cell under conditions in which the artificial protein chimera increases the amount of the target protein produced by the cell relative to a cell that does not include the heterologous nucleic acid.

25. The method of claim 24 wherein the protein is a secreted protein.

26. A cell that contains an endogenous gene encoding a secreted protein and a heterologous nucleic acid that comprises a sequence encoding an artificial transcription factor that increases the amount of the secreted protein produced by the cell relative to a cell that does not include the heterologous nucleic acid.

27. The cell of claim 26 wherein the cell is a eukaryotic cell, and the secreted protein is insulin.

10

28. The cell of claim 26 wherein the artificial transcription factor specifically binds to an endogenous DNA site that is also specifically bound by 08\_D04\_p65.

29. The cell of claim 26 wherein the artificial transcription factor specifically binds to an endogenous DNA site and the artificial transcription factor competes with 08\_D04\_p65 for binding to the endogenous DNA site.

30. The cell of claim 26 wherein the artificial transcription factor comprises an amino acid sequence as follows:

20 CX<sub>(2-5)</sub>CXXXBXRXSHJXRHX<sub>(3-5)</sub>HX<sub>(1-6)</sub>BXCX<sub>(2-5)</sub>CXXXBXRDXHJXTHX<sub>(3-5)</sub>H (SEQ ID NO:45); or

CX<sub>(2-5)</sub>CXXXBXRDXHJXTHX<sub>(3-5)</sub>HX<sub>(1-6)</sub>BXCX<sub>(2-5)</sub>CXXXBXVXSSJXRHX<sub>(3-5)</sub>H (SEQ ID NO:46)

where B is phenylalanine or tyrosine; and J is a hydrophobic amino acid.

25

31. A method of producing insulin, the method comprising:

providing the cell of claim 24, and

maintaining the cell under conditions in which the artificial transcription factor increases the amount of insulin produced by the cell relative to a cell that does not include the heterologous nucleic acid.

30

32. An artificial transcription factor comprising at least two zinc finger domain, wherein the artificial transcription factor induces expression of an endogenous insulin gene in a mammalian cell that does not express an endogenous insulin gene in the absence of the artificial transcription factor.

5

33. An artificial transcription factor that alters sensitivity of the cell to a toxic agent relative to an identical cell that does not contain the nucleic acid.

34. A cell that contains and expresses a nucleic acid encoding an artificial  
10 transcription factor that alters sensitivity of the cell to a toxic agent relative to an identical cell that does not contain the nucleic acid.

35. The cell of claim 34 wherein the toxic agent is a drug.

15

36. The cell of claim 34 wherein the sensitivity is increased.

37. The cell of claim 34 wherein the sensitivity is decreased.

38. The cell of claim 34 wherein the cell is a fungal cell.

20

39. The cell of claim 38 wherein the toxic agent is ketoconazole.

40. The cell of claim 34 wherein the artificial transcription factor comprises three zinc finger domains.

25

41. The cell of claim 39 wherein the artificial transcription factor binds to an endogenous DNA site and the artificial transcription factor competes with a zinc finger protein listed in Table 5 for binding to the endogenous DNA site.

30

42. A method of altering the drug resistance of a fungal cell, the method comprising:

altering the expression or activity of a protein that is at least 70% identical to AQY1, YJR147W, YLL052C, YLL053C, or YPL091W in the cell.

43. A method of identifying an artificial chimeric protein that alters the sensitivity  
5 of a cell to a toxic agent, the method comprising:

providing a nucleic acid library that comprises a plurality of nucleic acids, each nucleic acid of the plurality encoding a chimeric protein that comprises an array of at least three zinc finger domains wherein at least two adjacent zinc finger domains do not occur adjacent to each other in a naturally occurring protein;

10 introducing members of the library into replicates of a test cell to yield transformed cells;

cultivating the transformed cells in the presence of a toxic agent; and

identifying, from the transformed cells, a cell whose sensitivity to the toxic agent is altered relative to the test cell.

15

44. The method of claim 43 wherein the test cell is a fungal cell, and the toxic agent is an anti-fungal agent.

45. The method of claim 43 wherein the test cell is a cancer cell, and the toxic  
20 agent is an anti-mitotic agent.

46. The method of claim 43 wherein the chimeric protein encoded by each nucleic acid of the plurality comprises a transcriptional regulatory domain.

25 47. The method of claim 46 further comprising constructing a nucleic acid that encodes a second chimeric protein that comprises the array of zinc finger domains of the chimeric protein encoded by the library member in the selected cell, but does not include the transcriptional regulatory domain of the chimeric protein encoded by the library member in the identified cell.

30

48. The method of claim 47 further comprising constructing a nucleic acid that encodes a second chimeric protein that comprises (i) the array of zinc finger domains of

the chimeric protein encoded by the library member in the selected cell, and (ii) a transcriptional regulatory domain, other than the transcriptional regulatory domain of the chimeric protein encoded by the library member in the identified cell.

5           49. A nucleic acid comprising a sequence encoding an artificial transcription factor comprising three zinc finger domains, wherein expression of the artificial transcription factor induces a neuronal phenotype in at least one vertebrate cell.

10           50. The nucleic acid of claim 49 wherein at least one of the zinc finger domains has the sequence:

Cys-X<sub>2-5</sub>-Cys-X<sub>3</sub>-X<sub>a</sub>-X-Gln-X<sub>b</sub>-X-Ser-Asn-His-X<sub>3-5</sub>-His (SEQ ID NO:250)

Cys-X<sub>2-5</sub>-Cys-X<sub>3</sub>-X<sub>a</sub>-X-Gln-X<sub>b</sub>-X-Ser-Asn-His-X<sub>3-5</sub>-His (SEQ ID NO:251); or

Cys-X<sub>2-5</sub>-Cys-X<sub>3</sub>-X<sub>a</sub>-X-Cys-X<sub>b</sub>-X-Ser-Asn-His-X<sub>3-5</sub>-His (SEQ ID NO:252),

wherein X<sub>a</sub> is phenylalanine or tyrosine; and X<sub>b</sub> is a hydrophobic amino acid.

15

51. The nucleic acid of claim 50 wherein the artificial transcription factor comprises the sequence: Cys-X<sub>2-5</sub>-Cys-X<sub>3</sub>-X<sub>a</sub>-X-Gln-X<sub>b</sub>-X-Ser-Asn-His-X<sub>3-5</sub>-His-X<sub>1-6</sub>-Cys-X<sub>2-5</sub>-Cys-X<sub>3</sub>-X<sub>a</sub>-X-Gln-X<sub>b</sub>-X-Ser-Asn-His-X<sub>3-5</sub>-His-X<sub>1-6</sub>-Cys-X<sub>2-5</sub>-Cys-X<sub>3</sub>-X<sub>a</sub>-X-Cys-X<sub>b</sub>-X-Ser-Asn-His-X<sub>3-5</sub>-His (SEQ ID NO:253), wherein X<sub>a</sub> is phenylalanine or tyrosine; and X<sub>b</sub> is a hydrophobic amino acid.

20

52. A method of inducing neurite formation in a vertebrate cell, the method comprising:

providing a vertebrate cell that contains the nucleic acid of claim 44; and

25

maintaining the vertebrate cell under conditions in which the artificial transcription factor is produced and neurite formation is induced.

53. The method of claim 52 wherein the vertebrate cell is a mammalian cell.

30

54. The method of claim 52 wherein the mammalian cell is a human cell.

55. The method of claim 52 wherein the vertebrate cell is a stem cell prior to production of the artificial transcription factor.

56. A nucleic acid comprising a sequence encoding an artificial transcription  
5 factor comprised of three zinc finger domains, wherein expression of the artificial transcription factor induces osteogenesis in at least one vertebrate cell.

57. The nucleic acid of claim 56 wherein at least one of the zinc finger domains  
has the sequence:  
10 Cys-X<sub>2-5</sub>-Cys-X<sub>3</sub>-X<sub>a</sub>-X-Arg-X<sub>b</sub>-X-Asp-Lys-His-X<sub>3-5</sub>-His (SEQ ID NO:254);  
Cys-X<sub>2-5</sub>-Cys-X<sub>3</sub>-X<sub>a</sub>-X-Gln-X<sub>b</sub>-X-Thr-His-His-X<sub>3-5</sub>-His (SEQ ID NO:255);  
Cys-X<sub>2-5</sub>-Cys-X<sub>3</sub>-X<sub>a</sub>-X-Val-X<sub>b</sub>-X-Ser-Thr-His-X<sub>3-5</sub>-His (SEQ ID NO:256) or;  
Cys-X<sub>2-5</sub>-Cys-X<sub>3</sub>-X<sub>a</sub>-X-Arg-X<sub>b</sub>-X-Asp-Lys-His-X<sub>3-5</sub>-His (SEQ ID NO:257),  
wherein X<sub>a</sub> is phenylalanine or tyrosine; and X<sub>b</sub> is a hydrophobic amino acid.

15 58. The nucleic acid of claim 57 wherein the artificial transcription factor comprises the amino acid sequence:  
Cys-X<sub>2-5</sub>-Cys-X<sub>3</sub>-X<sub>a</sub>-X-Arg-X<sub>b</sub>-X-Asp-Lys-His-X<sub>3-5</sub>-His-X<sub>1-6</sub>-Cys-X<sub>2-5</sub>-Cys-X<sub>3</sub>-  
X<sub>a</sub>-X-Gln-X<sub>b</sub>-X-Thr-His-His-X<sub>3-5</sub>-His-X<sub>1-6</sub>-Cys-X<sub>2-5</sub>-Cys-X<sub>3</sub>-X<sub>a</sub>-X-Val-X<sub>b</sub>-X-Ser-Thr-  
20 His-X<sub>3-5</sub>-His-X<sub>1-6</sub>-Cys-X<sub>2-5</sub>-Cys-X<sub>3</sub>-X<sub>a</sub>-X-Arg-X<sub>b</sub>-X-Asp-Lys-His-X<sub>3-5</sub>-His (SEQ ID  
NO:258), wherein X<sub>a</sub> is phenylalanine or tyrosine; and X<sub>b</sub> is a hydrophobic amino acid..

59. A method of inducing osteogenesis in a vertebrate cell, the method comprising:  
25 providing a vertebrate cell that contains the nucleic acid of claim 44; and  
maintaining the vertebrate cell under conditions in which the artificial transcription factor is produced and osteogenesis is induced.

60. A method of altering the differentiative capacity of a stem cell, the method  
30 comprising:  
providing a stem cell and a nucleic acid that comprises a sequence encoding an artificial transcription factor comprises of a plurality of zinc finger domains,

wherein the artificial transcription factor alters the differentiative capacity of the stem cell;

introducing the nucleic into the stem cell; and

maintaining the stem cell under conditions in which the artificial transcription factor is produced thereby altering the differentiative capacity of the stem cell.

61. The method of claim 60 wherein the artificial transcription factor induces differentiation of the stem cell.

10

62. The method of claim 60 wherein the artificial transcription factor enhances self-renewal potential of the stem cell.

63. The method of claim 60 wherein the stem cell is an embryonic stem cell.

15

64. The method of claim 60 wherein the stem cell is a vertebrate stem cell or a plant stem cell.

65. The method of claim 62 wherein the stem cell is a hematopoietic stem cell, a neuronal progenitor cell or muscular progenitor cell.

20

66. A method of identifying an artificial transcription factor, the method comprising:

providing a nucleic acid library that comprises a plurality of nucleic acids, each encoding a different artificial transcription factor, each artificial transcription comprising an array of at least two zinc finger domains and a regulatory domain that activates or represses transcription;

25

providing cell that have a given trait;

introducing members of the nucleic acid library into the cells;

30

identifying a member of the library that alters the given trait; and

preparing a coding nucleic acid that comprises a sequence encoding a DNA binding polypeptide that comprises the array of zinc finger domains from the



identified member, but does not include a regulatory domain identical to the regulatory domain of the identified member.

67. The method of claim 66 wherein the DNA binding polypeptide is lacks the  
5 regulatory domain of the identified member.

68. The method of claim 66 wherein the DNA binding polypeptide comprises a  
regulatory domain that is mutated relative to the regulatory domain of the identified  
member.  
10

69. The method of claim 67 wherein the DNA binding polypeptide comprises a  
regulatory domain of opposite functionality relative to the regulatory domain of the  
identified member.

70. The method of claim 66, further comprising introducing the coding nucleic  
15 acid into a cell and assessing the given trait of the cell.

71. The method of claim 66 wherein the step of identifying comprises identifying  
cells having a property selected from the group consisting of: resistance to a given  
20 environmental condition; differentiation; dedifferentiation; proliferation; apoptosis;  
serum-independence; pathogen resistance; and pathogen sensitivity.

72. A nucleic acid library comprising a first plurality of nucleic acids and a  
second plurality of nucleic acids, wherein  
25 (a) each nucleic acid of the first plurality encodes an artificial protein chimera  
comprising at least two zinc finger domains and a first functional domain that activates  
transcription, and  
(b) each nucleic acid of the second plurality encodes an artificial protein chimera  
comprising at least two zinc finger domains, and does not include the first functional  
30 domain.

73. The nucleic acid library of claim 72 wherein the artificial protein chimera encoded by each nucleic acid of the second plurality comprises a second functional domain, different from the first functional domain.

5           74. The nucleic acid library of claim 72 wherein the first functional domain is an activation domain and the second functional domain is a repression domain.

75. The nucleic acid library of claim 73 wherein the first functional domain is an activation domain and the second functional domain is an activation domain, with  
10       different efficacy from the first activation domain.

76. The nucleic acid library of claim 72 wherein the first functional domain is a histone deacetylase domain.

15           77. A method of identifying a protein chimera, the method comprising:  
          providing the nucleic acid library of claim 72;  
          introducing members of the nucleic acid library into cells that have a given trait;  
          and  
          identifying a member of the library which alters the given trait.

20

78. A method of identifying a plurality of protein chimeras, the method comprising:

          providing replicate cells of a test cell that comprises a nucleic acid encoding a first artificial protein chimera, wherein expression of the first artificial protein chimera alters a  
25       given trait of the test cell;

          introducing a member of a nucleic acid library into each of the replicate cells, the nucleic acid library comprising a plurality of nucleic acids, each encoding a different artificial protein chimera that comprises two zinc finger domains; and

          screening the replicate cells to identify a cell in which the given trait is further  
30       altered, wherein each replicate cell expresses the protein chimera encoded by the first member of the library and a second protein chimera encoded by the introduced member of the nucleic acid library.

79. A method of preparing a modified cell, the method comprising providing a nucleic acid library that comprises a plurality of nucleic acids, each encoding a different artificial protein chimera, each protein chimera comprising at least two zinc finger domains;

5 identifying a first and a second member of the library which alters a given trait of a cell; and

preparing a cell that can express first and second polypeptides, wherein the first and second polypeptides are encoded by the first and second identified library members, respectively.

10

80. The method of claim 79 wherein the step of identifying comprises introducing members of the nucleic acid library into replicates of the cell to provided transformed cells, and identifying a first and second cell in which the given trait is altered.

15 81. The method of claim 79 further comprising evaluating the given trait for the prepared cell.

82. The method of claim 79 wherein the preparing comprises introducing a first gene encoding the first polypeptide and a second gene encoding the second polypeptide  
20 into the cell.

83. The method of claim 82 wherein the first and second gene are components of the same nucleic acid.

25 84. The method of claim 79 wherein the preparing comprises fusing a first cell that comprises a first gene encoding the first polypeptide to a second cell that comprises a second gene encoding the second polypeptide.

85. A method of identifying a protein chimera, the method comprising:  
30 providing a nucleic acid library that comprises a plurality of nucleic acids, each encoding a different artificial protein chimera that comprises at least two zinc finger domains;

introducing members of the nucleic acid library into cells that have a given trait;  
identifying a member of the library which alters the given trait; and  
preparing a second library that comprises a plurality of nucleic acids, each  
encoding

5 (1) a variant that differs from the artificial protein chimera corresponding  
to the identified member by between one and six amino acid substitutions, insertions, or  
deletions,

(2) a protein chimera that comprises the zinc finger domains of the  
artificial protein chimera corresponding to the identified member and an additional zinc  
10 finger domain, wherein the additional zinc finger domain varies among the members of  
the second library,

(3) a variant of the artificial protein chimera corresponding to the  
identified member, wherein the variant has a subset of the zinc finger domain positions  
replaced with other zinc finger domains and at least one invariant zinc finger domain that  
15 is identical to the zinc finger domain at a corresponding position in the artificial protein  
chimera corresponding to the identified member, or

(4) a variant of the artificial protein chimera corresponding to the  
identified member, wherein, among the members of the second library, one or more zinc  
finger domain positions are varied such that the particular domain in the artificial protein  
20 chimera corresponding to the identified member at that position occurs at a frequency  
greater than other zinc finger domains at that position.

86. A method of identifying a target of artificial transcription factors, the method  
comprising:

25 providing a nucleic acid library that comprises a plurality of nucleic acids, each  
encoding a different artificial transcription factor, each transcription factor comprising at  
least two zinc finger domains;

introducing members of the library into replicates of a test cell to provide a  
plurality of transformed cells;

30 maintaining the transformed cells under conditions in which the artificial  
transcription factor is expressed;

identifying a plurality of phenotypically altered cells from the plurality of transformed cells, wherein each phenotypically altered cell has an altered phenotype relative to the test cell;

5        profiling transcripts or protein abundance in each phenotypically altered cell of the plurality to provide a profile for each phenotypically altered cell; and

      comparing the profiles to each other to identify one or more transcripts or proteins whose abundance is similarly altered in at least two phenotypically altered cells of the plurality relative to the test cell.

10        87. A method of evaluating a cell, the method comprising:

      providing a modified cell that contains a heterologous nucleic acid comprising a sequence encoding an artificial transcription factor comprising at least two zinc finger domains, wherein expression of the artificial transcription factor alters a phenotypic trait of the cell relative to a reference cell that does not express the artificial transcription factor;

15        identifying a target gene whose expression is altered in modified cell relative to the reference cell; and

      evaluating the phenotypic trait of a test cell wherein the test cell contains the heterologous nucleic acid and expresses the artificial transcription factor, and the activity of the target gene is altered in the test cell.

20

      88. The method of claim 87 wherein the activity of the target gene is altered by a genetic mutation.

25        89. The method of claim 87 wherein the activity of the target gene is altered by treatment with a double-stranded RNA or an antisense oligonucleotide or a ribozyme.

      90. The method of claim 87 wherein the activity of the target gene is altered by overexpression of the target gene.

30

      91. A method of evaluating an artificial transcription factor, the method comprising:

providing a modified cell that contains a heterologous nucleic acid comprising a sequence encoding an artificial transcription factor comprising at least two zinc finger domains, wherein expression of the artificial transcription factor alters a phenotypic trait of the cell relative to a reference cell that does not express the artificial transcription factor; and  
5 introducing library nucleic acids into replicates of the modified cell; and  
identifying a library nucleic acid which attenuates the alteration of the phenotypic trait by the artificial transcription factor.

10 92. The method of claim 91 wherein the library nucleic acids comprise cDNA library nucleic acids.

93. The method of claim 91 wherein the library nucleic acids comprises nucleic acids encoding different artificial protein chimeras.

15 94. The method of claim 93 wherein the different artificial protein chimeras include different zinc finger domains.

95. A method of identifying a protein chimera, the method comprising:  
20 providing a nucleic acid library that comprises a plurality of nucleic acids, each encoding a different artificial protein chimera that comprises at least two zinc finger domains, wherein at least one zinc finger domain is from a naturally-occurring protein;  
introducing members of the nucleic acid library into cells that have a given trait; and  
25 identifying a cell in which a member of the library alters the given trait.

96. A method of identifying a protein chimera, the method comprising:  
providing a nucleic acid library that comprises a plurality of nucleic acids, each encoding a different artificial protein chimera that comprises at least two zinc finger  
30 domains, wherein at least one zinc finger domain of at least one member of the plurality comprises an amino acid sequence listed in Table 1;

introducing members of the nucleic acid library into cells that have a given trait; and

identifying a cell in which a member of the library alters the given trait.

5           97. A method of identifying a protein chimera, the method comprising:

          providing a library of cells, the library comprising a plurality of cells, wherein each cell includes a nucleic acid encoding a polypeptide comprising a first and a second zinc finger domain, wherein (1) the first and second zinc finger domains of the polypeptide encoded by each nucleic acid of the plurality are each identical to zinc finger domains from naturally occurring proteins and either (i) do not occur in the same naturally occurring protein or (ii) occur in the same naturally occurring protein in a different configuration than in the polypeptide, (2) the first zinc finger domain varies among nucleic acids of the plurality, and (3) the second zinc finger domain varies among nucleic acids of the plurality;

10           identifying a library cell whose phenotype differs from a reference cell; and

          recovering the nucleic acid from the identified library cell.

          98. An isolated nucleic acid encoding an artificial transcription factor that improves solubility of a heterologous, over-expressed protein in a cell that produces the artificial transcription factor.

          99. The nucleic acid of claim 98 wherein the artificial transcription factor comprises a plurality of zinc finger domains.

25

          100. The nucleic acid of claim 98 wherein the cell is bacterial cell.

          101. The nucleic acid of claim 98 wherein the protein is a mammalian protein.

30           102. The nucleic acid of claim 101 wherein the protein comprises the AKT protein.

103. The nucleic acid of claim 99 wherein the plurality of zinc finger domains comprise domains: QSTR-DSAR-RDHT-WSNR or VSTR-DGNV-QSNR-QSNK.

104. A modified cell comprising the heterologous nucleic acid of any one of  
5 claims 98 to 103.

105. A method of producing a heterologous target protein, the method comprising:

10 providing the modified cell of claim 104 wherein the modified cell comprises a second nucleic acid that comprises a sequence encoding a heterologous target protein; and

maintaining the modified cell under conditions wherein the artificial transcription factor and the heterologous target protein are produced.

15 106. The method of claim 105 wherein the modified cell is a culture cell.

107. The method of claim 105 wherein the modified cell is in a subject.

108. A method of producing a cellular product, the method comprising:

20 providing a modified cell of claim 1;  
maintaining the modified cell under conditions in which the artificial transcription factor is produced; and

recovering a product produced by the cultured cell, wherein the product is other than the artificial transcription factor.

25

109. A method of transferring an altered trait from a first cell to a second cell, the method comprising:

30 providing a nucleic acid library that comprises a plurality of nucleic acids, each encoding a different artificial protein chimera that comprises at least two zinc finger domains;

introducing members of the nucleic acid library into first cells that have a given trait to provide transformed cells;



identifying an altered cell from the transformed cells in which a member of the library alters the given trait;

recovering a nucleic acid library member from the identified, altered cell;

introducing the nucleic acid library member into second cells, wherein the  
5 second cells differ from the first cells by a phenotypic trait other than the given trait; and  
evaluating a second cell that includes the nucleic acid library member and  
expresses the artificial protein chimera that the nucleic acid library member encodes.

110. The method of claim 109 wherein the first and second cells are eukaryotic.

10

111. The method of claim 110 wherein the first and second cells are yeast cells.

112. The method of claim 110 wherein the first and second cells are mammalian  
cells.

15

113. The method of claim 112 wherein the first and second cells differ by the  
proliferative properties.

114. The method of claim 113 wherein the first cells are cancer cells, and the  
20 second cells are non-cancerous.

115. The method of claim 109 wherein the evaluated second cell is evaluated for  
an alteration to the given trait.

25 116. An isolated polypeptide comprising an amino acid sequence selected from  
the group consisting of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 260, 262, and 264.

117. An isolated nucleic acid comprising a nucleic acid sequence that encodes the  
polypeptide of claim 116.

30

118. A nucleic acid comprising a sequence encoding an artificial transcription  
factor comprised of three zinc finger domains, wherein expression of the artificial

transcription factor alters a property of at least one eukaryotic cell, wherein the property is selected from the group consisting of viral replication, virus production, and viral infectivity.

5           119. A nucleic acid comprising a sequence encoding an artificial transcription factor comprised of three zinc finger domains, wherein expression of the artificial transcription factor alters an ability of a eukaryotic cell to regulate a stem cell that is co-cultured with the eukaryotic cell or that is cultured in media conditioned by the eukaryotic cell.

10

          120. A nucleic acid comprising a sequence encoding an artificial transcription factor comprised of three zinc finger domains, wherein expression of the artificial transcription factor alters an ability of a mammalian culture cell to glycosylate a secreted protein.

15

          121. The nucleic acid of claim 120 wherein the secreted protein is a heterologous protein that comprises at least one immunoglobulin variable domain.

          122. The nucleic acid of claim 120 wherein the culture cell is a CHO cell.

20

          123. A nucleic acid comprising a sequence encoding an artificial transcription factor comprised of three zinc finger domains, wherein expression of the artificial transcription factor alters the ability of a cell to take up exogenous nucleic acid.




FIG. 1




FIG. 2




FIG. 3A

4/26





FIG. 3B

5/26



**FIG. 4**

6/26





FIG. 5



7/26



**FIG. 6**






FIG. 7

9/26



**FIG. 8**

10/26



293 HeLa  
stable transfection transient transfection

FIG. 9

A partial directory of zinc  
finger-DNA interactions

3-bp sequence	zinc finger
GAA	QSNR
GAC	CSNR
GAG	RSNR
GAT	ISNR
GCA	QSSR
GCC	-
GCG	RDER
GCT	VSTR

FIG. 10A

Mixing and matching zinc fingers





FIG. 10B

13/26

**FIG. 11**

14/26




FIG. 12






FIG. 13

16/26

**NEURO1-P65 (ALSO CALLED 08\_D1)**

QSNR1-QSNK-CSNR1-p65

NUCLEIC ACID SEQUENCE

ATGGTGTACCCCTACGACGTGCCCGACTACGCCGAATTGCCTCCAAAAAGAAGAGAAAGGTAG  
 GGATCCgaattcccggggaaaaaccgTTTGAGTGTAAAGATTGCGGGAAAGCTTTCATTTCAGAA  
 GTCAAACCTCATCAGACACCAGAGAACTCACaccgggggaaaaaccgTACAAGTGTGAAGAATGT  
 GGCAAAGCTTTTACCCAATCCTCAAACCTTACTAAACATAAGAAAATTTCATaccgggggaaaaac  
 cgTATAAATGTAAAGCAATGTGGGAAAGCTTTTGGATGTCCCTCAAACCTTCGAAGGCATGGAAG  
 GACTCACaccggtgaaaaagcgggccgctaaattcTACCTGCCAGATACAGACGATCGTCACCGG  
 ATTGAGGAGAAACGTAAAAGGACATATGAGACCTTCAAGAGCATCATGAAGAAGAGTCCTTTCA  
 GCGGACCCACCGACCCCCGGCCTCCACCTCGACGCATTGCTGTGCCTTCCCGCAGCTCAGCTTC  
 TGTCCCCAAGCCAGCACCCCGCCCTATCCCTTTACGTCATCCCTGAGCACCATCAACTATGAT  
 GAGTTTCCCACCATGGTGTTCCTTCTGGGCAGATCAGCCAGGCCTCGGCCTTGCCCCGGCCC  
 CTCCCCAAGTCCTGCCCCAGGCTCCAGCCCCTGCCCCTGCTCCAGCCATGGTATCAGCTCTGGC  
 CCAGGCCCCAGCCCCTGTCCCAGTCCTAGCCCCAGGCCCTCCTCAGGCTGTGGCCCCACCTGCC  
 CCAAGCCCACCCAGGCTGGGGAAGGAACGCTGTCAGAGGCCCTGCTGCAGCTGCAGTTTGATG  
 ATGAAGACCTGGGGGCCTTGCTTGGCAACAGCACAGACCCAGCTGTGTTACAGACCTGGCATC  
 CGTCGACAACTCCGAGTTTCAGCAGCTGCTGAACCAGGGCATACTGTGGCCCCCACACAAC  
 GAGCCCATGCTGATGGAGTACCCTGAGGCTATAACTCGCCTAGTGACAGCCAGAGGCCCCCGG  
 ACCAGCTCCTGCTCCACTGGGGGCCCCGGGGCTCCCCAATGGCCTCCTTTCAGGAGATGAAGA  
 CTTCTCCTCCATTGCGGACATGGACTTCTCAGCCCTGCTGAGTCAG TAA (SEQ ID  
 NO:201)

PROTEIN SEQUENCE

MVYPYDVPDYAELPPKKRKVGIRIPGEKPFECKDCGKAFIQKSNLIRHQRTHTGEKPYKCEEC  
 GKAFQTQSSNLTKHKKIHTGEKPYKCKQCGKAFGCPSNLRRHGRTHTEKAAAKFYLPDTPDRHR  
 IEEKRKRTYETFKSIMKSPFSGPTDPRPPPRRIAVPSRSSASVPKPAPQYPFTSSLSTINYD  
 EFPTMVFPSPGQISQASALAPAPPQVLPQAPAPAPAPAMVSALAQAPAPVPVLPAPPPQAVAPPA  
 PKPTQAGEGTLSEALLQLQFDDDELGALLGNSTDPVFTDLASVDNSEFQQLLNQGI PVAPHTT  
 EPMLMEYPEAITRLVTAQRPPDPAPAPLGAPGLPNGLLSGDEDFSSIADMDFSALLSQ (SEQ  
 ID NO:202)

**FIG. 14**

17/26

**OSTEO1-P65 (ALSO CALLED S045-15-D11 )**

RDKR-QTHR1-VSTR-RDKR-p65

NUCLEIC ACID SEQUENCE

ATGGTGTACCCCTACGACGTGCCGACTACGCCGAATTGCCTCCAAAAAGAAGAGAAAGGTAG  
 GGATCCgaattcccggggaaaaaccgTATGTATGCGATGTAGAGGGATGTACGTGGAAATTTGC  
 CCGCTCAGATAAGCTCAACAGACACAAGAAAAGGCACaccggggaaaaaccgTATGAGTGTAC  
 GATTGCGGAAAGTCCTTTAGGCAGAGCACCCACCTCACTCGGCACCGGAGGATCCACaccgggg  
 aaaaaccgTATGAGTGTAACTACTGTGGAAAAACCTTTAGTGTGAGCTCAACCCTTATTAGACA  
 TCAGAGAATCCACaccggggaaaaaccgTATGTATGCGATGTAGAGGGATGTACGTGGAAATTT  
 GCCCGCTCAGATAAGCTCAACAGACACAAGAAAAGGCACaccggtgaaaaagcgggccgctaaat  
 tcTACCTGCCAGATACAGACGATCGTCACCGGATTGAGGAGAAACGTAAAAGGACATATGAGAC  
 CTTCAAGAGCATCATGAAGAAGAGTCCTTTCAGCGGACCCACCGACCCCCGGCCTCCACCTCGA  
 CGCATTGCTGTGCCTTCCCGCAGCTCAGCTTCTGTCCCCAAGCCAGCACCCCAGCCCTATCCCT  
 TTACGTCATCCCTGAGCACCATCAACTATGATGAGTTTCCACCATGGTGTTTCCTTCTGGGCA  
 GATCAGCCAGGCCTCGGCCTTGGCCCCGGCCCCCTCCCAAGTCCTGCCCCAGGCTCCAGCCCCCT  
 GCCCCTGCTCCAGCCATGGTATCAGCTCTGGCCCAGGCCCCAGCCCCCTGTCCAGTCCTAGCCC  
 CAGGCCCTCCTCAGGCTGTGGCCCCACCTGCCCCCAAGCCACCCAGGCTGGGGAAGGAACGCT  
 GTCAGAGGCCCTGCTGCAGCTGCAGTTTGATGATGAAGACCTGGGGGCCTTGCTTGGAACAGC  
 ACAGACCCAGCTGTGTTACAGACCTGGCATCCGTCGACAACTCCGAGTTTCAGCAGCTGCTGA  
 ACCAGGGCATACCTGTGGCCCCCACACAACCTGAGCCCATGCTGATGGAGTACCCTGAGGCTAT  
 AACTCGCCTAGTGACAGCCAGAGGCCCCCCGACCCAGCTCCTGCTCCACTGGGGGCCCGGGG  
 CTCCCCAATGGCCTCCTTTCAGGAGATGAAGACTTCTCCTCCATTGCGGACATGGACTTCTCAG  
 CCCTGCTGAGTCAG TAA (SEQ ID NO:203)

PROTEIN SEQUENCE

MVYPYDVDPDYAELPPKKRKRKVGIRIPGEKPFECKDCGKAFIQKSNLIRHQRHTTGEKPYACPVE  
SCDRRFSDSSNLTRHIRIHTGEKPYACPVESCDRRFSDSSNLTRHIRIHTGEKAAAKFYLPDTD  
 DRHRIEEKRKRTYETFKSIMKKSPFSGPTDPRPPPRRIAVPSRSSASVPKPAPQYPFTSSLST  
 INYDEFPTMVFP SGQISQASALAPAPPQVLPQAPAPAPAPAMVSALAQAAPVPVLAPGPPOAV  
 APPAPKPTQAGEGTLSEALLQLQFDDDELGALLGNSTDPAVFTDLASVDNSEFQQLLNQGI PVA  
 PHTTEPMLMEYPEAITRLVTAQRPPDPAPAPLGA PGLPNGLLSGDEDFSSIADMDFSALLSQ  
 (SEQ ID NO:204)

**FIG. 15**

18/26

08\_D04\_p65:

RSHR-RDHT-VSSR

NUCLEIC ACID SEQUENCE

ATGGTGTACCCCTACGACGTGCCCCGACTACGCCGAATTGCTTCCAAAAAAGAAGAGAAAGGTA  
GGATCCgaattcccggggaaaaaccgTATAAGTGCATGGAGTGTGGGAAGGCTTTTAACCGCAG  
GTCACACCTCACACGGCACCAGCGGATTCACaccggggaaaaaccgTTCCAGTGTAAACTTGT  
CAGCGAAAGTTCTCCCGGTCCGACCACCTGAAGACCCACACCAGGACTCATaccggggaaaaac  
cgTATACATGTAAACAGTGTGGGAAGCCTTCAGTGTTCAGTTCCTTCGAAGACATGAAAC  
CACTCACaccggtgaaaaagcggcgctaaattcTACCTGCCAGATACAGACGATCGTCACCGG  
ATTGAGGAGAAACGTAAAAGGACATATGAGACCTTCAAGAGCATCATGAAGAAGAGTCCTTTCA  
GCGGACCCACCGACCCCCGGCCTCCACCTCGACGCATTGCTGTGCCTTCCCGCAGCTCAGCTTC  
TGTCCCCAAGCCAGCACCCAGCCCTATCCCTTTACGTCATCCCTGAGCACCATCAACTATGAT  
GAGTTTCCCACCATGGTGTTCCTTCTGGGCAGATCAGCCAGGCCTCGGCCTTGGCCCCGGCCC  
CTCCCCAAGTCCTGCCCCAGGCTCCAGCCCCTGCCCTGCTCCAGCCATGGTATCAGCTCTGGC  
CCAGGCCCCAGCCCCTGTCCCAGTCCTAGCCCCAGGCCCTCCTCAGGCTGTGGCCCCACCTGCC  
CCCAAGCCCACCCAGGCTGGGGAAGGAACGCTGTTCAGAGGCCCTGCTGCAGCTGCAGTTTGATG  
ATGAAGACCTGGGGGCCTTGCTTGGCAACAGCACAGACCCAGCTGTGTTCACAGACCTGGCATC  
CGTCGACAACTCCGAGTTTCAGCAGCTGCTGAACCAGGGCATACTGTGGCCCCCACAACCT  
GAGCCCATGCTGATGGAGTACCCTGAGGCTATAACTCGCCTAGTGACAGCCCAGAGGCCCCCG  
ACCCAGCTCCTGCTCCACTGGGGGCCCCGGGGCTCCCAATGGCCTCCTTTTCAGGAGATGAAGA  
CTTCTCCTCCATTGCGGACATGGACTTCTCAGCCCTGCTGAGTCAG TAA (SEQ ID  
NO:205)

PROTEIN SEQUENCE

MVYPYDVPDYAELPPKKRKVGIRIPGEKP YKMECGKAFNRRSHLTRHQRIHTGEKP FQCKTC  
QRKFSRSDHLKTHTRHTGEKP YTCKQCGKAFSVSSSLRRHETHTGEKAAAKFYLPDTPDDRHR  
IEEKRKRITYETFKSIMKKSPPSGPTDPRPPPRRIAVPSRSSASVPKPAPQPYPTSSLSTINYD  
EFPTMVFPSPGQISQASALAPAPPQVLPOAPAPAPAPAMVSALAQAPAPVPVLAQPPQAVAPPA  
PKPTQAGEGTLSEALLQLQFDDDLGALLGNSTDPAVFDTLASVDNSEFQQLLNQGI PVAPHTT  
EPMLMEYPEAITRLVTAQRPPDPAPAPLGAPGLPNGLLSGDEDFSSIADMDFSALLSQ (SEQ  
ID NO:206)

FIG. 16

19/26

Name: P\_B08

QSNR1-DSNR-DSNR-p65

NUCLEIC ACID SEQUENCE

ATGGTGTACCCCTACGACGTGCCCCGACTACGCCGAATTGCCTCCAAAAAAGAAGAGAAAGGTAAG  
GGATCCgaattcccggggaaaaaaccgTTTGAGTGTAAAGATTGCGGGAAAGCTTTCATTCAGAA  
GTCAAACCTCATCAGACACCAGAGAACTCACaccgggggaaaaaaccgTATGCTTGCCCTGTCGAG  
TCTTGCGATCGCCGCTTTTCTGATTCTGTCGAACCTTACCCGCCATATCCGCATCCACaccgggg  
aaaaaaccgTATGCTTGCCCTGTCGAGTCTGCGATCGCCGCTTTTCTGATTCTGTCGAACCTTAC  
CCGCCATATCCGCATCCACaccgggtgaaaaagcgggccgctaaattcTACCTGCCAGATACAGAC  
GATCGTCACCGGATTGAGGAGAAACGTAAAAGGACATATGAGACCTTCAAGAGCATCATGAAGA  
AGAGTCCTTTCAGCGGACCCACCGACCCCGGCCTCCACCTCGACGCATTGCTGTGCCTTCCCG  
CAGCTCAGCTTCTGTCCCCAAGCCAGCACCCAGCCCTATCCCTTTACGTCATCCCTGAGCACC  
ATCAACTATGATGAGTTTCCCACCATGGTGTTCCTTCTGGGCAGATCAGCCAGGCCTCGGCCT  
TGGCCCCGGCCCCCTCCCCAAGTCCTGCCCCAGGCTCCAGCCCCCTGCCCCTGCTCCAGCCATGGT  
ATCAGCTCTGGCCCAGGCCCCAGCCCTGTCCAGTCTTAGCCCCAGGCCCTCCTCAGGCTGTG  
GCCCCACCTGCCCCAAGCCCACCCAGGCTGGGGAAGGAACGCTGTGAGAGGCCCTGCTGCAGC  
TGCAGTTTGATGATGAAGACCTGGGGGCCTTGCTTGGCAACAGCACAGACCCAGCTGTGTTAC  
AGACCTGGCATCCGTCGACAACTCCGAGTTTCAGCAGCTGCTGAACCAGGGCATACTGTGGCC  
CCCCACACAACTGAGCCCATGCTGATGGAGTACCCTGAGGCTATAACTCGCCTAGTGACAGCCC  
AGAGGCCCCCCGACCCAGCTCCTGCTCCACTGGGGGGCCCCGGGGCTCCCCAATGGCCTCCTTTC  
AGGAGATGAAGACTTCTCCTCCATTGCGGACATGGACTTCTCAGCCCTGCTGAGTCAG TAA  
(SEQ ID NO:207)

PROTEIN SEQUENCE

MVYPYDVPDYAELPPKKRKVGIRIPGEKPFECKDCGKAFTQKSNLIRHQRTHTGEKP YACPVE  
SCDRRFSDSSNLTRHIRIHTGEKP YACPVESCDRRFSDSSNLTRHIRIHTGEKAAAKFYLPD TD  
DRHRIEEKRKRTYETFKSIMKSPFSGPTDPRPPPRRIAVPSRSSASVPKPAPQYPFTSSLST  
IN YDEFPTMVFPSGQISQASALAPAPPQVL PQAPAPAPAPAMVSALA QAPAPVPVLAPGPPQAV  
APPAPKPTQAGEGTLSEALLQLQFDDDLGALLGNSTDPAVF TDLASVDNSEFQQLLNQGI PVA  
PHTTEPMLMEYPEAITRLVTAQRPPDPAPAPL GAPGLPNGLLSGDEDFSSIADMDFSALLSQ  
(SEQ ID NO:208)

FIG. 17

20/26

Name: K\_D10

QSHV-WSNR-WSNR-RDNQ-kid

NUCLEIC ACID SEQUENCE

ATGGTGTACCCCTACGACGTGCCCCGACTACGCCGAATTGCCTCCAAAAAGAAGAGAAAGGTAGG  
GGATCCgaattcccggggaaaaaccgTATGAGTGTGATCACTGTGGAAAATCCTTTAGCCAGAG  
CTCTCATCTGAATGTGCACAAAAGAACTCACaccgggggaaaaaccgTACAGATGTGAGGAATGT  
GGCAAAGCCTTTAGGTGGCCCTCAAACCTTACTAGACATAAGAGAATTCAcaccgggggaaaaac  
cgTACAGATGTGAGGAATGTGGCAAAGCCTTTAGGTGGCCCTCAAACCTTACTAGACATAAGAG  
AATTCACaccgggggaaaaaccgTTTGCTGCCCTGAGTGTCTTAAGCGCTTCATGAGATCCGAC  
AACCTGACCCAGCATATCAAGACCCACaccggtgaaaaagcgggccgctaaattcGTGTCACTGA  
CATTGGAAGATGTGGCTGTGCTCTTTACTCGGGACGAGTGGAAGAAGCTGGATCTGTCTCAGAG  
AAGCCTGTACCGTGAGGTGATGCTGGAGAATTACAGCAACCTGGCCTCCATGGCAGGATTCCTG  
TTTACCAAACCAAAGGTGATCTCCCTGTTGCAGCAAGGAGAGGATCCCTGGTAA (SEQ ID  
NO:209)

PROTEIN SEQUENCE

MVYPYDVPDYAELPPKKRKVGIRIPGEKPYECDHCGKSFSQSSHLNVHKRTHTGEKPYRCEEC  
GKAFRWPSNLTRHKRIHTGEKPYRCEECGKAFRWPSNLTRHKRIHTGEKPFACPECPKRFMRS  
DLQHIKTHTGEKAAAKFVSVTFEDVAVLFTRDEWKKLDLSQRSLYREVMLENYSNLASMAGFL  
FTKPKVISLLQQGEDPW (SEQ ID NO:210)

FIG. 18

21/26

Name: K\_F02

DSAR2-RDKR-RDER1-QTHR1-kid

NUCLEIC ACID SEQUENCE

ATGGTGTACCCCTACGACGTGCCCGACTACGCCGAATTGCCTCCAAAAAGAAGAGAAAGGTAG  
GGATCCgaattcccggggaaaaaccgTACTCCTGTGGCATTGTGGCAAATCCTTCTCTGACTC  
CAGTGCCAAAAGGAGACACTGCATTCTACACaccgggggaaaaaccgTATGTATGCGATGTAGAG  
GGATGTACGTGGAAATTTGCCCGCTCAGATAAGCTCAACAGACACAAGAAAAGGCACaccgggg  
aaaaaccgTATGTATGCGATGTAGAGGGATGTACGTGGAAATTTGCCCGCTCAGATGAGCTCAA  
CAGACACAAGAAAAGGCACaccgggggaaaaaccgTATGAGTGTACGATTGCGGAAAGTCCTTT  
AGGCAGAGCACCCACCTCACTCGGCACCGGAGGATCCACaccggtgaaaaagcgggccgctaaat  
tcGTGTCAGTGACATTTGAAGATGTGGCTGTGCTCTTTACTCGGGACGAGTGGAAGAAGCTGGA  
TCTGTCTCAGAGAAGCCTGTACCGTGAGGTGATGCTGGAGAATTACAGCAACCTGGCCTCCATG  
GCAGGATTCCTGTTTACCAAACCAAAGGTGATCTCCCTGTTGCAGCAAGGAGAGGATCCCTGGT  
AA (SEQ ID NO:211)

PROTEIN SEQUENCE

MVYPYDVPDYAELPPKKRKVGIRIPGEKP~~YSCGICGKSFS~~DSSAKRRHCILHTGEKP~~YVCDVE~~  
~~GCTWKFARSDKLN~~RHKKRHTGEKP~~YVCDVE~~GCTWKFARSD~~ELNRHKKRHT~~GEKP~~YECHDCGKSF~~  
~~RQSTHLTRHRR~~IHTGEKAAAKFVSVTFEDVAVLFT~~RDEWKKLDLS~~Q~~RS~~LYREVMLENYSNLASM  
AGFLFTKPKVISLLOQGEDPW (SEQ ID NO:212)

FIG. 19

22/26

Name: K12\_A11

RDHT-QSNV2-QTHR1-QFNR-kid

NUCLEIC ACID SEQUENCE

ATGGTG[TACCCCTACGACGTGCCCGACTACGCCGAATTG][CCTCCAAAAAGAAGAGAAAGGTAG]  
GGATCCgaattcccggggaaaaaccgTTCCAGTGTAAACTTGTCTAGCGAAAGTTCTCCCGGTC  
CGACCACCTGAAGACCCACACCAGGACTCATaccggggaaaaaccgTATGTTTGCTCAAAATGT  
GGGAAAGCCTTCACTCAGAGTTCAAATCTGACTGTACATCAAAAAATCCACaccggggaaaaac  
cgTATGAGTGTACGATTGCGGAAAGTCCTTTAGGCAGAGCACCCACCTCACTCGGCACCGGAG  
GATCCACaccggggaaaaaccgTATAAGTGTCAATGTGGGAAAGCCTTTATTCAATCCTTT  
AACCTTCGAAGACATGAGAGAACTCACaccggtgaaaaagcggccgctaaattcGTGTCTAGTGA  
CATTTGAAGATGTGGCTGTGCTCTTTACTCGGGACGAGTGGAAGAAGCTGGATCTGTCTCAGAG  
AAGCCTGTACCGTGAGGTGATGCTGGAGAATTACAGCAACCTGGCCTCCATGGCAGGATTCCTG  
TTTACCAAACCAAAGGTGATCTCCCTGTTGCAGCAAGGAGAGGATCCCTGGTAA (SEQ ID  
NO:213)

PROTEIN SEQUENCE

MVYPYDVPDYAELPPKKRKVGIRIPGEKP[FQCKTCQRKFSRSDHLKTHTRHTTGEK][PYVCSKC  
GKAFTQSSNLTVHQKIHTGEKPYECHDCGKSFRQSTHLTRHRRITHTGEKPYKCHQCGKAFIQSF  
NLRRHERHTHTGEKAAAKFVSVTFEDVAVLFTTRDEWKKLDLSQRSLYREVMLENYSNLASMAFL  
FTKPKVISLLQOGEDPW (SEQ ID NO:214)

FIG. 20



23/26

**K44-16-E12**

QSHV-QSSR1-QTHR1-kid

NUCLEIC ACID SEQUENCE

ATGGTGTACCCCTACGACGTGCCCCGACTACGCCGAATTGCCTCCAAAAAAGAAGAGAAAGGTAG  
GGATCCgaattccccggggaaaaaacgTATGAGTGTGATCACTGTGGAAAATCCTTTAGCCAGAG  
CTCTCATCTGAATGTGCACAAAAGAACTCACaccggggaaaaaacgTATAAGTGCCCTGATTGT  
GGGAAGAGTTTTAGTCAGAGTTCAGCCTCATTCGCCACCAGCGGACACACaccggggaaaaac  
cgTATGAGTGTACGATTGCGGAAAGTCCTTTAGGCAGAGCACCCACCTCACTCGGCACCGGAG  
GATCCACaccggtgaaaaagcgccgctaattcGTGTCAGTGACATTTGAAGATGTGGCTGTG  
CTCTTTACTCGGGACGAGTGGAAGAAGCTGGATCTGTCTCAGAGAAGCCTGTACCGTGAGGTGA  
TGCTGGAGAATTACAGCAACCTGGCCTCCATGGCAGGATTCCTGTTTACCAAACCAAAGGTGAT  
CTCCCTGTTGCAGCAAGGAGAGGATCCCTGGTAA (SEQ ID NO:215)

PROTEIN SEQUENCE

MVYPYDVPDYAELPPKKRKVGIRIPGEKPYECDHCGKSFSSQSSHLNVHKRTHTGEKPYKCPDC  
GKSFSQSSSLIRHQRTHTGEKPYECHDCGKSFRQSTHLTRHRRITHGEKAAAKFVSVTFEDVAV  
LFTRDEWKKLDLSQRSLYREVMLENYSNLASMAFLFTKPKVISLLQQGEDPW (SEQ ID  
NO:216)

**FIG. 21**

24/26

**K13\_B08**

QSNR1-QSSR1-QTHR1-RDKR-KID

NUCLEIC ACID SEQUENCE

ATGGTGTAACCCCTACGACGTGCCCGACTACGCCGAATTGCCTCCAAAAAGAAGAGAAAGGTAG  
GGATCCgaattccccggggaaaaaccgTTTGAGTGTAAAGATTGCGGGAAAGCTTTCATTCAGAA  
GTCAAACCTCATCAGACACCAGAGAACTCACaccggggaaaaaccgTATAAGTGCCCTGATTGT  
GGGAAGAGTTTTAGTCAGAGTTCAGCCTCATTCGCCACCAGCGGACACACaccggggaaaaac  
cgTATGAGTGTACGATTGCGGAAAGTCCTTTAGGCAGAGCACCCACCTCACTCGGCACCGGAG  
GATCCACaccggggaaaaaccgTATGTATGCGATGTAGAGGGATGTACGTGGAAATTTGCCCGC  
TCAGATAAGCTCAACAGACACAAGAAAAGGCACaccggtgaaaaagcggccgctaaattcGTGT  
CAGTGACATTTGAAGATGTGGCTGTGCTCTTTACTCGGGACGAGTGGAAGAAGCTGGATCTGTC  
TCAGAGAAGCCTGTACCGTGAGGTGATGCTGGAGAATTACAGCAACCTGGCCTCCATGGCAGGA  
TTCCTGTTTACCAAACCAAAGGTGATCTCCCTGTTGCAGCAAGGAGAGGATCCCTGGTAA  
(SEQ ID NO:217)

PROTEIN SEQUENCE

MVYPYDVPDYAELPPKKRKVGIRIPGEKPFECKDCGKAFLQKSNLIRHQRTHTGEKPYKCPDC  
GKSFSSQLIRHQRTHTGEKPYECHDCGKSFQSTHLTRHRRRIHTGEKPYVCDVEGCTWKFAR  
SDKLNRRHKKRHTGEKAAAKFVSVTFEDVAVLFTREDEWKLDLSQRSLYREVMLENYSNLASMAG  
FLFTKPKVISLLQOGEDPW (SEQ ID NO:218)

**FIG. 22**

25/26

F104\_p65

RDHT-RSHR-QSHR2-p65

NUCLEIC ACID SEQUENCE

ATGGTG TACCCCTACGACGTGCCCCACTACGCCGAATTG CCTCCAAAAAAGAAGAGAAAGGTAG  
GGATCC gaattcccggggaaaaaccg TTCCAGTGTAAAACCTTGTCAGCGAAAGTTCTCCCGGTC  
CGACCACCTGAAGACCCACACCAGGACTCAT accggggaaaaaccg TATAAGTGCATGGAGTGT  
GGGAAGGCTTTTAACCGCAGGTCACACCTCACACGGCACCAGCGGATTCA Caccggggaaaaac  
cgTATAAATGCGGCCAGTGTGGGAAGTTCTACTCGCAGGTCTCCACCTCACCCGCCACCAGAA  
AATCCACaccggtgaaaaagcgggcgctaaattc TACCTGCCAGATACAGACGATCGTCACCGG  
ATTGAGGAGAAACGTAAAAGGACATATGAGACCTTCAAGAGCATCATGAAGAAGAGTCCTTTCA  
GCGGACCCACCGACCCCCGGCCTCCACCTCGACGCATTGCTGTGCCTTCCCGCAGCTCAGCTTC  
TGTCCCCAAGCCAGCACCCAGCCCTATCCCTTTACGTCATCCCTGAGCACCATCAACTATGAT  
GAGTTTCCACCATGGTGTTTCCTTCTGGGCAGATCAGCCAGGCCTCGGCCTTGGCCCCGGCCC  
CTCCCCAAGTCCTGCCCCAGGCTCCAGCCCCTGCCCTGCTCCAGCCATGGTATCAGCTCTGGC  
CCAGGCCCCAGCCCCTGTCCCAGTCCTAGCCCCAGGCCCTCCTCAGGCTGTGGCCCCACCTGCC  
CCCAAGCCCACCCAGGCTGGGGAAGGAACGCTGTGTCAGAGGCCCTGCTGCAGCTGCAGTTTGATG  
ATGAAGACCTGGGGGCCTTGCTTGGAACAGCACAGACCCAGCTGTGTTACAGACCTGGCATC  
CGTCGACAACCTCCGAGTTTCAGCAGCTGCTGAACCAGGGCATACTGTGGCCCCCACACAAC  
GAGCCCATGCTGATGGAGTACCCTGAGGCTATAACTCGCCTAGTGACAGCCAGAGGCCCCCG  
ACCCAGCTCCTGCTCCACTGGGGGCCCCGGGGCTCCCCAATGGCCTCCTTTCAGGAGATGAAGA  
CTTCTCCTCCATTGCGGACATGGACTTCTCAGCCCTGCTGAGTCAG TAA (SEQ ID  
NO: 219)

PROTEIN SEQUENCE

MVYPYDVPDYAELPPKKRKVGIRIPGEKP FQCKTCQRKFSSRSDHLKTHTRHTGEKP YKCMEC  
GKAFNRRSHLTRHQRIHTGEKP YKCGQCCKFYQSQVSHLTRHQKIHTGEKAAAKFYLPDTPDRHR  
IEEKRKRTYETFKSIMKKSPFSGPTDPRPPPRRIAVPSRSSASVPKPAPOYPFTSSLSTINYD  
EFPTMVFPSGQISQASALAPAPPQVLPQAPAPAPAPAMVSALAQAPAPVPVLPAPGPPQAVAPPA  
PKPTQAGEGTLSEALLQLQFDDEDLGALLGNSTDPVAVFTDLASVDNSEFQQLLNQGI PVAPHTT  
EPMLMEYPEAITRLVTAQRPPDPAPAPLGAPGLPNGLLSGDEDFSSIADMDFSALLSQ (SEQ  
ID NO: 220)

FIG. 23

26/26

**F121\_p65**

QSHT-RSHR-RDHT-p65

NUCLEIC ACID SEQUENCE

ATGGTG[TACCCCTACGACGTGCCCGACTACGCCGAATTG[CCTCCAAAAAAGAAGAGAAAGGTA]G  
GGATCCgaattcccggggaaaaaccgTACAAATGTGAAGAATGTGGCAAAGCCTTTAGGCAGTC  
CTCACACCTTACTACACATAAGATAATTCATaccggggaaaaaccgTATAAGTGCATGGAGTGT  
GGGAAGGCTTTTAACCGCAGGTACACCTCACACGGCACCAGCGGATTACAccgggggaaaaac  
cgTTCCAGTGTA AAACTTGT CAGCGAAAGTTCTCCCGGTCCGACCACCTGAAGACCCACACCAG  
GACTCATaccggtgaaaaagcgggcgctaaattcTACCTGCCAGATACAGACGATCGTCACCGG  
ATTGAGGAGAAACGTAAAAGGACATATGAGACCTTCAAGAGCATCATGAAGAAGAGTCCTTTCA  
GCGGACCCACCGACCCCCGGCCTCCACCTCGACGCATTGCTGTGCCCTTCCGCGAGCTCAGCTTC  
TGTCCCCAAGCCAGCACCCAGCCCTATCCCTTTACGTCATCCCTGAGCACCATCAACTATGAT  
GAGTTTCCCACCATGGTGTTTCCTTCTGGGCAGATCAGCCAGGCCTCGGCCTTGGCCCCGGCCC  
CTCCCCAAGTCCTGCCCCAGGCTCCAGCCCCTGCCCCTGCTCCAGCCATGGTATCAGCTCTGGC  
CCAGGCCCCAGCCCTGTCCCAGTCTTAGCCCGAGGCCCTCCTCAGGCTGTGGCCCCACCTGCC  
CCCAAGCCCACCCAGGCTGGGGAAGGAACGCTGT CAGAGGCCCTGCTGCAGCTGCAGTTTGA TG  
ATGAAGACCTGGGGGCCTTGCTTGGCAACAGCACAGACCCAGCTGTGTT CACAGACCTGGCATC  
CGTCGACAACTCCGAGTTTCAGCAGCTGCTGAACCAGGGCATACTGTGGCCCCCACA CA ACT  
GAGCCCATGCTGATGGAGTACCCTGAGGCTATAACTCGCCTAGTGACAGCCAGAGGCCCCCG  
ACCCAGCTCCTGCTCCACTGGGGGCCCCGGGGCTCCCCAATGGCCTCCTTT CAGGAGATGAAGA  
CTTCTCCTCCATTGCGGACATGGACTTCTCAGCCCTGCTGAGTCAG TAA (SEQ ID  
NO:221)

PROTEIN SEQUENCE

MVYPYDVPDYAELPPKKRKVGIRIPGEKP[YKCEECKGAFRQSSHLTTHKIIHTGEKP[YKCMEC  
GKA FNRRSHLTRHQRIHTGEKP[FQCKTCQRKFSRSDHLKTHTRTHTGEKAAAKFYLPD TDDRHR  
IEEKRKRITYETFKSIMKKSPFSGPTDPRPPPRRIAVPSRSSASVPKPAPQYPFTSSLSTINYD  
EFPTMVFPSPGQISQASALAPAPPQVLPOAPAPAPAPAMVSALAQAPAPVPVLAPGPPQAVAPPA  
PKPTQAGEGTLSEALLQLQFDDLDL GALLGNSTDPAVF TDLASVDNSEFQQLLNQGIPVAPHTT  
EPMLMEYPEAITRLVTAQRPPDPAPAPL GAPGLPNGLLSGDEDFSSIADMDFSALLSQ (SEQ  
ID NO:222)

**FIG. 24**

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/KR02/02309

**A. CLASSIFICATION OF SUBJECT MATTER****IPC7 C12N 5/00**

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

IPC7 C12N 5/00

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

NCBI pubmed database, Delphion Research Intellectual Property network database, STN CAplus

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Gene Ther 2000 Jun;7(12):1076-83 see entire document	1
A	J Biol Chem 2000 Oct 20;275(42):32617-27 see entire document	1-6,7-16, 22-23
A	Biochemistry 1998 Sep 29;37(39):13827-34 see entire document	1-6,7-16, 22-23
A	Biochemistry 2000 Apr 18;39(15):4383-90 see entire document	1-6,7-16, 22-23
A	J Biol Chem 2002 Nov 1;277(44):42224-32 see entire document	1-6,7-16, 22-23
A	Hum Mol Genet 2000 Jul 22;9(12):1853-64 see entire document	1-6,7-16, 22-23

☐ Further documents are listed in the continuation of Box C.☐ See patent family annex.

\* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&amp;" document member of the same patent family

Date of the actual completion of the international search

26 MARCH 2003 (26.03.2003)

Date of mailing of the international search report

26 MARCH 2003 (26.03.2003)

Name and mailing address of the ISA/KR

Korean Intellectual Property Office  
920 Dunsan-dong, Seo-gu, Daejeon 302-701,  
Republic of Korea

Facsimile No. 82-42-472-7140

Authorized officer

LIM, Hea Joon

Telephone No. 82-42-481-5590

